[{"id": 249001, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294285/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "Eprosartan, Telmisartan, Eprosartan, Nebivolol, Hydrochlorothiazide, Telmisartan", "updated_at": 1767369485}, {"id": 249002, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Prednisolone", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention.  These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity.  Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure.  The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294286/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, Fluorometholone, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249003, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Prednisone", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention.  These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity.  Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure.  The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294287/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249004, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Pregabalin", "severity": "Moderate", "effect": "Pregabalin has been associated with the development of angioedema, and coadministration with other drugs that are also known to cause angioedema (e.g., ACE inhibitors, angiotensin II receptor antagonists, renin inhibitors) may theoretically increase the risk.", "source": "DDInter", "management_text": "Clinicians and patients should be aware of the potential for increased risk of angioedema when pregabalin is prescribed with other drugs that are also known to cause angioedema.  Patients should be advised to promptly discontinue these medications and seek medical attention if they develop signs or symptoms suggestive of angioedema such as swelling of the face, extremities, eyes, lips, or tongue, and difficulty swallowing or breathing.", "mechanism_text": "Synergism", "recommendation": "Clinicians and patients should be aware of the potential for increased risk of angioedema when pregabalin is prescribed with other drugs that are also known to cause angioedema.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294288/", "reference_text": "[1] \"Product Information. Lyrica (pregabalin).\" Pfizer U.S. Pharmaceuticals Group  (2005):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Sacubitril, Nebivolol", "updated_at": 1767369485}, {"id": 249005, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Procarbazine", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications.  MAOIs alone quite commonly produce orthostatic hypotension.  This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission.  The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.  Close monitoring for development of hypotension is recommended.  Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294289/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[5] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[8] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[9] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[10] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[11] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[12] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[13] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249006, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Prochlorperazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294290/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249007, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294291/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249008, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294292/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249009, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294293/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249010, "ingredient1": "Dextropropoxyphene", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294294/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249011, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294295/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249012, "ingredient1": "Quazepam", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294296/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249013, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Quetiapine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294297/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249014, "ingredient1": "Ramipril", "ingredient2": "Azilsartan medoxomil", "severity": "Major", "effect": "Coadministration of an ACE inhibitor in combination with an angiotensin II receptor antagonist may increase the risk of hyperkalemia, hypotension, syncope, and renal dysfunction due to additive or synergistic effects on the renin-angiotensin system.", "source": "DDInter", "management_text": "Dual blockade of the renin-angiotensin-aldosterone system by adding an ACE inhibitor to an angiotensin II receptor antagonist is not recommended, especially in patients with diabetic nephropathy.  Most patients receiving the combination do not obtain any additional benefit compared to monotherapy.  However, if the combination is considered medically necessary, serum electrolytes, blood pressure, and renal function should be closely monitored.  Routine monitoring of electrolytes and renal function may be indicated in the elderly or patients with worsening heart failure or a risk for dehydration.  Potassium supplementation should generally be avoided unless it is closely monitored, and patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as weakness, listlessness, confusion, tingling of the extremities, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Dual blockade of the renin-angiotensin-aldosterone system by adding an ACE inhibitor to an angiotensin II receptor antagonist is not recommended, especially in patients with diabetic nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294298/", "reference_text": "[1] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Atacand (candesartan).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Micardis (telmisartan).\" Boehringer-Ingelheim  (2001):[4] Laverman GD, Navis G, Henning RH, De Jong PE, De Zeeuw D \"Dual renin-angiotensin system blockade at optimal doses for proteinuria.\" Kidney Int 62 (2002):  1020-5[5] Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH \"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.\" Kidney Int 63 (2003):  1874-80[6] Rossing K, Jacobsen P, Pietraszek L, Parving HH \"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.\" Diabetes Care 26 (2003):  2268-74[7] Jacobsen P, Andersen S, Jensen BR, Parving HH \"Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.\" J Am Soc Nephrol 14 (2003):  992-9[8] McMurray JJ, Ostergren J, Swedberg K, et al. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.\" Lancet 362 (2003):  767-71[9] Pfeffer MA, McMurray JJ, Velazquez EJ, et al. \"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.\" N Engl J Med 349 (2003):  1893-1906[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] ONTARGET Investigators, Yusuf S, Teo KK, et al. \"Telmisartan, ramipril, or both in patients at high risk for vascular events.\" N Engl J Med 358 (2008):  1547-59[12] Mann JF, Schmieder RE, McQueen M, et al. \"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.\" Lancet 372 (2008):  547-53[13] Guthrie RM \"Review of ONTARGET: treating patients at high risk for vascular events with telmisartan, ramipril, or both. Commentary.\" Postgrad Med 121 (2009):  202-4[14] National Kidney Foundation \"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update.\" Am J Kidney Dis 60 (2012):  850-86[15] EMA. European Medicines Agency \"PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system: recommendation will now be considered by CHMP for final opinion.  http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Renin-angiotensin_sys\"   (2014):[16] MHRA. Medicines and Healthcare Regulatory Agency \"Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function--new warnings.  http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON426905\"   (2014):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide, Amlodipine, Valsartan, Simvastatin, Atorvastatin, Lovastatin, More", "alternatives_b": "Nebivolol", "updated_at": 1767369485}, {"id": 249015, "ingredient1": "Rasagiline", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications.  MAOIs alone quite commonly produce orthostatic hypotension.  This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission.  The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.  Close monitoring for development of hypotension is recommended.  Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294299/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[5] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[8] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[9] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[10] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[11] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[12] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[13] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Pramipexole, Amantadine", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249016, "ingredient1": "Remifentanil", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294300/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249017, "ingredient1": "Remimazolam", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294301/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249018, "ingredient1": "Riociguat", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Riociguat may potentiate the action of antihypertensive agents and other vasodilators.  Symptomatic hypotension may occur.  Riociguat stimulates soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system that binds with nitric oxide (NO) to catalyze the synthesis of cyclic guanosine monophosphate (cGMP).  The resultant accumulation of cGMP in vascular smooth muscle cells leads to peripheral vasodilation and blood pressure decreases.", "source": "DDInter", "management_text": "Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.  A reduction in the starting dosage of riociguat to 0.5 mg three times a day should be considered for patients who may not tolerate the hypotensive effect of riociguat.  Periodic systemic blood pressure monitoring is recommended.  If systolic blood pressure remains greater than 95 mmHg and the patient has no signs or symptoms of hypotension, the dosage may be increased by 0.5 mg three times a day every 2 weeks as tolerated, up to a maximum of 2.5 mg three times a day.  If hypotension develops at any time during treatment, the dosage should be reduced by 0.5 mg three times a day.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294302/", "reference_text": "[1] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc  (2013):", "alternatives_a": "Bosentan, Ambrisentan, Macitentan, Metyrosine", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249019, "ingredient1": "Risperidone", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294303/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249020, "ingredient1": "Rofecoxib", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294304/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Sacubitril, Nebivolol", "updated_at": 1767369485}, {"id": 249021, "ingredient1": "Safinamide", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications.  MAOIs alone quite commonly produce orthostatic hypotension.  This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission.  The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.  Close monitoring for development of hypotension is recommended.  Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294305/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[5] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[8] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[9] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[10] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[11] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[12] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[13] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Pramipexole, Amantadine", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249022, "ingredient1": "Salsalate", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294306/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Hydrochlorothiazide, Sacubitril", "updated_at": 1767369485}, {"id": 249023, "ingredient1": "Secobarbital", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294307/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249024, "ingredient1": "Selegiline", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications.  MAOIs alone quite commonly produce orthostatic hypotension.  This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission.  The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.  Close monitoring for development of hypotension is recommended.  Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294308/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[5] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[8] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[9] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[10] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[11] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[12] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[13] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Pramipexole, Amantadine", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249025, "ingredient1": "Selexipag", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents.", "source": "DDInter", "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.  If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.  Treatment guidelines should be consulted for the optimum management of pulmonary arterial hypertension.", "mechanism_text": "Synergism", "recommendation": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294309/", "reference_text": "[1] Buchdahl RM, Taylor P, Warner JD \"Nebulised ribavirin for adenovirus pneumonia.\" Lancet 2 (1985):  1070-1[2] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome  (2001):[3] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[4] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corporation  (2002):[5] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc  (2005):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249026, "ingredient1": "Sildenafil", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications.  These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.", "source": "DDInter", "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.  Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294310/", "reference_text": "[1] \"Product Information. Viagra (sildenafil).\" Pfizer U.S. Pharmaceuticals  (2001):[2] \"Product Information. Levitra (vardenafil).\" Bayer  (2003):[3] \"Product Information. Stendra (avanafil).\" Vivus Inc  (2012):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249027, "ingredient1": "Sirolimus", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The use of mTOR (mammalian target of rapamycin) inhibitors has been associated with the development of angioedema, and coadministration with other drugs that are also known to cause angioedema such as ACE inhibitors, angiotensin II receptor antagonists, and renin inhibitors may increase the risk.", "source": "DDInter", "management_text": "Clinicians and patients should be aware of the potential for increased risk of angioedema when mTOR inhibitors are prescribed with other drugs that are also known to cause angioedema.  Patients should be advised to promptly discontinue these medications and seek medical attention if they develop signs or symptoms suggestive of angioedema such as swelling of the face, extremities, eyes, lips, or tongue, and difficulty swallowing or breathing.", "mechanism_text": "Synergism", "recommendation": "Clinicians and patients should be aware of the potential for increased risk of angioedema when mTOR inhibitors are prescribed with other drugs that are also known to cause angioedema.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294311/", "reference_text": "[1] \"Product Information. Rapamune (sirolimus).\" Wyeth-Ayerst Laboratories  (2001):[2] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[3] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Acetylcysteine, Nandrolone, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, More", "alternatives_b": "Sacubitril, Nebivolol", "updated_at": 1767369485}, {"id": 249028, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Nitrous acid", "severity": "Moderate", "effect": "Coadministration with antihypertensive agents, diuretics, vasodilators, or phosphodiesterase-5 (PDE5) inhibitors may potentiate the hypotensive effect of sodium nitrite.  Since sodium nitrite can cause serious hypotension and methemoglobin formation, patients may be at increased risk for complications related to inadequate perfusion and oxygenation.", "source": "DDInter", "management_text": "Sodium nitrite should be used with caution in the presence of concomitant antihypertensive agents, diuretics, vasodilators, or PDE5 inhibitors.  Hemodynamics should be monitored during and after administration of sodium nitrite, and the infusion rate decreased if significant hypotension occurs.  In addition, methemoglobin levels should be monitored and oxygen administered during treatment whenever possible.", "mechanism_text": "Synergism", "recommendation": "Sodium nitrite should be used with caution in the presence of concomitant antihypertensive agents, diuretics, vasodilators, or PDE5 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294313/", "reference_text": "[1] \"Product Information. Sodium Nitrite (sodium nitrite).\" Hope Pharmaceuticals  (2012):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249029, "ingredient1": "Sodium oxybate", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294314/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249030, "ingredient1": "Sufentanil", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294318/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249031, "ingredient1": "Sulindac", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294319/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249032, "ingredient1": "Tacrolimus", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Coadministration of tacrolimus with ACE inhibitors or angiotensin II receptor antagonists may increase the risk of hyperkalemia associated with the use of these drugs, particularly in patients with renal impairment.", "source": "DDInter", "management_text": "Serum potassium levels and renal function should be monitored regularly when tacrolimus is used in combination with ACE inhibitors or angiotensin II receptor antagonists.  Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration.  Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Serum potassium levels and renal function should be monitored regularly when tacrolimus is used in combination with ACE inhibitors or angiotensin II receptor antagonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294320/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More", "alternatives_b": "Sacubitril, Nebivolol", "updated_at": 1767369485}, {"id": 249033, "ingredient1": "Tadalafil", "ingredient2": "Azilsartan medoxomil", "severity": "Minor", "effect": "Based on their pharmacology, phosphodiesterase-5 (PDE5) inhibitors may conceivably potentiate the hypotensive effect of antihypertensive medications.  These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation.", "source": "DDInter", "management_text": "Patients should be advised of the potential for interaction and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, or fainting.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised of the potential for interaction and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, or fainting.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294321/", "reference_text": "[1] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals  (2008):[3] \"Product Information. Entadfi (finasteride-tadalafil).\" Veru Inc  (2021):", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249034, "ingredient1": "Temazepam", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294322/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249035, "ingredient1": "Temsirolimus", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The use of mTOR (mammalian target of rapamycin) inhibitors has been associated with the development of angioedema, and coadministration with other drugs that are also known to cause angioedema such as ACE inhibitors, angiotensin II receptor antagonists, and renin inhibitors may increase the risk.", "source": "DDInter", "management_text": "Clinicians and patients should be aware of the potential for increased risk of angioedema when mTOR inhibitors are prescribed with other drugs that are also known to cause angioedema.  Patients should be advised to promptly discontinue these medications and seek medical attention if they develop signs or symptoms suggestive of angioedema such as swelling of the face, extremities, eyes, lips, or tongue, and difficulty swallowing or breathing.", "mechanism_text": "Synergism", "recommendation": "Clinicians and patients should be aware of the potential for increased risk of angioedema when mTOR inhibitors are prescribed with other drugs that are also known to cause angioedema.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294323/", "reference_text": "[1] \"Product Information. Rapamune (sirolimus).\" Wyeth-Ayerst Laboratories  (2001):[2] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[3] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals  (2009):", "alternatives_a": "Entrectinib, Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "Hydrochlorothiazide, Sacubitril, Nebivolol", "updated_at": 1767369485}, {"id": 249036, "ingredient1": "Tetrabenazine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294324/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Dextromethorphan, Valbenazine, Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249037, "ingredient1": "Thiethylperazine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294325/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249038, "ingredient1": "Thioridazine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294326/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249039, "ingredient1": "Thiothixene", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294327/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249040, "ingredient1": "Tinzaparin", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "The concomitant use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and heparin or low molecular weight heparins may increase the risk of hyperkalemia.", "source": "DDInter", "management_text": "Caution is advised if ACE inhibitors or ARBs are used with heparin or low molecular weight heparin.  Serum potassium and renal function should be checked regularly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if ACE inhibitors or ARBs are used with heparin or low molecular weight heparin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294328/", "reference_text": "[1] \"Product Information. Cozaar (losartan).\" Merck & Co., Inc  (2001):[2] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[3] \"Product Information. Avapro (irbesartan).\" Bristol-Myers Squibb  (2001):[4] \"Product Information. Teveten (eprosartan).\" SmithKline Beecham  (2001):[5] \"Product Information. Atacand (candesartan).\" Astra-Zeneca Pharmaceuticals  (2001):[6] \"Product Information. Micardis (telmisartan).\" Boehringer-Ingelheim  (2001):[7] \"Product Information. Benicar (olmesartan).\" Sankyo Pharma  (2002):[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14[10] \"Product Information. Edarbi (azilsartan).\" Takeda Pharmaceuticals America  (2011):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol", "updated_at": 1767369485}, {"id": 249041, "ingredient1": "Tizanidine", "ingredient2": "Azilsartan medoxomil", "severity": "Major", "effect": "Tizanidine may potentiate the hypotensive effect of some medications secondary to its alpha-2 adrenergic activity.", "source": "DDInter", "management_text": "A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications.  Although single doses of less than 8 mg of tizanidine have not been shown effective for spasticity in controlled clinical studies, it may be prudent to initiate treatment with 4 mg doses and gradually increase in 2 to 4 mg increments until optimum effect is achieved.  The dose can be repeated at 6 to 8 hour intervals as needed, up to a maximum of three doses in 24 hours and a total daily dosage of 36 mg.  However, experience with single doses exceeding 8 mg and daily doses exceeding 24 mg is limited.  Close monitoring for development of hypotension is recommended.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294329/", "reference_text": "[1] \"Product Information. Zanaflex (tizanidine).\" Acorda Therapeutics  (2001):", "alternatives_a": "Sacubitril", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249042, "ingredient1": "Tolmetin", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294330/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249043, "ingredient1": "Tolvaptan", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Coadministration with tolvaptan can potentiate the risk of hyperkalemia in patients treated with other drugs that are known to increase serum potassium.", "source": "DDInter", "management_text": "Serum potassium levels should be checked regularly during concomitant therapy with tolvaptan and other agents that can increase serum potassium such as ACE inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim.  Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration.  Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Serum potassium levels should be checked regularly during concomitant therapy with tolvaptan and other agents that can increase serum potassium such as ACE inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294331/", "reference_text": "[1] \"Product Information. Samsca (tolvaptan).\" Otsuka American Pharmaceuticals Inc  (2009):", "alternatives_a": "Conivaptan", "alternatives_b": "Amlodipine, Sacubitril, Hydrochlorothiazide, Nebivolol", "updated_at": 1767369485}, {"id": 249044, "ingredient1": "Trandolapril", "ingredient2": "Azilsartan medoxomil", "severity": "Major", "effect": "Coadministration of an ACE inhibitor in combination with an angiotensin II receptor antagonist may increase the risk of hyperkalemia, hypotension, syncope, and renal dysfunction due to additive or synergistic effects on the renin-angiotensin system.", "source": "DDInter", "management_text": "Dual blockade of the renin-angiotensin-aldosterone system by adding an ACE inhibitor to an angiotensin II receptor antagonist is not recommended, especially in patients with diabetic nephropathy.  Most patients receiving the combination do not obtain any additional benefit compared to monotherapy.  However, if the combination is considered medically necessary, serum electrolytes, blood pressure, and renal function should be closely monitored.  Routine monitoring of electrolytes and renal function may be indicated in the elderly or patients with worsening heart failure or a risk for dehydration.  Potassium supplementation should generally be avoided unless it is closely monitored, and patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as weakness, listlessness, confusion, tingling of the extremities, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Dual blockade of the renin-angiotensin-aldosterone system by adding an ACE inhibitor to an angiotensin II receptor antagonist is not recommended, especially in patients with diabetic nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294332/", "reference_text": "[1] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Atacand (candesartan).\" Astra-Zeneca Pharmaceuticals  (2001):[3] \"Product Information. Micardis (telmisartan).\" Boehringer-Ingelheim  (2001):[4] Laverman GD, Navis G, Henning RH, De Jong PE, De Zeeuw D \"Dual renin-angiotensin system blockade at optimal doses for proteinuria.\" Kidney Int 62 (2002):  1020-5[5] Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH \"Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.\" Kidney Int 63 (2003):  1874-80[6] Rossing K, Jacobsen P, Pietraszek L, Parving HH \"Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.\" Diabetes Care 26 (2003):  2268-74[7] Jacobsen P, Andersen S, Jensen BR, Parving HH \"Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.\" J Am Soc Nephrol 14 (2003):  992-9[8] McMurray JJ, Ostergren J, Swedberg K, et al. \"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.\" Lancet 362 (2003):  767-71[9] Pfeffer MA, McMurray JJ, Velazquez EJ, et al. \"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.\" N Engl J Med 349 (2003):  1893-1906[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] ONTARGET Investigators, Yusuf S, Teo KK, et al. \"Telmisartan, ramipril, or both in patients at high risk for vascular events.\" N Engl J Med 358 (2008):  1547-59[12] Mann JF, Schmieder RE, McQueen M, et al. \"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.\" Lancet 372 (2008):  547-53[13] Guthrie RM \"Review of ONTARGET: treating patients at high risk for vascular events with telmisartan, ramipril, or both. Commentary.\" Postgrad Med 121 (2009):  202-4[14] National Kidney Foundation \"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update.\" Am J Kidney Dis 60 (2012):  850-86[15] EMA. European Medicines Agency \"PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system: recommendation will now be considered by CHMP for final opinion.  http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Renin-angiotensin_sys\"   (2014):[16] MHRA. Medicines and Healthcare Regulatory Agency \"Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function--new warnings.  http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON426905\"   (2014):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "Nebivolol", "updated_at": 1767369485}, {"id": 249045, "ingredient1": "Tranylcypromine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications.  MAOIs alone quite commonly produce orthostatic hypotension.  This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission.  The interaction has been reported with the concomitant use of beta-blockers.", "source": "DDInter", "management_text": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.  Close monitoring for development of hypotension is recommended.  Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294333/", "reference_text": "[1] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1992):  106-8[2] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[3] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[4] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[5] Ban TA \"Drug interactions with psychoactive drugs.\" Dis Nerv Syst 36 (1975):  164-6[6] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[8] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983):  307-10[9] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993):  77-8[10] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[11] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[12] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[13] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249046, "ingredient1": "Trazodone", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294334/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249047, "ingredient1": "Treprostinil", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents.", "source": "DDInter", "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.  If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.  Treatment guidelines should be consulted for the optimum management of pulmonary arterial hypertension.", "mechanism_text": "Synergism", "recommendation": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294335/", "reference_text": "[1] Buchdahl RM, Taylor P, Warner JD \"Nebulised ribavirin for adenovirus pneumonia.\" Lancet 2 (1985):  1070-1[2] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome  (2001):[3] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[4] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corporation  (2002):[5] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc  (2005):[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249048, "ingredient1": "Triamcinolone", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention.  These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity.  Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure.  The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294336/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, Mupirocin, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249049, "ingredient1": "Triamterene", "ingredient2": "Azilsartan medoxomil", "severity": "Major", "effect": "Concomitant use of angiotensin II receptor blockers (ARBs) and potassium-sparing diuretics may increase the risk of hyperkalemia.  Inhibition of angiotensin II results in decreased aldosterone secretion, which can lead to increases in serum potassium that may be additive with that induced by potassium-sparing diuretics.", "source": "DDInter", "management_text": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium-sparing diuretics, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.  Serum potassium and renal function should be checked prior to initiating therapy and regularly thereafter, and potassium supplementation as well as the use of potassium-containing salt substitutes should be avoided unless absolutely necessary and the benefits outweigh the potential risks.  Patients should be given counseling on the appropriate levels of potassium and fluid intake, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.  If spironolactone is prescribed with an ARB, some investigators recommend that its dosage not exceed 25 mg/day in high-risk patients.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if angiotensin II receptor blockers must be used concurrently with potassium-sparing diuretics, particularly in patients with renal impairment, diabetes, old age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium such as nonsteroidal anti-inflammatory drugs, beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294337/", "reference_text": "[1] Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J \"Hyperkalemia in the elderly.\" Clin Chem 30 (1984):  1409-12[2] McNay JL, Oran E \"Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870).\" Metabolism 19 (1970):  58-70[3] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982):  21-5[4] \"Product Information. Midamor (amiloride).\" Merck & Co., Inc  (2001):[5] \"Product Information. Cozaar (losartan).\" Merck & Co., Inc  (2001):[6] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals  (2001):[7] \"Product Information. Atacand (candesartan).\" Astra-Zeneca Pharmaceuticals  (2001):[8] Obialo CI, Ofili EO, Mirza T \"Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.\" Am J Cardiol 90 (2002):  663-5[9] Bozkurt B, Agoston I, Knowlton AA \"Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines.\" J Am Coll Cardiol 41 (2003):  211-4[10] Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH \"Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.\" BMJ 327 (2003):  147-9[11] Jarman PR, Mather HM \"Diabetes may be independent risk factor for hyperkalaemia.\" BMJ 327 (2003):  812[12] Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D \"Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study.\" BMJ 327 (2003):  1141-2[13] \"Spironolactone + ace inhibitor or sartan: risk of hyperkalaemia.\" Prescrire Int 13 (2004):  58[14] McMurray JJ, O'Meara E \"Treatment of heart failure with spironolactone--trial and tribulations.\" N Engl J Med 351 (2004):  526-8[15] Tamirisa KP, Aaronson KD, Koelling TM \"Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.\" Am Heart J 148 (2004):  971-8[16] Masoudi FA, Gross CP, Wang Y, et al. \"Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.\" Circulation 112 (2005):  39-47[17] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006):  49-58[18] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[19] Desai AS, Swedberg K, McMurray JJ, et al. \"Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.\" J Am Coll Cardiol 50 (2007):  1959-66[20] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14[21] Fujii H, Nakahama H, Yoshihara F, Nakamura S, Inenaga T, Kawano Y \"Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.\" Kobe J Med Sci 51 (2005):  1-6[22] Jarman PR, Kehely AM, Mather HM \"Hyperkalaemia in diabetes: prevalence and associations.\" Postgrad Med J 71 (1995):  551-2[23] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997):  646-56[24] Large DM, Carr PH, Laing I, Davies M \"Hyperkalaemia in diabetes mellitus--potential hazards of coexisting hyporeninaemic hypoaldosteronism.\" Postgrad Med J 60 (1984):  370-3", "alternatives_a": "Amlodipine, Sacubitril, Hydrochlorothiazide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249050, "ingredient1": "Triazolam", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294338/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249051, "ingredient1": "Trifluoperazine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294339/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249052, "ingredient1": "Triflupromazine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294340/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249053, "ingredient1": "Alimemazine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294341/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249054, "ingredient1": "Trimethoprim", "ingredient2": "Azilsartan medoxomil", "severity": "Major", "effect": "The use of trimethoprim in combination with other potassium-sparing drugs or potassium salts may increase the risk of hyperkalemia.  Trimethoprim inhibits sodium reabsorption and potassium excretion by blocking sodium channels in the renal distal tubules.", "source": "DDInter", "management_text": "Serum potassium and sodium levels as well as renal function should be closely monitored during coadministration of trimethoprim with other potassium-sparing drugs or potassium salts, particularly in patients receiving high-dose or long-term trimethoprim treatment and in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration.  A dosage reduction of trimethoprim is recommended in renal dysfunction (50% reduction for CrCl between 15 and 30 mL/min).  Patients should be given dietary counseling to avoid excessive intake of potassium-rich foods and salt substitutes, and advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.  Trimethoprim should be discontinued if hyperkalemia occurs.", "mechanism_text": "Synergism", "recommendation": "Serum potassium and sodium levels as well as renal function should be closely monitored during coadministration of trimethoprim with other potassium-sparing drugs or potassium salts, particularly in patients receiving high-dose or long-term trimethoprim treatment and in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294342/", "reference_text": "[1] \"Product Information. Bactrim (sulfamethoxazole-trimethoprim).\" Roche Laboratories  (2022):[2] Lawson DH, O'Connor PC, Jick H \"Drug attributed alterations in potassium handling in congestive cardiac failure.\" Eur J Clin Pharmacol 23 (1982):  21-5[3] Greenberg S, Reiser IW, Chou SY \"Hyperkalemia with high-dose trimethoprim-sulfamethoxazole therapy.\" Am J Kidney Dis 22 (1993):  603-6[4] Choi MJ, Fernandez PC, Patnaik A, Coupaye-Gerard B, D'Andrea D, Szerlip H, Kleyman TR \"Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS.\" N Engl J Med 328 (1993):  703-6[5] Velazquez H, Perazella MA, Wright FS, Ellison DH \"Renal mechanism of trimethoprim-induced hyperkalemia.\" Ann Intern Med 119 (1993):  296-301[6] Smith GW, Cohen SB \"Hyperkalaemia and non-oliguric renal failure associated with trimethoprim.\" Br Med J 308 (1994):  454[7] Modest GA, Price B, Mascoli N \"Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole.\" Ann Intern Med 120 (1994):  437[8] Pennypacker LC, Mintzer J, Pitner J \"Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole.\" Ann Intern Med 120 (1994):  437[9] Canaday DH, Johnson JR \"Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole.\" Ann Intern Med 120 (1994):  438[10] Lawson DH \"Adverse reactions to potassium chloride.\" Q J Med 43 (1974):  433-40[11] Hsu I, Wordell CJ \"Hyperkalemia and high-dose trimethoprim/sulfamethoxazole.\" Ann Pharmacother 29 (1995):  427-9[12] Marinella MA \"Reversible hyperkalemia associated with trimethoprim-sulfamethoxazole.\" Am J Med Sci 310 (1995):  115-7[13] Mihm LB, Rathbun RC, Resmantargoff BH \"Hyperkalemia associated with high-dose trimethoprim-sulfamethoxazole in a patient with the acquired immunodeficiency syndrome.\" Pharmacotherapy 15 (1995):  793-7[14] Alappan R, Perazella MA, Buller GK \"Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole.\" Ann Intern Med 124 (1996):  316-20[15] Witt JM, Koo JM, Danielson BD \"Effect of standard-dose trimethoprim/sulfamethoxazole on the serum potassium concentration in elderly men.\" Ann Pharmacother 30 (1996):  347-50[16] Thomas RJ \"Severe hyperkalemia with trimethoprim-quinapril.\" Ann Pharmacother 30 (1996):  413-4[17] Eiam-Ong S, Kurtzman NA, Sabatini S \"Studies on the mechanism of trimethoprim-induced hyperkalemia.\" Kidney Int 49 (1996):  1372-8[18] Perazella MA, Mahnensmith RL \"Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose.\" Clin Nephrol 46 (1996):  187-92[19] Bugge JF \"Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs.\" J Intern Med 240 (1996):  249-51[20] Perazella MA, Alappan R, Buller GK \"Hyperkalemia and trimethoprim-sulfamethoxazole.\" Ann Intern Med 125 (1996):  1015[21] Fouche R, Bernardin G, Roger PM, Corcelle P, Simler JM, Mattei M \"Hyperkaliemia in a patient given high-dose trimethoprim-sulfamethoxazole.\" Presse Med 25 (1996):  2044[22] Marinella MA \"Severe hyperkalemia associated with trimethoprim-sulfamethoxazole and spironolactone.\" Infect Dis Clin Pract 6 (1997):  256-8[23] Perlmutter EP, Sweeney D, Herskovits G, Kleiner M \"Case report: severe hyperkalemia in a geriatric patient receiving standard doses of trimethoprim-sulfamethoxazole.\" Am J Med Sci 311 (1996):  84-5[24] Marinella MA \"Trimethoprim-sulfamethoxazole associated with hyperkalemia.\" West J Med 167 (1997):  356-8[25] Koc M, Bihorac A, Ozener CI, Kantarci G, Akoglu E \"Severe hyperkalemia in two renal transplant recipients treated with standard dose of trimethoprim-sulfamethoxazole.\" Am J Kidney Dis 36 (2000):  u59-64[26] Martin J, Mourton S, Nicholls G \"Severe hyperkalaemia with prescription of potassium-retaining agents in an elderly patient.\" N Z Med J 116 (2003):  U542[27] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006):  49-58[28] \"Prevent-ERR: sulfamethoxazole and trimethoprim-induced hyperkalemia.\" ISMP Medication Safety Alert! 13(Dec 4) (2008):  3[29] Noto H, Kaneko Y, Takano T, Kurokawa K \"Severe hyponatremia and hyperkalemia induced by trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia.\" Intern Med 34 (1995):  96-9[30] Lin SH, Kuo AA, Yu FC, Lin YF \"Reversible voltage-dependent distal renal tubular acidosis in a patient receiving standaard doses of trimethoprim-sulphamethoxazole.\" Nephrol Dial Transplant 12 (1997):  1031-33[31] Mori H, Kuroda Y, Imamura S, et al. \"Hyponatremia and/or hyperkalemia in patients treated with the standard dose of trimethoprim-sulfamethoxazole.\" Intern Med 42 (2003):  665-9[32] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14[33] Perazella MA, Mahnensmith RL \"Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeostasis.\" J Gen Intern Med 12 (1997):  646-56[34] Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM \"Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study.\" Arch Intern Med 170 (2010):  1045-9[35] Lee SW, Park SW, Kang JM \"Intraoperative hyperkalemia induced by administration of trimethoprim-sulfamethoxazole in a patient receiving angiotensin receptor blockers.\" J Clin Anesth 26 (2014):  427-8", "alternatives_a": "Sulfadiazine, Sulfamethoxazole, Sulfamethizole, Sulfisoxazole, Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, More", "alternatives_b": "Sacubitril, Aliskiren, Nebivolol", "updated_at": 1767369485}, {"id": 249055, "ingredient1": "Trimipramine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294343/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Citalopram, Duloxetine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249056, "ingredient1": "Valdecoxib", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294344/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Sacubitril, Nebivolol", "updated_at": 1767369485}, {"id": 249057, "ingredient1": "Vardenafil", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications.  These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.", "source": "DDInter", "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.  Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294345/", "reference_text": "[1] \"Product Information. Viagra (sildenafil).\" Pfizer U.S. Pharmaceuticals  (2001):[2] \"Product Information. Levitra (vardenafil).\" Bayer  (2003):[3] \"Product Information. Stendra (avanafil).\" Vivus Inc  (2012):", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Tolterodine, Phenazopyridine, Trospium, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Flavoxate, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249058, "ingredient1": "Zaleplon", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294349/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249059, "ingredient1": "Ziprasidone", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294350/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 249060, "ingredient1": "Zolpidem", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294351/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 249061, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Phenyl salicylate", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294532/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 249062, "ingredient1": "Abarelix", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294533/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249063, "ingredient1": "Abiraterone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294534/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249064, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Acetazolamide", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294535/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249065, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Salbutamol", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294537/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249066, "ingredient1": "Aldesleukin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294538/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249067, "ingredient1": "Alfentanil", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294539/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249068, "ingredient1": "Alfuzosin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294540/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tamsulosin, Terazosin, Tadalafil, Finasteride, Silodosin, Dutasteride", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249069, "ingredient1": "Amantadine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294541/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ropinirole, Opicapone, Cabergoline, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249070, "ingredient1": "Amifampridine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294542/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249071, "ingredient1": "Amiloride", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294543/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Eplerenone, Finerenone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249072, "ingredient1": "Aminophylline", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294544/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249073, "ingredient1": "Amiodarone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294545/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Magnesium oxide, Linaclotide, Naloxone, More", "updated_at": 1767369485}, {"id": 249074, "ingredient1": "Amisulpride", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294546/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249075, "ingredient1": "Amitriptyline", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294547/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249076, "ingredient1": "Amoxapine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294548/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249077, "ingredient1": "Amphetamine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294549/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, More", "updated_at": 1767369485}, {"id": 249078, "ingredient1": "Anagrelide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294550/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249079, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Apalutamide", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294551/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249080, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Apomorphine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294552/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249081, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Aripiprazole", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294553/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249082, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Arsenic trioxide", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294554/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249083, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Asenapine", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294556/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249084, "ingredient1": "Acetylsalicylic acid", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294557/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Ticagrelor, Betrixaban, Clopidogrel, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, Magnesium citrate, More", "updated_at": 1767369485}, {"id": 249085, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Astemizole", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294558/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 249086, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Atomoxetine", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294559/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249087, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Azilsartan medoxomil", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294560/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249088, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Azithromycin", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294561/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Naloxone, More", "updated_at": 1767369485}, {"id": 249089, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Bedaquiline", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294562/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249090, "ingredient1": "Benazepril", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294563/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, More", "updated_at": 1767369485}, {"id": 249091, "ingredient1": "Bendroflumethiazide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294564/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249092, "ingredient1": "Benzphetamine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294565/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249093, "ingredient1": "Benzthiazide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294566/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 249094, "ingredient1": "Bepridil", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294567/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249095, "ingredient1": "Betamethasone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294568/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249096, "ingredient1": "Bethanechol", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294569/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ambenonium, Pilocarpine, Cevimeline, Pyridostigmine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249097, "ingredient1": "Bicalutamide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294570/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane, Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249098, "ingredient1": "Blinatumomab", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294571/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249099, "ingredient1": "Bosutinib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294572/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249100, "ingredient1": "Brexpiprazole", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294573/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249101, "ingredient1": "Bromfenac", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294574/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249102, "ingredient1": "Bumetanide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294575/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249103, "ingredient1": "Buprenorphine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294576/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249104, "ingredient1": "Bupropion", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294577/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249105, "ingredient1": "Burosumab", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "Concomitant use of burosumab with oral phosphate and/or active vitamin D analogs may increase the risk of hyperphosphatemia and hypervitaminosis D due to additive pharmacologic effects.", "source": "DDInter", "management_text": "Oral phosphate and active vitamin D analogs should be discontinued one week prior to initiation of burosumab treatment.  Fasting serum phosphorus concentration should be below the reference range for age prior to initiation of treatment.  Some authorities advise that, if necessary, vitamin D replacement or supplementation with inactive forms of vitamin D may be started or continued as per local guidelines and under serum calcium and phosphate monitoring.", "mechanism_text": "Synergism", "recommendation": "Oral phosphate and active vitamin D analogs should be discontinued one week prior to initiation of burosumab treatment.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294578/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Crysvita (burosumab).\" Ultragenyx Pharmaceutical  (2018):", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Etidronic acid, Denosumab, Ibandronate, Cholecalciferol, Risedronic acid, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Sodium sulfate, More", "updated_at": 1767369485}, {"id": 249106, "ingredient1": "Butorphanol", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294579/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249107, "ingredient1": "Cabozantinib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294580/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249108, "ingredient1": "Captopril", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294582/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 249109, "ingredient1": "Cariprazine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294583/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249110, "ingredient1": "Cefiderocol", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294584/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249111, "ingredient1": "Celecoxib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294585/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tamsulosin, Tinidazole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249112, "ingredient1": "Ceritinib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294586/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249113, "ingredient1": "Chloroquine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294587/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249114, "ingredient1": "Chlorothiazide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294588/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249115, "ingredient1": "Chlorpromazine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294589/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249116, "ingredient1": "Chlorthalidone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294590/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249117, "ingredient1": "Choline salicylate", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294591/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249118, "ingredient1": "Cilostazol", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294592/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ticagrelor, Betrixaban, Clopidogrel, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249119, "ingredient1": "Cinoxacin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294593/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249120, "ingredient1": "Ciprofloxacin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294594/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Tetracycline, Polymyxin B, Chloramphenicol, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Naloxone, Hydroxocobalamin, Fomepizole, More", "updated_at": 1767369485}, {"id": 249121, "ingredient1": "Cisapride", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294595/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249122, "ingredient1": "Citalopram", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294596/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249123, "ingredient1": "Clarithromycin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294597/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249124, "ingredient1": "Clofazimine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294598/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dapsone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249125, "ingredient1": "Clomipramine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294599/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249126, "ingredient1": "Clozapine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294600/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249127, "ingredient1": "Cocaine (nasal)", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294601/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249128, "ingredient1": "Codeine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294602/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone, Benzonatate, Clofedanol, Dextromethorphan, Pentoxyverine", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249129, "ingredient1": "Corticotropin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294604/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249130, "ingredient1": "Tetracosactide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294606/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Mecasermin rinfabate, Pegvisomant, Somapacitan", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249131, "ingredient1": "Crizotinib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294607/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249132, "ingredient1": "Cyclobenzaprine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294608/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Methocarbamol, Chlormezanone", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249133, "ingredient1": "Cycloserine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294609/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249134, "ingredient1": "Dalfampridine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294610/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249135, "ingredient1": "Dasatinib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294611/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249136, "ingredient1": "Daunorubicin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294612/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Rucaparib, Bortezomib, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249137, "ingredient1": "Doxorubicin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294613/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249138, "ingredient1": "Deflazacort", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294614/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249139, "ingredient1": "Degarelix", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294615/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249140, "ingredient1": "Delafloxacin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294616/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249141, "ingredient1": "Desipramine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294617/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249142, "ingredient1": "Desvenlafaxine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294618/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249143, "ingredient1": "Deutetrabenazine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294619/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249144, "ingredient1": "Dexamethasone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294620/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, Flunisolide, Olopatadine, Vitamin A, Fluticasone, Ipratropium, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate, Hydroxocobalamin, More", "updated_at": 1767369485}, {"id": 249145, "ingredient1": "Dexfenfluramine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294621/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249146, "ingredient1": "Dexmethylphenidate", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294622/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249147, "ingredient1": "Dextroamphetamine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294623/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249148, "ingredient1": "Dezocine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294624/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249149, "ingredient1": "Diclofenamide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294625/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249150, "ingredient1": "Diclofenac", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294626/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Fluocinolone acetonide, Fluorometholone, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 249151, "ingredient1": "Diethylpropion", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294627/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249152, "ingredient1": "Diflunisal", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294628/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249153, "ingredient1": "Disopyramide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294629/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249154, "ingredient1": "Dofetilide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294630/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249155, "ingredient1": "Dolasetron", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294631/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 249156, "ingredient1": "Donepezil", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294632/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249157, "ingredient1": "Doxapram", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294633/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Nitric Oxide, Ivacaftor, Elexacaftor, Lumacaftor", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249158, "ingredient1": "Doxepin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294634/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249159, "ingredient1": "Doxepin (topical)", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294635/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249160, "ingredient1": "Dronabinol", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294636/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249161, "ingredient1": "Dronedarone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294637/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, More", "updated_at": 1767369485}, {"id": 249162, "ingredient1": "Droperidol", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294638/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249163, "ingredient1": "Duloxetine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294639/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, Magnesium citrate, More", "updated_at": 1767369485}, {"id": 249164, "ingredient1": "Efavirenz", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294640/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249165, "ingredient1": "Enalapril", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294641/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 249166, "ingredient1": "Encorafenib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294642/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249167, "ingredient1": "Enoxacin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294643/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249168, "ingredient1": "Entrectinib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294644/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249169, "ingredient1": "Enzalutamide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294645/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249170, "ingredient1": "Ephedrine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294646/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Phenylephrine, Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249171, "ingredient1": "Epirubicin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294647/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249172, "ingredient1": "Eprosartan", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294648/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249173, "ingredient1": "Erdafitinib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib.  The mechanism appears to be related to the pharmacodynamic effects of fibroblast growth factor receptor (FGFR) inhibition by erdafitinib.  Inhibition of FGFR has been shown to lead to an increase in serum phosphate levels.", "source": "DDInter", "management_text": "Close monitoring for hyperphosphatemia is recommended throughout treatment with FGFR inhibitors such as erdafitinib and futibatinib, particularly when used concomitantly with agents that may alter serum phosphate levels.  Some authorities advise monthly phosphate level monitoring during treatment along with dose adjustment guidelines and use of phosphate-lowering therapy based on serum phosphate levels included in its product labeling.  The manufacturer of erdafitinib also recommends avoiding concomitant use with agents that may alter serum phosphate levels before its initial dose increase period, which is between 14 to 21 days of starting erdafitinib therapy and is based on serum phosphate levels.  If concomitant use with agents known to increase serum phosphate levels is required after this initial dose increase period, close monitoring of patient tolerability and serum phosphate levels is recommended.  To minimize the risk of hyperphosphatemia, some authorities also recommend that patients restrict their phosphate intake to 600 mg to 800 mg daily.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for hyperphosphatemia is recommended throughout treatment with FGFR inhibitors such as erdafitinib and futibatinib, particularly when used concomitantly with agents that may alter serum phosphate levels.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294649/", "reference_text": "[1] \"Product Information. Balversa (erdafitinib).\" Janssen Products, LP  (2019):[2] \"Product Information. Lytgobi (futibatinib).\" Taiho Oncology, Inc.  (2022):", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium sulfate, Linaclotide, Plecanatide, Lubiprostone, More", "updated_at": 1767369485}, {"id": 249174, "ingredient1": "Eribulin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294650/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249175, "ingredient1": "Ertapenem", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294651/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249176, "ingredient1": "Erythromycin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294652/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dirithromycin, Lincomycin, Troleandomycin, Clindamycin, Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Naloxone, Hydroxocobalamin, More", "updated_at": 1767369485}, {"id": 249177, "ingredient1": "Escitalopram", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294653/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 249178, "ingredient1": "Etacrynic acid", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294654/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249179, "ingredient1": "Etodolac", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294655/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 249180, "ingredient1": "Ezogabine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294656/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249181, "ingredient1": "Fenfluramine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294657/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone, Brivaracetam, Topiramate, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, Lacosamide, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249182, "ingredient1": "Fenoprofen", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294658/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249183, "ingredient1": "Fentanyl", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294659/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine, Dihydrocodeine, More", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 249184, "ingredient1": "Flecainide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294661/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249185, "ingredient1": "Fluconazole", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294662/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Caspofungin, Micafungin, Amphotericin B, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249186, "ingredient1": "Fludrocortisone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294663/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249187, "ingredient1": "Fluoxetine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294664/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249188, "ingredient1": "Fluphenazine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294665/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249189, "ingredient1": "Flurbiprofen", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294666/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Neomycin, Chlorhexidine, Povidone-iodine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249190, "ingredient1": "Flutamide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294667/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249191, "ingredient1": "Fluvoxamine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294668/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249192, "ingredient1": "Foscarnet", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294669/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249193, "ingredient1": "Fosinopril", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294670/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249194, "ingredient1": "Fostemsavir", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294671/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249195, "ingredient1": "Furosemide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294672/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249196, "ingredient1": "Galantamine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294673/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249197, "ingredient1": "Gatifloxacin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294674/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249198, "ingredient1": "Gemifloxacin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294675/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249199, "ingredient1": "Gilteritinib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294676/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, More", "updated_at": 1767369485}, {"id": 249200, "ingredient1": "Glasdegib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294677/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, More", "updated_at": 1767369485}, {"id": 249201, "ingredient1": "Goserelin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294678/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249202, "ingredient1": "Granisetron", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294679/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 249203, "ingredient1": "Grepafloxacin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294680/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249204, "ingredient1": "Halofantrine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294681/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249205, "ingredient1": "Haloperidol", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294682/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249206, "ingredient1": "Halothane", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294683/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249207, "ingredient1": "Diamorphine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294684/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249208, "ingredient1": "Histrelin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294685/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249209, "ingredient1": "Hydrochlorothiazide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294686/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Sacubitril, Aliskiren, Nebivolol, Amlodipine, Aliskiren, Tamsulosin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249210, "ingredient1": "Hydrocodone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294687/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Benzonatate, Clofedanol, Dextromethorphan, Pentoxyverine", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249211, "ingredient1": "Hydrocortisone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294688/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Tetracycline, Minocycline, Amphotericin B, Miconazole, Doxycycline, Metronidazole, Clotrimazole, Epinephrine, Chlorhexidine, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249212, "ingredient1": "Hydroflumethiazide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294689/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249213, "ingredient1": "Hydromorphone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294690/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 249214, "ingredient1": "Hydroxychloroquine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294691/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249215, "ingredient1": "Hydroxyzine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294692/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Clobazam, Meprobamate, Alprazolam, Lorazepam, Chlordiazepoxide, Halazepam, Clorazepic acid, Buspirone, Diazepam, Oxazepam", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249216, "ingredient1": "Ibuprofen", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294693/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Alprostadil, Ubidecarenone, Ivabradine, Adenosine, Regadenoson, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 249217, "ingredient1": "Ibutilide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294694/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249218, "ingredient1": "Idarubicin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294695/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Mitomycin, Dactinomycin", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249219, "ingredient1": "Iloperidone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294696/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249220, "ingredient1": "Imipramine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294697/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249221, "ingredient1": "Indapamide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294698/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249222, "ingredient1": "Indomethacin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294699/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Fluocinolone acetonide, Fluorometholone, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Fluocinolone acetonide, Fluorometholone, Tolazoline, Rabeprazole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Plecanatide, Magnesium citrate, Lubiprostone, More", "updated_at": 1767369485}, {"id": 249223, "ingredient1": "Inotuzumab ozogamicin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294700/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249224, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294701/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249225, "ingredient1": "Interferon alfa-2b", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294702/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249226, "ingredient1": "Interferon alfa-n1", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294703/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249227, "ingredient1": "Interferon alfa-n3", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294704/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249228, "ingredient1": "Interferon alfacon-1", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294705/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249229, "ingredient1": "Interferon beta-1a", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294706/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249230, "ingredient1": "Interferon gamma-1b", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294707/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249231, "ingredient1": "Irbesartan", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294708/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249232, "ingredient1": "Isocarboxazid", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294709/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249233, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Ivosidenib", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294710/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249234, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294711/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Linaclotide, Naloxone, More", "updated_at": 1767369485}, {"id": 249235, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Ketoprofen", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294712/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249236, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Ketorolac", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294713/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Homatropine, Atropine, Scopolamine, Methscopolamine, Tropicamide, Phenylephrine, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 249237, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294714/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249238, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294715/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Methenamine, Spectinomycin, Nitrofurantoin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249239, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Lenvatinib", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294716/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249240, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Leuprolide", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294717/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249241, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Levofloxacin", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294718/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249242, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294720/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249243, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Levomilnacipran", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294721/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249244, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294722/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249245, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Lidocaine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294723/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Procaine, Tetracaine, Clemastine, Tetracaine, Mepyramine, Diphenhydramine, Tripelennamine, Pheniramine, Neomycin, Chlorhexidine, Povidone-iodine, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249246, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Lindane", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294724/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Disulfiram", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249247, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Lisdexamfetamine", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294725/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249248, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Lisinopril", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294726/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 249249, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294727/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249250, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294728/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249251, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294729/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249252, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Losartan", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294730/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249253, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Loxapine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294731/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249254, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Lumateperone", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294732/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249255, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294733/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249256, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Macimorelin", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294735/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Galactose, Magnesium sulfate, Gonadorelin, Vitamin A, Caffeine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249257, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Mannitol", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294737/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Sorbitol, Sulfamethizole, Sodium citrate, Magnesium citrate, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Alvimopan, Sorbitol, Tegaserod, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249258, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294738/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249259, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Mazindol", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294739/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249260, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Meclofenamic acid", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294740/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249261, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Mefenamic acid", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294741/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Plecanatide, More", "updated_at": 1767369485}, {"id": 249262, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Mefloquine", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294742/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249263, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Meloxicam", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294743/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Ropivacaine, Chloroprocaine, Levobupivacaine, Tetracaine, Bupivacaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Rabeprazole, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 249264, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Meperidine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294744/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 249265, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Meropenem", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294745/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249266, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294746/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249267, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Methadone", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294747/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249268, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Metamfetamine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294748/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249269, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Methazolamide", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294749/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249270, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294750/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249271, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294751/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249272, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Methylphenidate", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294753/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249273, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Methylprednisolone", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294754/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Dapsone, Azelaic acid, Adapalene, Fluocinolone acetonide, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249274, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294755/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249275, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Metolazone", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294756/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249276, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294757/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249277, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Midostaurin", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294758/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249278, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Mifepristone", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294759/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249279, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Milnacipran", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294760/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249280, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294761/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249281, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Moexipril", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294763/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249282, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Molindone", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294764/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249283, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Morphine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294765/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 249284, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Moxifloxacin", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294766/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249285, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Muromonab", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294767/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249286, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Nabumetone", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294768/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 249287, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Nalbuphine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294769/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249288, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294770/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249289, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Naproxen", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294771/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Plecanatide, Magnesium citrate, Lubiprostone, More", "updated_at": 1767369485}, {"id": 249290, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294772/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 249291, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Nelarabine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294773/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Methotrexate, Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Cytarabine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249292, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Neostigmine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294774/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ambenonium, Pilocarpine, Cevimeline, Pyridostigmine, Latanoprost, Apraclonidine, Pilocarpine, Clonidine, Acetylcholine, Betaxolol, Bimatoprost, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249293, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294775/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249294, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Nilutamide", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294776/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249295, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294777/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249296, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294778/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249297, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Ofloxacin", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294779/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide, Hydroxocobalamin, More", "updated_at": 1767369485}, {"id": 249298, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Olanzapine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294780/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249299, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294781/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249300, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Olmesartan", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294782/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249301, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Ondansetron", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294783/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249302, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Opium", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294784/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249303, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294785/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249304, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Osimertinib", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294786/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249305, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294787/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249306, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Oxamniquine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294788/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Praziquantel", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249307, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Oxaprozin", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294789/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249308, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294790/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249309, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294791/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 249310, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Oxymorphone", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294792/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249311, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Oxytocin", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294793/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Methylergometrine, Misoprostol, Ergometrine, Dinoprostone, Terlipressin, Desmopressin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249312, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294795/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249313, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Palonosetron", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294796/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Aprepitant, Scopolamine, Nabilone, Rolapitant", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 249314, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Panobinostat", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294797/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249315, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Paroxetine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294798/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249316, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Pasireotide", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294799/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249317, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Pazopanib", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294800/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249318, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Peginterferon alfa-2a", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294801/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249319, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Peginterferon alfa-2b", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294802/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249320, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Peginterferon beta-1a", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294803/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249321, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Pemoline", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294804/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249322, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Pentamidine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294805/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Miltefosine, Nifurtimox, Benznidazole", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249323, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Pentazocine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294806/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249324, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Perflutren", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294807/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249325, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Perindopril", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294808/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, Plecanatide, More", "updated_at": 1767369485}, {"id": 249326, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Perphenazine", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294809/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249327, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Phendimetrazine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294810/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249328, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Phenelzine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294811/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249329, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Phentermine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294812/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249330, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Phenylbutazone", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294813/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249331, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Phenylpropanolamine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294814/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Phenylephrine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249332, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Physostigmine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294815/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Latanoprost, Apraclonidine, Pilocarpine, Clonidine, Acetylcholine, Betaxolol, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Guanethidine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249333, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Pimavanserin", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294816/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249334, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Pimozide", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294817/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249335, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Piperazine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294818/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Thiabendazole, Levamisole, Pyrantel, Ivermectin, Mebendazole, Albendazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249336, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Piroxicam", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294819/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Magnesium carbonate, Plecanatide, More", "updated_at": 1767369485}, {"id": 249337, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Pitolisant", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294820/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249338, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Polythiazide", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294821/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249339, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Posaconazole", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294823/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Itraconazole, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249340, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294824/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249341, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Prednisolone", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294825/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Mometasone furoate, Amcinonide, Budesonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249342, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Prednisone", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294826/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Budesonide, Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249343, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Primaquine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294827/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249344, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Probucol", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294828/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249345, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Procainamide", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294829/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249346, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Prochlorperazine", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294830/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249347, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Promazine", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294831/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249348, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294832/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 249349, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Propafenone", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294833/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249350, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294834/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249351, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Propofol", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294835/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 249352, "ingredient1": "Dextropropoxyphene", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294836/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249353, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294837/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249354, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Quetiapine", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294838/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249355, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Quinapril", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294839/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Lactitol, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 249356, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Quinidine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294840/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tocainide, Moricizine, Bretylium", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Linaclotide, Naloxone, Fomepizole, More", "updated_at": 1767369485}, {"id": 249357, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Quinine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294841/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249358, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Ramipril", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294842/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Naloxegol, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, More", "updated_at": 1767369485}, {"id": 249359, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Ranolazine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294843/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alprostadil, Ubidecarenone, Ivabradine, Adenosine, Regadenoson", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249360, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Relugolix", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294844/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249361, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Remifentanil", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294845/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249362, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Ribociclib", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294846/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249363, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Rilpivirine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294847/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249364, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Rimantadine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294848/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249365, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Risperidone", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294849/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249366, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Rivastigmine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294850/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249367, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Rofecoxib", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294851/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249368, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Romidepsin", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294852/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249369, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Salsalate", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294853/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Acetaminophen, Ziconotide, Methoxyflurane", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249370, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Saquinavir", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294854/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, More", "updated_at": 1767369485}, {"id": 249371, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Selpercatinib", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294855/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Linaclotide, Naloxone, Hydroxocobalamin, More", "updated_at": 1767369485}, {"id": 249372, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Sertraline", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294856/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249373, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Sevoflurane", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294857/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 249374, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Sibutramine", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294858/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lorcaserin, Orlistat, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249375, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Siponimod", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294859/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249376, "ingredient1": "Solifenacin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294862/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249377, "ingredient1": "Sorafenib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294863/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249378, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Sotalol", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294864/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acebutolol, Labetalol, Nadolol, Propranolol, Metoprolol, Carvedilol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249379, "ingredient1": "Sodium phosphate, monobasic", "ingredient2": "Sparfloxacin", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294865/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249380, "ingredient1": "Spironolactone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294867/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Eplerenone, Finerenone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, More", "updated_at": 1767369485}, {"id": 249381, "ingredient1": "Sufentanil", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294868/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Etomidate, Ketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249382, "ingredient1": "Sulindac", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294869/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249383, "ingredient1": "Sunitinib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294870/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249384, "ingredient1": "Tacrine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294871/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249385, "ingredient1": "Tacrolimus", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294872/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Phenolphthalein, Plecanatide, Magnesium citrate, Bisacodyl, Lactitol, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 249386, "ingredient1": "Tamoxifen", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294873/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249387, "ingredient1": "Tapentadol", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294874/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249388, "ingredient1": "Telavancin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294876/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Methenamine, Spectinomycin, Nitrofurantoin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249389, "ingredient1": "Telithromycin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294877/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dirithromycin, Lincomycin, Troleandomycin, Clindamycin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, Linaclotide, Naloxone, More", "updated_at": 1767369485}, {"id": 249390, "ingredient1": "Telmisartan", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294878/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249391, "ingredient1": "Terbutaline", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294879/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Formoterol, Orciprenaline, Pirbuterol, Isoprenaline, Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Budesonide, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, More", "updated_at": 1767369485}, {"id": 249392, "ingredient1": "Terfenadine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294880/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249393, "ingredient1": "Tetrabenazine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294881/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249394, "ingredient1": "Theophylline", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294882/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249395, "ingredient1": "Thiethylperazine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294883/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249396, "ingredient1": "Thioridazine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294884/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249397, "ingredient1": "Thiothixene", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294885/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249398, "ingredient1": "Tizanidine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294886/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Methocarbamol, Chlormezanone", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249399, "ingredient1": "Tolmetin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294887/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249400, "ingredient1": "Toremifene", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294888/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249401, "ingredient1": "Torasemide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294889/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249402, "ingredient1": "Tramadol", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294890/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Dihydrocodeine, Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249403, "ingredient1": "Trandolapril", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294891/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Felodipine, Amlodipine, Verapamil, Bisoprolol", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "updated_at": 1767369485}, {"id": 249404, "ingredient1": "Tranylcypromine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294892/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249405, "ingredient1": "Trazodone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294893/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249406, "ingredient1": "Triamcinolone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294894/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Mometasone furoate, Amcinonide, Budesonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249407, "ingredient1": "Triamcinolone (ophthalmic)", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The overuse or abuse of laxatives can cause significant loss of electrolytes and potentiate the risk of hypokalemia associated with corticosteroid therapy.  Corticosteroids promote the retention of sodium and water and the excretion of potassium.  Although these effects are primarily associated with mineralocorticoids like fludrocortisone, they may also occur with higher dosages of glucocorticoids or adrenocorticotropic agents, particularly if given systemically for longer than brief periods.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant therapy with corticosteroids, particularly if fludrocortisone or large doses of a glucocorticoid or adrenocorticotropic agent is given, patients should be counseled to recognize potential signs and symptoms of hypokalemia such as fatigue, myalgia, and muscle weakness.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294895/", "reference_text": "[1] Seale JP, Compton MR \"Side-effects of corticosteroid agents.\" Med J Aust 144 (1986):  139-42[2] Lieberman P, Patterson R, Kunske R \"Complications of long-term steroid therapy for asthma.\" J Allergy Clin Immunol 49 (1972):  329-36[3] Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF \"The mineralocorticoid effects of high dose hydrocortisone.\" BMJ 310 (1995):  656-7[4] Swartz SL, Dluhy RG \"Corticosteroids: clinical pharmacology and therapeutic use.\" Drugs 16 (1978):  238-55[5] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[6] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[7] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45", "alternatives_a": "Mometasone furoate, Amcinonide, Budesonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Ciclesonide, More", "alternatives_b": "Alvimopan, Sodium sulfate, Sorbitol, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249408, "ingredient1": "Triamterene", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294896/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Eplerenone, Finerenone", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249409, "ingredient1": "Trichlormethiazide", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294897/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, More", "updated_at": 1767369485}, {"id": 249410, "ingredient1": "Triclabendazole", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294898/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Praziquantel", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249411, "ingredient1": "Trifluoperazine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294899/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249412, "ingredient1": "Triflupromazine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294900/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249413, "ingredient1": "Alimemazine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294901/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Phenolphthalein, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249414, "ingredient1": "Trimipramine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294902/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249415, "ingredient1": "Triptorelin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294903/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249416, "ingredient1": "Trovafloxacin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294904/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Prucalopride, Linaclotide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249417, "ingredient1": "Urea", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294905/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Tromethamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249418, "ingredient1": "Valbenazine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294906/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Inotersen, Tafamidis", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Magnesium oxide, More", "updated_at": 1767369485}, {"id": 249419, "ingredient1": "Valdecoxib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294907/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249420, "ingredient1": "Valsartan", "ingredient2": "Sodium phosphate, monobasic", "severity": "Major", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.  Bowel-cleansing phosphate preparations should not be used in patients who have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  In patients at risk for acute phosphate nephropathy, baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be performed.  Patients should be advised not to exceed the recommended dosage of their bowel-cleansing preparation and to drink sufficient quantities of clear fluids during before, during, and after bowel cleansing.  Limited data suggest that administration of an electrolyte rehydration solution may attenuate the electrolyte abnormalities and hypovolemia.  Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel-cleansing phosphate preparations are prescribed in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294908/", "reference_text": "[1] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[2] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[3] FDA. Food and Drug Admnistration \"Oral sodium phosphate products for bowel cleansing.  http://www.fda.gov/cder/drug/InfoSheets/HCP/OSP_solutionHCP.pdf\"   (2007):", "alternatives_a": "Amlodipine, Sacubitril, Aliskiren, Nebivolol, Amlodipine, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, More", "alternatives_b": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, Linaclotide, Magnesium carbonate, More", "updated_at": 1767369485}, {"id": 249421, "ingredient1": "Vandetanib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294909/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Dabrafenib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, Cobimetinib, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "updated_at": 1767369485}, {"id": 249422, "ingredient1": "Vardenafil", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294910/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249423, "ingredient1": "Vasopressin", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294911/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249424, "ingredient1": "Vemurafenib", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294912/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249425, "ingredient1": "Venlafaxine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interactions apply only to products containing sodium biphosphate that are used for bowel cleansing.  They do not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold and/or prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294913/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[5] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[6] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[9] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Naldemedine, Prucalopride, More", "updated_at": 1767369485}, {"id": 249426, "ingredient1": "Vilazodone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294914/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249427, "ingredient1": "Voriconazole", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294916/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Itraconazole, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Prucalopride, More", "updated_at": 1767369485}, {"id": 249428, "ingredient1": "Vortioxetine", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294917/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "alternatives_b": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "updated_at": 1767369485}, {"id": 249429, "ingredient1": "Ziprasidone", "ingredient2": "Sodium phosphate, monobasic", "severity": "Moderate", "effect": "The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing.  It does not apply to products containing sodium biphosphate that are used for other, non-laxative related purposes.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.  Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly.  Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process.  Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose.  Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.", "mechanism_text": "Others", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/294918/", "reference_text": "[1] Hill AG, Parry BR \"Hypokalaemia following bowel cleansing with sodium phosphate.\" N Z Med J 109 (1996):  347[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249430, "ingredient1": "Dextropropoxyphene", "ingredient2": "Bumetanide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295225/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 249431, "ingredient1": "Dextropropoxyphene", "ingredient2": "Chlorothiazide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295226/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Methyclothiazide, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Tramadol, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 249432, "ingredient1": "Doxazosin", "ingredient2": "Dextropropoxyphene", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295227/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naloxone, Naltrexone, Tapentadol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249433, "ingredient1": "Eplerenone", "ingredient2": "Dextropropoxyphene", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295228/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Dezocine, Tramadol, Methadone, Naloxone, Nalbuphine", "alternatives_b": "Finerenone", "updated_at": 1767369485}, {"id": 249434, "ingredient1": "Guanfacine", "ingredient2": "Dextropropoxyphene", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295229/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Acetaminophen, Dezocine, Tramadol, Methadone, Ibuprofen, Celecoxib, Acetylsalicylic acid, More", "alternatives_b": "Rauwolfia serpentina root, Reserpine, Deserpidine", "updated_at": 1767369485}, {"id": 249435, "ingredient1": "Diamorphine", "ingredient2": "Dextropropoxyphene", "severity": "Major", "effect": "Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene.", "source": "DDInter", "management_text": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.  Dosage reductions may be appropriate.  Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects.  Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295230/", "reference_text": "[1] Abernethy DR, Greenblatt DJ, Morse DS, Shader RI \"Interaction of propoxyphene with diazepam, alprazolam and lorazepam.\" Br J Clin Pharmacol 19 (1985):  51-7[2] Hansen BS, Dam M, Brandt J, et al. \"Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man.\" Acta Neurol Scand 61 (1980):  357-67[3] Abernethy DR, Greenblatt DJ, Steel K, Shader RI \"Impairment of hepatic drug oxidation by propoxyphene.\" Ann Intern Med 97 (1982):  223-4[4] Peterson GR, Covault HP, Hostetler RM \"Acute inhibition of microsomal drug metabolism by propoxphene in narcotic tolerant/dependent mice.\" Life Sci 22 (1978):  2087-96[5] Shorr RI, Griffin MR, Daugherty JR, Ray WA \"Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene.\" J Gerontol 47 (1992):  m111-5[6] Puckett WH Jr, Visconti JA \"Orphenadrine and propoxyphene.\" N Engl J Med 283 (1970):  544[7] Pearson RE, Salter FJ \"Drug interaction? Orphenadrine with propoxyphene.\" N Engl J Med 282 (1970):  1215[8] \"Product Information. Darvon (propoxyphene).\" Lilly, Eli and Company  (2001):", "alternatives_a": "Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid", "alternatives_b": "Acamprosate, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 249436, "ingredient1": "Dextropropoxyphene", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295231/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249437, "ingredient1": "Dextropropoxyphene", "ingredient2": "Prazosin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295232/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tramadol, Naloxone, Naltrexone, Tapentadol", "alternatives_b": "Rauwolfia serpentina root, Reserpine, Deserpidine", "updated_at": 1767369485}, {"id": 249438, "ingredient1": "Dextropropoxyphene", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene.", "source": "DDInter", "management_text": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.  Dosage reductions may be appropriate.  Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects.  Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295233/", "reference_text": "[1] Abernethy DR, Greenblatt DJ, Morse DS, Shader RI \"Interaction of propoxyphene with diazepam, alprazolam and lorazepam.\" Br J Clin Pharmacol 19 (1985):  51-7[2] Hansen BS, Dam M, Brandt J, et al. \"Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man.\" Acta Neurol Scand 61 (1980):  357-67[3] Abernethy DR, Greenblatt DJ, Steel K, Shader RI \"Impairment of hepatic drug oxidation by propoxyphene.\" Ann Intern Med 97 (1982):  223-4[4] Peterson GR, Covault HP, Hostetler RM \"Acute inhibition of microsomal drug metabolism by propoxphene in narcotic tolerant/dependent mice.\" Life Sci 22 (1978):  2087-96[5] Shorr RI, Griffin MR, Daugherty JR, Ray WA \"Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene.\" J Gerontol 47 (1992):  m111-5[6] Puckett WH Jr, Visconti JA \"Orphenadrine and propoxyphene.\" N Engl J Med 283 (1970):  544[7] Pearson RE, Salter FJ \"Drug interaction? Orphenadrine with propoxyphene.\" N Engl J Med 282 (1970):  1215[8] \"Product Information. Darvon (propoxyphene).\" Lilly, Eli and Company  (2001):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone", "alternatives_b": "Viloxazine", "updated_at": 1767369485}, {"id": 249439, "ingredient1": "Dextropropoxyphene", "ingredient2": "Terazosin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295234/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naloxone, Naltrexone, Tapentadol", "alternatives_b": "Finasteride, Dutasteride, Tadalafil", "updated_at": 1767369485}, {"id": 249440, "ingredient1": "Dextropropoxyphene", "ingredient2": "Upadacitinib", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295235/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Oliceridine, Naltrexone, Oxymorphone, Tapentadol, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Fentanyl, Methadone, Naloxone, Nalbuphine", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 249441, "ingredient1": "Bazedoxifene", "ingredient2": "Apalutamide", "severity": "Moderate", "effect": "Coadministration with apalutamide may decrease the plasma concentrations of drugs that are substrates of the metabolic enzymes CYP450 3A4, CYP450 2C19, CYP450 2C9, and uridine diphosphate glucuronosyltransferase (UGT), as well as substrates of the membrane transporters organic anion transporting polypeptide (OATP) 1B1, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP).", "source": "DDInter", "management_text": "Caution is advised when apalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, CYP450 2C19, CYP450 2C9, UGT, OATP1B1, P-gp and/or BCRP, particularly sensitive substrates or those with a narrow therapeutic range.  Substitution for these medications is recommended when possible, or monitor for potential loss of therapeutic efficacy if coadministration is required.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a CYP450 inducer like apalutamide and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when apalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, CYP450 2C19, CYP450 2C9, UGT, OATP1B1, P-gp and/or BCRP, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295237/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Erleada (apalutamide).\" Janssen Biotech, Inc.  (2018):", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Enzalutamide, Relugolix, Bicalutamide, More", "alternatives_b": "Raloxifene, Prasterone, Danazol, Diethylstilbestrol", "updated_at": 1767369485}, {"id": 249442, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Conjugated estrogens", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.  Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors.  Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295238/", "reference_text": "[1] \"Product Information. Cinryze (C1 esterase inhibitor, human).\" ViroPharma Incorporated  (2022):[2] \"Product Information. Berinert (C1 esterase inhibitor, human).\" CSL Behring LLC  (2022):[3] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012):  902-9[4] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals  (2015):", "alternatives_a": "Betibeglogene autotemcel, Streptokinase, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249443, "ingredient1": "Human C1-esterase inhibitor", "ingredient2": "Bazedoxifene", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.  Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors.  Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295239/", "reference_text": "[1] \"Product Information. Cinryze (C1 esterase inhibitor, human).\" ViroPharma Incorporated  (2022):[2] \"Product Information. Berinert (C1 esterase inhibitor, human).\" CSL Behring LLC  (2022):[3] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012):  902-9[4] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals  (2015):", "alternatives_a": "Mifepristone, Ulipristal", "alternatives_b": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 249444, "ingredient1": "Carbamazepine", "ingredient2": "Bazedoxifene", "severity": "Moderate", "effect": "Coadministration of bazedoxifene with inducers of uridine diphosphate glucuronosyl transferase (UGT) enzymes may decrease the plasma concentrations of bazedoxifene, which is primarily metabolized by UGT1A1, 1A8, and 1A10, and to a lesser extent, UGT1A9.  A reduction in bazedoxifene exposure may be associated with an increased risk of endometrial hyperplasia.", "source": "DDInter", "management_text": "Dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from bazedoxifene therapy.  If bleeding occurs, appropriate diagnostic measures should be implemented to exclude endometrial hyperplasia.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from bazedoxifene therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295240/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):[4] Shen L, Ahmad S, Park S, et al. \"In vitro metabolism, permeability, and efflux of bazedoxifene in humans.\" Drug Metab Dispos 38 (2010):  1471-9", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Prasterone, Diethylstilbestrol", "updated_at": 1767369485}, {"id": 249445, "ingredient1": "Carfilzomib", "ingredient2": "Bazedoxifene", "severity": "Major", "effect": "Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have occurred during treatment with carfilzomib, and concurrent use of other agents also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when carfilzomib is used with other drugs that can increase the risk of thrombosis.  Thromboprophylaxis should be considered according to local treatment protocols.  Close monitoring for thromboembolic events is recommended in patients with known risk factors (e.g., prior thrombosis, hyperlipidemia, hypertension, smoking) for thromboembolism.  Patients should be advised to seek immediate medical attention if they develop symptoms of thromboembolism, such as shortness of breath, chest pain, hemoptysis, or arm or leg swelling or pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when carfilzomib is used with other drugs that can increase the risk of thrombosis.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295241/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Kyprolis (carfilzomib).\" Onyx Pharmaceuticals Inc  (2012):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "Mifepristone, Ulipristal", "updated_at": 1767369485}, {"id": 249446, "ingredient1": "Conestat alfa", "ingredient2": "Bazedoxifene", "severity": "Moderate", "effect": "Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.  Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors.  Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis-stimulating agents, or selective estrogen receptor modulators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295242/", "reference_text": "[1] \"Product Information. Cinryze (C1 esterase inhibitor, human).\" ViroPharma Incorporated  (2022):[2] \"Product Information. Berinert (C1 esterase inhibitor, human).\" CSL Behring LLC  (2022):[3] Gandhi PK, Gentry WM, Bottorff MB \"Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.\" Pharmacotherapy 32 (2012):  902-9[4] \"Product Information. Ruconest (conestat alfa).\" Valeant Pharmaceuticals  (2015):", "alternatives_a": "Hemin, Voxelotor, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "Mifepristone, Ulipristal", "updated_at": 1767369485}, {"id": 249447, "ingredient1": "Drospirenone", "ingredient2": "Bazedoxifene", "severity": "Moderate", "effect": "The use of bazedoxifene-conjugated estrogens in combination with progestins has not been evaluated.  Safety and efficacy of this combination are unknown.", "source": "DDInter", "management_text": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.  Since the bazedoxifene component is intended to reduce the risk of endometrial hyperplasia, a possible precursor to endometrial cancer, there should be no need for progestin therapy under such circumstances.", "mechanism_text": "Others", "recommendation": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295243/", "reference_text": "[1] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):", "alternatives_a": "Ulipristal, Norelgestromin, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Estetrol, Ethinylestradiol, Norgestimate, Etynodiol, More", "alternatives_b": "Ospemifene, Prasterone, Raloxifene, Conjugated estrogens, Estrone, Diethylstilbestrol, Estradiol, Chlorotrianisene, Ethinylestradiol", "updated_at": 1767369485}, {"id": 249448, "ingredient1": "Etonogestrel", "ingredient2": "Bazedoxifene", "severity": "Moderate", "effect": "The use of bazedoxifene-conjugated estrogens in combination with progestins has not been evaluated.  Safety and efficacy of this combination are unknown.", "source": "DDInter", "management_text": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.  Since the bazedoxifene component is intended to reduce the risk of endometrial hyperplasia, a possible precursor to endometrial cancer, there should be no need for progestin therapy under such circumstances.", "mechanism_text": "Others", "recommendation": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295244/", "reference_text": "[1] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):", "alternatives_a": "Ulipristal, Norelgestromin, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Estetrol, Ethinylestradiol", "alternatives_b": "Ospemifene, Raloxifene, Prasterone, Danazol, Conjugated estrogens, Estrone, Diethylstilbestrol, Estradiol, Chlorotrianisene, Ethinylestradiol", "updated_at": 1767369485}, {"id": 249449, "ingredient1": "Fosphenytoin", "ingredient2": "Bazedoxifene", "severity": "Moderate", "effect": "Coadministration of bazedoxifene with inducers of uridine diphosphate glucuronosyl transferase (UGT) enzymes may decrease the plasma concentrations of bazedoxifene, which is primarily metabolized by UGT1A1, 1A8, and 1A10, and to a lesser extent, UGT1A9.  A reduction in bazedoxifene exposure may be associated with an increased risk of endometrial hyperplasia.", "source": "DDInter", "management_text": "Dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from bazedoxifene therapy.  If bleeding occurs, appropriate diagnostic measures should be implemented to exclude endometrial hyperplasia.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from bazedoxifene therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295246/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):[4] Shen L, Ahmad S, Park S, et al. \"In vitro metabolism, permeability, and efflux of bazedoxifene in humans.\" Drug Metab Dispos 38 (2010):  1471-9", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Raloxifene, Prasterone, Danazol, Diethylstilbestrol", "updated_at": 1767369485}, {"id": 249450, "ingredient1": "Bazedoxifene", "ingredient2": "Lenalidomide", "severity": "Major", "effect": "Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of lenalidomide.", "source": "DDInter", "management_text": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone.  Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.  It is not known whether prophylactic anticoagulation or antiplatelet therapy may lessen the risk of venous thromboembolic events.  The decision to take prophylactic measures should be done carefully after a thorough assessment of underlying risk factors.  If a thromboembolic event occurs during therapy with lenalidomide, treatment must be discontinued and standard anticoagulation therapy initiated.  Once anticoagulation is stabilized and complications of the thromboembolic event under control, lenalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks.  Anticoagulation therapy should be continued during the remaining course of lenalidomide treatment.", "mechanism_text": "Synergism", "recommendation": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving lenalidomide with dexamethasone.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295248/", "reference_text": "[1] \"Product Information. Revlimid (lenalidomide).\" Celgene Corporation  (2006):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Mifepristone, Prasterone", "updated_at": 1767369485}, {"id": 249451, "ingredient1": "Bazedoxifene", "ingredient2": "Levonorgestrel", "severity": "Moderate", "effect": "The use of bazedoxifene-conjugated estrogens in combination with progestins has not been evaluated.  Safety and efficacy of this combination are unknown.", "source": "DDInter", "management_text": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.  Since the bazedoxifene component is intended to reduce the risk of endometrial hyperplasia, a possible precursor to endometrial cancer, there should be no need for progestin therapy under such circumstances.", "mechanism_text": "Others", "recommendation": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295249/", "reference_text": "[1] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):", "alternatives_a": "Ulipristal, Norelgestromin, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Estetrol, Ethinylestradiol, Norgestimate, Etynodiol, More", "alternatives_b": "Ospemifene, Raloxifene, Prasterone, Danazol, Conjugated estrogens, Estrone, Diethylstilbestrol, Chlorotrianisene, Ethinylestradiol", "updated_at": 1767369485}, {"id": 249452, "ingredient1": "Bazedoxifene", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration with lorlatinib may decrease the plasma concentrations of drugs that are substrates of the uridine diphosphate glucuronosyl transferase (UGT) enzymes.  The proposed mechanism involves increased metabolic clearance due to induction of UGT by lorlatinib.", "source": "DDInter", "management_text": "Caution is advised when lorlatinib is used concurrently with drugs that are known UGT substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lorlatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when lorlatinib is used concurrently with drugs that are known UGT substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295250/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group  (2018):", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "alternatives_b": "Ospemifene, Prasterone, Raloxifene, Diethylstilbestrol", "updated_at": 1767369485}, {"id": 249453, "ingredient1": "Bazedoxifene", "ingredient2": "Medroxyprogesterone acetate", "severity": "Moderate", "effect": "The use of bazedoxifene-conjugated estrogens in combination with progestins has not been evaluated.  Safety and efficacy of this combination are unknown.", "source": "DDInter", "management_text": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.  Since the bazedoxifene component is intended to reduce the risk of endometrial hyperplasia, a possible precursor to endometrial cancer, there should be no need for progestin therapy under such circumstances.", "mechanism_text": "Others", "recommendation": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295251/", "reference_text": "[1] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):", "alternatives_a": "Ulipristal, Norelgestromin, Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Estetrol, Ethinylestradiol, Dienogest, Etynodiol, More", "alternatives_b": "Prasterone, Danazol, Conjugated estrogens, Estrone, Diethylstilbestrol, Estradiol, Chlorotrianisene, Ethinylestradiol", "updated_at": 1767369485}, {"id": 249454, "ingredient1": "Bazedoxifene", "ingredient2": "Megestrol acetate", "severity": "Moderate", "effect": "The use of bazedoxifene-conjugated estrogens in combination with progestins has not been evaluated.  Safety and efficacy of this combination are unknown.", "source": "DDInter", "management_text": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.  Since the bazedoxifene component is intended to reduce the risk of endometrial hyperplasia, a possible precursor to endometrial cancer, there should be no need for progestin therapy under such circumstances.", "mechanism_text": "Others", "recommendation": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295252/", "reference_text": "[1] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):", "alternatives_a": "Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Dienogest, Etynodiol, Ulipristal, Norelgestromin, Norgestimate, Etynodiol, More", "alternatives_b": "Ulipristal, Danazol, Ospemifene, Raloxifene, Prasterone, Conjugated estrogens, Estrone, Diethylstilbestrol, Estradiol, Chlorotrianisene, Ethinylestradiol", "updated_at": 1767369485}, {"id": 249455, "ingredient1": "Bazedoxifene", "ingredient2": "Norethisterone", "severity": "Moderate", "effect": "The use of bazedoxifene-conjugated estrogens in combination with progestins has not been evaluated.  Safety and efficacy of this combination are unknown.", "source": "DDInter", "management_text": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.  Since the bazedoxifene component is intended to reduce the risk of endometrial hyperplasia, a possible precursor to endometrial cancer, there should be no need for progestin therapy under such circumstances.", "mechanism_text": "Others", "recommendation": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295254/", "reference_text": "[1] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):", "alternatives_a": "Nafarelin, Octreotide, Elagolix, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Relugolix, Lanreotide, Gonadorelin, Ulipristal, More", "alternatives_b": "Ospemifene, Prasterone, Danazol, Conjugated estrogens, Estrone, Diethylstilbestrol, Chlorotrianisene, Ethinylestradiol", "updated_at": 1767369485}, {"id": 249456, "ingredient1": "Bazedoxifene", "ingredient2": "Norgestrel", "severity": "Moderate", "effect": "The use of bazedoxifene-conjugated estrogens in combination with progestins has not been evaluated.  Safety and efficacy of this combination are unknown.", "source": "DDInter", "management_text": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.  Since the bazedoxifene component is intended to reduce the risk of endometrial hyperplasia, a possible precursor to endometrial cancer, there should be no need for progestin therapy under such circumstances.", "mechanism_text": "Others", "recommendation": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295255/", "reference_text": "[1] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):", "alternatives_a": "Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Ulipristal, Norelgestromin, Norgestimate, Etynodiol, Estradiol, Desogestrel, More", "alternatives_b": "Ospemifene, Raloxifene, Prasterone, Danazol, Conjugated estrogens, Estrone, Diethylstilbestrol, Estradiol, Chlorotrianisene, Ethinylestradiol", "updated_at": 1767369485}, {"id": 249457, "ingredient1": "Bazedoxifene", "ingredient2": "Ospemifene", "severity": "Moderate", "effect": "The concurrent use of ospemifene with estrogens or other estrogen agonists/antagonists has not been evaluated.", "source": "DDInter", "management_text": "Due to the lack of clinical data, concomitant use of ospemifene with estrogens or other estrogen agonists/antagonists is not recommended.", "mechanism_text": "Others", "recommendation": "Due to the lack of clinical data, concomitant use of ospemifene with estrogens or other estrogen agonists/antagonists is not recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295257/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Osphena (ospemifene).\" Shionogi USA Inc  (2013):", "alternatives_a": "Ulipristal, Danazol, Mifepristone, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Ospemifene, Ulipristal, Prasterone, Danazol", "updated_at": 1767369485}, {"id": 249458, "ingredient1": "Bazedoxifene", "ingredient2": "Phenobarbital", "severity": "Moderate", "effect": "Coadministration of bazedoxifene with inducers of uridine diphosphate glucuronosyl transferase (UGT) enzymes may decrease the plasma concentrations of bazedoxifene, which is primarily metabolized by UGT1A1, 1A8, and 1A10, and to a lesser extent, UGT1A9.  A reduction in bazedoxifene exposure may be associated with an increased risk of endometrial hyperplasia.", "source": "DDInter", "management_text": "Dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from bazedoxifene therapy.  If bleeding occurs, appropriate diagnostic measures should be implemented to exclude endometrial hyperplasia.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from bazedoxifene therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295258/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):[4] Shen L, Ahmad S, Park S, et al. \"In vitro metabolism, permeability, and efflux of bazedoxifene in humans.\" Drug Metab Dispos 38 (2010):  1471-9", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "Raloxifene, Prasterone, Danazol, Diethylstilbestrol", "updated_at": 1767369485}, {"id": 249459, "ingredient1": "Bazedoxifene", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Coadministration of bazedoxifene with inducers of uridine diphosphate glucuronosyl transferase (UGT) enzymes may decrease the plasma concentrations of bazedoxifene, which is primarily metabolized by UGT1A1, 1A8, and 1A10, and to a lesser extent, UGT1A9.  A reduction in bazedoxifene exposure may be associated with an increased risk of endometrial hyperplasia.", "source": "DDInter", "management_text": "Dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from bazedoxifene therapy.  If bleeding occurs, appropriate diagnostic measures should be implemented to exclude endometrial hyperplasia.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from bazedoxifene therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295259/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):[4] Shen L, Ahmad S, Park S, et al. \"In vitro metabolism, permeability, and efflux of bazedoxifene in humans.\" Drug Metab Dispos 38 (2010):  1471-9", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Prasterone, Danazol, Diethylstilbestrol", "updated_at": 1767369485}, {"id": 249460, "ingredient1": "Bazedoxifene", "ingredient2": "Pomalidomide", "severity": "Major", "effect": "Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, estrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of pomalidomide.", "source": "DDInter", "management_text": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving pomalidomide.  Prophylactic antithrombotic measures should be considered after assessing underlying risk factors such as health history and concomitant medications.  Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.", "mechanism_text": "Synergism", "recommendation": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving pomalidomide.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295260/", "reference_text": "[1] \"Product Information. Pomalyst (pomalidomide).\" QLT Phototherapeutics Inc  (2013):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Mifepristone, Ulipristal, Prasterone, Danazol", "updated_at": 1767369485}, {"id": 249461, "ingredient1": "Bazedoxifene", "ingredient2": "Primidone", "severity": "Moderate", "effect": "Coadministration of bazedoxifene with inducers of uridine diphosphate glucuronosyl transferase (UGT) enzymes may decrease the plasma concentrations of bazedoxifene, which is primarily metabolized by UGT1A1, 1A8, and 1A10, and to a lesser extent, UGT1A9.  A reduction in bazedoxifene exposure may be associated with an increased risk of endometrial hyperplasia.", "source": "DDInter", "management_text": "Dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from bazedoxifene therapy.  If bleeding occurs, appropriate diagnostic measures should be implemented to exclude endometrial hyperplasia.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from bazedoxifene therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295261/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):[4] Shen L, Ahmad S, Park S, et al. \"In vitro metabolism, permeability, and efflux of bazedoxifene in humans.\" Drug Metab Dispos 38 (2010):  1471-9", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More", "alternatives_b": "Prasterone, Danazol, Diethylstilbestrol", "updated_at": 1767369485}, {"id": 249462, "ingredient1": "Bazedoxifene", "ingredient2": "Progesterone", "severity": "Moderate", "effect": "The use of bazedoxifene-conjugated estrogens in combination with progestins has not been evaluated.  Safety and efficacy of this combination are unknown.", "source": "DDInter", "management_text": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.  Since the bazedoxifene component is intended to reduce the risk of endometrial hyperplasia, a possible precursor to endometrial cancer, there should be no need for progestin therapy under such circumstances.", "mechanism_text": "Others", "recommendation": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295262/", "reference_text": "[1] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):", "alternatives_a": "Norgestimate, Etynodiol, Estradiol, Desogestrel, Dienogest, Dienogest, Etynodiol", "alternatives_b": "Ospemifene, Ulipristal, Prasterone, Danazol, Conjugated estrogens, Estrone, Diethylstilbestrol, Chlorotrianisene, Ethinylestradiol", "updated_at": 1767369485}, {"id": 249463, "ingredient1": "Bazedoxifene", "ingredient2": "Progesterone (topical)", "severity": "Moderate", "effect": "The use of bazedoxifene-conjugated estrogens in combination with progestins has not been evaluated.  Safety and efficacy of this combination are unknown.", "source": "DDInter", "management_text": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.  Since the bazedoxifene component is intended to reduce the risk of endometrial hyperplasia, a possible precursor to endometrial cancer, there should be no need for progestin therapy under such circumstances.", "mechanism_text": "Others", "recommendation": "Women treated with bazedoxifene-conjugated estrogens should not receive progestins, which have often been used to mitigate the risk of endometrial cancer associated with estrogen therapy in patients with an intact uterus.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295263/", "reference_text": "[1] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):", "alternatives_a": "Ulipristal, Danazol, Ospemifene, Raloxifene, Prasterone, Conjugated estrogens, Estrone, Diethylstilbestrol, Estradiol, Chlorotrianisene, Ethinylestradiol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249464, "ingredient1": "Bazedoxifene", "ingredient2": "Rifampicin", "severity": "Moderate", "effect": "Coadministration of bazedoxifene with inducers of uridine diphosphate glucuronosyl transferase (UGT) enzymes may decrease the plasma concentrations of bazedoxifene, which is primarily metabolized by UGT1A1, 1A8, and 1A10, and to a lesser extent, UGT1A9.  A reduction in bazedoxifene exposure may be associated with an increased risk of endometrial hyperplasia.", "source": "DDInter", "management_text": "Dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from bazedoxifene therapy.  If bleeding occurs, appropriate diagnostic measures should be implemented to exclude endometrial hyperplasia.", "mechanism_text": "Metabolism", "recommendation": "Dosage adjustments as well as increased clinical and laboratory monitoring should be considered whenever a UGT inducer is added to or withdrawn from bazedoxifene therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295264/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Duavee (bazedoxifene-conjugated estrogens).\" Pfizer U.S. Pharmaceuticals Group  (2013):[4] Shen L, Ahmad S, Park S, et al. \"In vitro metabolism, permeability, and efflux of bazedoxifene in humans.\" Drug Metab Dispos 38 (2010):  1471-9", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, More", "alternatives_b": "Raloxifene, Prasterone, Danazol, Diethylstilbestrol", "updated_at": 1767369485}, {"id": 249465, "ingredient1": "Conjugated estrogens", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration of oral estrogen replacement therapy may diminish the therapeutic effects of human growth hormone.  Some of the pharmacodynamic effects of human growth hormone are primarily mediated by insulin-like growth factor 1 (IGF-1), and orally administered estrogen can suppress growth hormone (GH)-dependent IGF-1 production in the liver.", "source": "DDInter", "management_text": "Patients receiving human growth hormone with oral estrogen replacement therapy should be monitored for potentially diminished GH efficacy.  A higher dosage of growth hormone may be required to maintain serum IGF-1 levels within the normal age-appropriate range in order to achieve the defined treatment goal.  Please consult individual product labeling for the appropriate initial dosage of growth hormone recommended.  Dosage adjustments as well as clinical and laboratory monitoring should be considered following the addition or discontinuation of oral estrogen replacement therapy during use of growth hormone.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving human growth hormone with oral estrogen replacement therapy should be monitored for potentially diminished GH efficacy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295265/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cook DM, Ludlam WH, Cook MB \"Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults.\" J Clin Endocrinol Metab 84 (1999):  3956-60", "alternatives_a": "Bazedoxifene", "alternatives_b": "Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 249466, "ingredient1": "Conjugated estrogens", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins.  Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.  The interaction has been reported primarily with oral contraceptives.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.  For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers.  Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).  Individual product labeling should be consulted for specific time frames.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Patients should be advised to notify their physician if they experience inadequate control of symptoms associated with estrogen deficiency (e.g., nocturnal sweating, vasomotor disturbances, atrophic vaginitis) or changes in the uterine bleeding profile.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295266/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[3] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[4] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984):  1125-6[5] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986):  384[6] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990):  124-5[7] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[8] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[9] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990):  101-5[10] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990):  241-7[11] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[12] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[13] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[14] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[15] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[16] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[17] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[19] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[20] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[21] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[22] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984):  1125-6[23] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[24] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[25] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[26] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[27] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[28] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories  (2001):[30] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[31] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[32] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[33] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[34] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[35] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[36] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[37] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[38] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000):  598-604[39] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[40] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[41] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[42] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003):  112-113[43] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003):  683-90[44] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003):  525-35[45] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002):  P25[46] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001):  A25[47] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Diethylstilbestrol, Bazedoxifene", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Duloxetine, Isocarboxazid, Esketamine, Phenelzine, More", "updated_at": 1767369485}, {"id": 249467, "ingredient1": "Tafamidis", "ingredient2": "Bazedoxifene", "severity": "Moderate", "effect": "Based on in vitro data, coadministration with tafamidis may increase the plasma concentrations and the risk of toxicity of drugs that are substrates of the transport protein breast cancer resistance protein (BCRP) (e.g., methotrexate, rosuvastatin, imatinib), uridine diphosphate glucuronosyltransferase (UGT) 1A1 (e.g., bictegravir, irinotecan, raltegravir), and/or uptake transporters OAT1 and OAT3 (organic anion transporters) (e.g., bumetanide, furosemide, lamivudine, methotrexate, oseltamivir, tenofovir, ganciclovir, adefovir, cidofovir, zidovudine, zalcitabine) at clinically relevant concentrations.  The proposed mechanism is decreased clearance due to tafamidis-mediated inhibition of the corresponding transport protein.", "source": "DDInter", "management_text": "Caution is advised if tafamidis is used concomitantly with drugs that are substrates of these transport proteins, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever tafamidis is added to or withdrawn from therapy with these drugs.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if tafamidis is used concomitantly with drugs that are substrates of these transport proteins, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295267/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[3] \"Product Information. Vyndaqel (tafamidis).\" Pfizer U.S. Pharmaceuticals Group  (2019):", "alternatives_a": "Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Pitolisant, Amifampridine, Deutetrabenazine", "alternatives_b": "Ulipristal, Danazol, Mifepristone, Ospemifene, Raloxifene, Prasterone, Conjugated estrogens, Estrone, Diethylstilbestrol, Estradiol, Chlorotrianisene, Ethinylestradiol", "updated_at": 1767369485}, {"id": 249468, "ingredient1": "Conjugated estrogens", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes.  The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295268/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc.  (2017):", "alternatives_a": "Diethylstilbestrol, Bazedoxifene", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249469, "ingredient1": "Thalidomide", "ingredient2": "Bazedoxifene", "severity": "Major", "effect": "Concomitant treatment with agents that can cause thrombosis such as erythropoiesis-stimulating agents, oestrogens, selective estrogen receptor modulators, or C1 esterase inhibitors may potentiate the risk of venous thromboembolic events associated with the use of thalidomide.  When used in multiple myeloma, there is an increased risk of venous thromboembolism such as deep venous thrombosis and pulmonary embolism.  This risk increases significantly when thalidomide is combined with standard chemotherapeutic agents and/or steroids.", "source": "DDInter", "management_text": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving thalidomide with standard chemotherapeutic agents and/or steroids.  Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.  Prophylaxis with anticoagulants such as low-molecular weight heparins or warfarin may be appropriate, but the decision to take thromboprophylactic measures should be made after careful assessment of underlying risk factors.  If a thromboembolic event occurs during therapy with thalidomide, treatment must be discontinued and standard anticoagulation therapy initiated.  Once anticoagulation is stabilized and complications of the thromboembolic event under control, thalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks.  Anticoagulation therapy should be continued during the remaining course of thalidomide treatment.", "mechanism_text": "Synergism", "recommendation": "Agents that are known to cause thrombosis should be used with caution in multiple myeloma patients receiving thalidomide with standard chemotherapeutic agents and/or steroids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295269/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Ulipristal, Prasterone, Danazol", "updated_at": 1767369485}, {"id": 249470, "ingredient1": "Tranexamic acid", "ingredient2": "Bazedoxifene", "severity": "Major", "effect": "There are no clinical data on the use of tranexamic acid in combination with estrogens or selective estrogen receptor modulators.  Because tranexamic acid is an antifibrinolytic agent, concomitant use may further exacerbate the risk of thrombotic events, including venous thromboembolism as well as arterial thromboses such as stroke and myocardial infarction, associated with estrogenic therapy.", "source": "DDInter", "management_text": "Caution and close monitoring for thromboembolic adverse effects are recommended if tranexamic acid is prescribed with estrogens or selective estrogen receptor modulators.  Patients should be advised to seek medical attention immediately if they experience potential signs and symptoms of blood clots such as chest pain, shortness of breath, hemoptysis, hematuria, sudden loss of vision, and pain, redness or swelling in an extremity.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for thromboembolic adverse effects are recommended if tranexamic acid is prescribed with estrogens or selective estrogen receptor modulators.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295270/", "reference_text": "[1] \"Product Information. Cyklokapron (tranexamic acid).\" Pharmacia and Upjohn  (2001):[2] van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR \"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and  progestogen type: results of the MEGA case-control study.\" BMJ 339 (2009):  b2921[3] Lidegaard O, Lokkegaard E, Svendsen AL, Agger C \"Hormonal contraception and risk of venous thromboembolism: national follow-up study.\" BMJ 339 (2009):  b2890[4] \"Product Information. Lysteda (tranexamic acid).\" Xanodyne Pharmaceuticals Inc  (2022):[5] Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM \"Estrogens, progestogens and thrombosis.\" J Thromb Haemost 1 (2003):  1371-80[6] Gomes MP, Deitcher SR \"Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review.\" Arch Intern Med 164 (2004):  1965-76", "alternatives_a": "Aprotinin, Aminocaproic acid", "alternatives_b": "Mifepristone, Ulipristal, Prasterone, Danazol, Chlorotrianisene", "updated_at": 1767369485}, {"id": 249471, "ingredient1": "Chlorothiazide", "ingredient2": "Opium", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295273/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Methyclothiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Tapentadol, Oxymorphone, Dezocine, Tramadol, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 249472, "ingredient1": "Eplerenone", "ingredient2": "Opium", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295274/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Finerenone", "alternatives_b": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Dezocine, Tramadol, Methadone, More", "updated_at": 1767369485}, {"id": 249473, "ingredient1": "Glycopyrronium (topical)", "ingredient2": "Belladonna", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties.  The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing.  Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).  Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation, use of a mouthpiece rather than face mask during nebulization, and not touching the eyes following topical application until hands are washed with soap and water.  Patients should be advised to contact their physician if they experience excessive anticholinergic adverse effects or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295275/", "reference_text": "[1] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim  (2002):[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[3] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim  (2002):[4] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals  (2012):[5] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012):  1717-21[6] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline  (2014):[7] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc.  (2018):[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty  (2018):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249474, "ingredient1": "Guanfacine", "ingredient2": "Opium", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295276/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Rauwolfia serpentina root, Reserpine, Deserpidine", "alternatives_b": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Acetaminophen, Dezocine, Tramadol, More", "updated_at": 1767369485}, {"id": 249475, "ingredient1": "Diamorphine", "ingredient2": "Opium", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295277/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Loperamide, Eluxadoline, Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid", "alternatives_b": "Acamprosate, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 249476, "ingredient1": "Opium", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295278/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Ibuprofen, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249477, "ingredient1": "St. John's Wort", "ingredient2": "Opium", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295279/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 249478, "ingredient1": "Upadacitinib", "ingredient2": "Opium", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295280/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Oliceridine, Naltrexone, Oxymorphone, Tapentadol, Butorphanol, Acetaminophen, Hydromorphone, More", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 249479, "ingredient1": "Bendroflumethiazide", "ingredient2": "Acetohexamide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295281/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "Trichlormethiazide, Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Mitapivat, Amphotericin B, Clindamycin, Trichlormethiazide, More", "updated_at": 1767369485}, {"id": 249480, "ingredient1": "Amobarbital", "ingredient2": "Nadolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295282/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Pentobarbital, More", "alternatives_b": "Sotalol, Pindolol, Betaxolol, Carteolol, Sotalol", "updated_at": 1767369485}, {"id": 249481, "ingredient1": "Amobarbital", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295283/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, More", "alternatives_b": "Polythiazide, Hydroflumethiazide, Chlorothiazide, Trichlormethiazide, Methyclothiazide, Furosemide, Trichlormethiazide, Bumetanide, Metolazone, Ascorbic acid, Hydroflumethiazide, More", "updated_at": 1767369485}, {"id": 249482, "ingredient1": "Anisindione", "ingredient2": "Bendroflumethiazide", "severity": "Minor", "effect": "Thiazide diuretics may reduce intravascular volume.  Higher plasma levels of clotting factors and decreased anticoagulant effect may result; however the effects may not be clinically significant.", "source": "DDInter", "management_text": "Management consists of monitoring coagulation parameters during the initial phase of coadministration.  Patients should be advised to promptly report any signs of blood clots (e.g. chest pain, shortness of breath, sudden loss of vision, or pain, redness or swelling in an extremity).", "mechanism_text": "Others", "recommendation": "Management consists of monitoring coagulation parameters during the initial phase of coadministration.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295284/", "reference_text": "[1] Ku LL, Ward CO, Durgin SJ \"A clinical study of drug interaction and anticoagulant therapy.\" Drug Intell Clin Pharm 4 (1970):  300-6[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[3] Robinson DS, Sylwester D \"Interaction of commonly prescribed drugs and warfarin.\" Ann Intern Med 72 (1970):  853-6", "alternatives_a": "Trichlormethiazide, Furosemide, Trichlormethiazide, Bumetanide, Tamsulosin, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249483, "ingredient1": "Bromfenac", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states.  The risk may be increased in patients on dietary sodium restriction.  At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure.  Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination.", "source": "DDInter", "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure.  If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295286/", "reference_text": "[1] Allan SG, Knox J, Kerr F \"Interaction between diuretics and indomethacin.\" Br Med J 283 (1981):  1611[2] McCarthy JT, Torres VE, Romero JC, et al. \"Acute intrinsic renal failure induced by indomethacin.\" Mayo Clin Proc 57 (1982):  289-96[3] Favre L, Glasson P, Vallotton MB \"Reversible acute renal failure from combined triamterene and indomethacin.\" Ann Intern Med 96 (1982):  317-20[4] Poe TE, Scott RB, Keith JF Jr \"Interaction of indomethacin with furosemide.\" J Fam Pract 16 (1983):  610-6[5] Ahmad S \"Indomethacin-bumetanide interaction: an alert.\" Am J Cardiol 54 (1984):  246-7[6] Dixey JJ, Noormohamed FH, Lant AF, Brewerton DA \"The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man.\" Br J Clin Pharmacol 23 (1987):  55-63[7] Brater DC, Fox WR, Chennavasin P \"Interaction studies with bumetanide and furosemide: effects of probenecid and of indomethacin on response to bumetanide in man.\" J Clin Pharmacol 21 (1981):  647-53[8] Smith DE, Brater DC, Lin ET, Benet LZ \"Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation.\" J Pharmacokinet Biopharm 7 (1979):  265-74[9] Mor R, Pitlik S, Rosenfeld JB \"Indomethacin- and Moduretic--induced hyperkalemia.\" Isr J Med Sci 19 (1983):  535-7[10] Kaufman J, Hamburger R, Matheson J, Flamenbaum W \"Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition.\" J Clin Pharmacol 21 (1981):  663-7[11] Favre L, Glasson P, Riondel A, Vallotton MB \"Interaction of diuretics and non-steroidal anti-inflammatory drugs in man.\" Clin Sci 64 (1983):  407-15[12] Pedrinelli R, Magagna A, Arzilli F, et al. \"Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension.\" Clin Pharmacol Ther 28 (1980):  722-31[13] Weinberg MS, Quigg RJ, Salant DJ, Bernard DB \"Anuric renal failure precipitated by indomethacin and triamterene.\" Nephron 40 (1985):  216-8[14] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988):  58-62[15] Gehr T, Sica DA, Steigler BW, Marshall C \"Interaction of triamterene-hydrochlorothiazide (T-H) and ibuprofen (I).\" Clin Pharmacol Ther 47 (1990):  200[16] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co., Inc  (2002):[17] Watkins J, Abbot EC, Hensby CN, Webster J, Dollery CT \"Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.\" Br Med J 281 (1980):  702-5[18] Ripley EB, Gehr TW, Wallace H, Wade J, Kish C, Sica DA \"The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone.\" Int J Clin Pharmacol Ther 32 (1994):  12-8[19] Desaulles E, Schwartz J \"A comparative study of the action of frusemide and methyclothiazide on renin release by rat kidney slices and the interaction with indomethacin.\" Br J Pharmacol 65 (1979):  193-6[20] Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV \"Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers.\" Eur J Clin Pharmacol 48 (1995):  247-51[21] Gurwitz JH, Everitt DE, Monane M, et al. \"The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons.\" J Gerontol A Biol Sci Med Sci 51 (1996):  m74-9[22] Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A \"NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.\" Arch Intern Med 158 (1998):  1108-12[23] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[24] Bennett WM \"Drug interactions and consequences of sodium restriction.\" Am J Clin Nutr 65 (1997):  S678-81[25] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006):  49-58[26] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Fluocinolone acetonide, Salicylic acid, Fluorometholone", "updated_at": 1767369485}, {"id": 249484, "ingredient1": "Calcium glycerophosphate", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients.  Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium.", "source": "DDInter", "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.  Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D.  Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.", "mechanism_text": "Excretion", "recommendation": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295287/", "reference_text": "[1] Alon U, Costanzo LS, Chan JC \"Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol.\" Miner Electrolyte Metab 10 (1984):  379-86[2] Parfitt AM \"Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism.\" Ann Intern Med 77 (1972):  557-63[3] Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW \"The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism.\" J Clin Invest 55 (1975):  1295-302[4] Parfitt AM \"The interactions of thiazide diuretics with parathyroid hormone and vitamin D. Studies in patients with hypoparathyroidism.\" J Clin Invest 51 (1972):  1879-88[5] Middler S, Pak CY, Murad F, Bartter FC \"Thiazide diuretics and calcium metabolism.\" Metabolism 22 (1973):  139-46[6] Parfitt AM \"Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism.\" N Engl J Med 281 (1969):  55-9[7] Gora ML, Seth SK, Bay WH, Visconti JA \"Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate.\" Clin Pharm 8 (1989):  227-9[8] Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R \"Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy.\" Can Med Assoc J 121 (1979):  591-4[9] Duarte CG, Winnacker JL, Becker KL, Pace A \"Thiazide-induced hypercalcemia.\" N Engl J Med 284 (1971):  828-30[10] Franciosa JA, Pierpont G \"Cardiovascular clinical pharmacology of impedance reducing agents.\" J Chronic Dis 34 (1981):  341-52[11] Santos F, Smith MJ, Chan JC \"Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide.\" Am J Dis Child 140 (1986):  139-42[12] Riis B, Christiansen C \"Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause.\" Metabolism 34 (1985):  421-4[13] Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B \"Calcium and magnesium metabolism during long-term treatment with thiazides.\" Scand J Urol Nephrol 15 (1981):  257-62[14] Drinka PJ, Nolten WE \"Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics.\" J Am Geriatr Soc 32 (1984):  405-7[15] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):", "alternatives_a": "Trichlormethiazide, Furosemide, Trichlormethiazide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249485, "ingredient1": "Chloral hydrate", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295291/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 249486, "ingredient1": "Dicoumarol", "ingredient2": "Bendroflumethiazide", "severity": "Minor", "effect": "Thiazide diuretics may reduce intravascular volume.  Higher plasma levels of clotting factors and decreased anticoagulant effect may result; however the effects may not be clinically significant.", "source": "DDInter", "management_text": "Management consists of monitoring coagulation parameters during the initial phase of coadministration.  Patients should be advised to promptly report any signs of blood clots (e.g. chest pain, shortness of breath, sudden loss of vision, or pain, redness or swelling in an extremity).", "mechanism_text": "Others", "recommendation": "Management consists of monitoring coagulation parameters during the initial phase of coadministration.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295292/", "reference_text": "[1] Ku LL, Ward CO, Durgin SJ \"A clinical study of drug interaction and anticoagulant therapy.\" Drug Intell Clin Pharm 4 (1970):  300-6[2] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971):  487-98[3] Robinson DS, Sylwester D \"Interaction of commonly prescribed drugs and warfarin.\" Ann Intern Med 72 (1970):  853-6", "alternatives_a": "Trichlormethiazide, Furosemide, Trichlormethiazide, Bumetanide, Tamsulosin, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Trichlormethiazide, More", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "updated_at": 1767369485}, {"id": 249487, "ingredient1": "Digitoxin", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Although diuretics and digitalis glycosides are frequently and appropriately used together, diuretic-induced hypokalemia and hypomagnesemia may predispose patients on digitalis to arrhythmias.", "source": "DDInter", "management_text": "Digoxin, potassium and magnesium levels should be followed closely.  Hypokalemia and hypomagnesemia should be treated appropriately.  Digitalis dose adjustments may be required.  Patients should be advised to notify their physicians if they experience signs of possible digoxin toxicity or electrolyte disturbances, such as weakness, lethargy, muscle pains or cramps, nausea, anorexia, visual disturbances, or irregular heartbeats.", "mechanism_text": "Synergism", "recommendation": "Digoxin, potassium and magnesium levels should be followed closely.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295293/", "reference_text": "[1] Semple P, Tilstone WJ, Lawson DH \"Furosemide and urinary digoxin clearance.\" N Engl J Med 293 (1975):  612-3[2] Brown DD, Dormois JC, Abraham GN, et al. \"Effect of furosemide on the renal excretion of digoxin.\" Clin Pharmacol Ther 20 (1976):  395-400[3] McAllister RG, Howell SM, Gomer MS, Selby JB \"Effect of intravenous furosemide on the renal excretion of digoxin.\" J Clin Pharmacol 16 (1976):  110-7[4] Tilstone WJ, Semple PF, Lawson DH, Boyle JA \"Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin.\" Clin Pharmacol Ther 22 (1977):  389-94[5] Malcolm AD, Leung FY, Fuchs JC, Duarte JE \"Digoxin kinetics during furosemide administration.\" Clin Pharmacol Ther 21 (1977):  567-74[6] Waldorff S, Hansen PB, Kjaergard H, Buch J, Egeblad H, Steiness E \"Amiloride-induced changes in digoxin dynamics and kinetics: abolition of digoxin-induced inotropism with amiloride.\" Clin Pharmacol Ther 30 (1981):  172-6[7] Macolic V, Vrhovac B \"Pharmacokinetics and interactions of digoxin, theophylline and furosemide in diseases with edema.\" Int J Clin Pharmacol Ther Toxicol 31 (1993):  6-11[8] Whang R, Oei TO, Watanabe A \"Frequency of hypomagnesemia in hospitalized patients receiving digitalis.\" Arch Intern Med 145 (1985):  655-6[9] Cohen L, Kitzes R \"Magnesium Sulfate and digitalis-toxic arrhythmias.\" JAMA 249 (1983):  2808-10[10] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61", "alternatives_a": "Trichlormethiazide, Chlorothiazide, Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249488, "ingredient1": "Dihydrotachysterol", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients.  Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium.", "source": "DDInter", "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.  Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D.  Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.", "mechanism_text": "Excretion", "recommendation": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295294/", "reference_text": "[1] Alon U, Costanzo LS, Chan JC \"Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol.\" Miner Electrolyte Metab 10 (1984):  379-86[2] Parfitt AM \"Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism.\" Ann Intern Med 77 (1972):  557-63[3] Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW \"The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism.\" J Clin Invest 55 (1975):  1295-302[4] Parfitt AM \"The interactions of thiazide diuretics with parathyroid hormone and vitamin D. Studies in patients with hypoparathyroidism.\" J Clin Invest 51 (1972):  1879-88[5] Middler S, Pak CY, Murad F, Bartter FC \"Thiazide diuretics and calcium metabolism.\" Metabolism 22 (1973):  139-46[6] Parfitt AM \"Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism.\" N Engl J Med 281 (1969):  55-9[7] Gora ML, Seth SK, Bay WH, Visconti JA \"Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate.\" Clin Pharm 8 (1989):  227-9[8] Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R \"Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy.\" Can Med Assoc J 121 (1979):  591-4[9] Duarte CG, Winnacker JL, Becker KL, Pace A \"Thiazide-induced hypercalcemia.\" N Engl J Med 284 (1971):  828-30[10] Franciosa JA, Pierpont G \"Cardiovascular clinical pharmacology of impedance reducing agents.\" J Chronic Dis 34 (1981):  341-52[11] Santos F, Smith MJ, Chan JC \"Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide.\" Am J Dis Child 140 (1986):  139-42[12] Riis B, Christiansen C \"Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause.\" Metabolism 34 (1985):  421-4[13] Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B \"Calcium and magnesium metabolism during long-term treatment with thiazides.\" Scand J Urol Nephrol 15 (1981):  257-62[14] Drinka PJ, Nolten WE \"Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics.\" J Am Geriatr Soc 32 (1984):  405-7[15] Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD \"Harrison's Principles of Internal Medicine.\" New York, NY: McGraw-Hill Health Professionals Division  (1998):", "alternatives_a": "Trichlormethiazide, Furosemide, Trichlormethiazide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, More", "alternatives_b": "Vitamin A, Beta carotene", "updated_at": 1767369485}, {"id": 249489, "ingredient1": "Dimethyl fumarate", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295295/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Polythiazide, Hydroflumethiazide, Chlorothiazide, Trichlormethiazide, Methyclothiazide, Furosemide, Trichlormethiazide, Bumetanide, Metolazone, Tamsulosin, Tinidazole, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, More", "updated_at": 1767369485}, {"id": 249490, "ingredient1": "Diroximel fumarate", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295296/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Polythiazide, Hydroflumethiazide, Chlorothiazide, Trichlormethiazide, Methyclothiazide, Furosemide, Trichlormethiazide, Bumetanide, Metolazone, Tamsulosin, Tinidazole, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, More", "updated_at": 1767369485}, {"id": 249491, "ingredient1": "Eravacycline", "ingredient2": "Bendroflumethiazide", "severity": "Minor", "effect": "The coadministration of diuretics and tetracyclines may result in decreased renal function manifested by increases in serum creatinine and blood urea nitrogen (BUN).", "source": "DDInter", "management_text": "Usually, no clinical intervention is necessary, unless decreases in renal function occur.  If renal function deteriorates, discontinuation of one or both agents may be necessary.", "mechanism_text": "Synergism", "recommendation": "Usually, no clinical intervention is necessary, unless decreases in renal function occur.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295297/", "reference_text": "[1] Jick H, Slone D, Shapiro S, et al. \"Tetracycline and drug-attributed rises in blood urea nitrogen: a report from the Boston Collaborative Drug Surveillance Program.\" JAMA 220 (1972):  377-9[2] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980):  203-7[3] Tannenberg AM \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972):  713[4] Alexander MR \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972):  713-4", "alternatives_a": "Polythiazide, Hydroflumethiazide, Chlorothiazide, Trichlormethiazide, Methyclothiazide, Furosemide, Trichlormethiazide, Bumetanide, Metolazone, Tamsulosin, Tinidazole, More", "alternatives_b": "Sarecycline", "updated_at": 1767369485}, {"id": 249492, "ingredient1": "Gadoxetic acid", "ingredient2": "Nadolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295298/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ferumoxsil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249493, "ingredient1": "Diamorphine", "ingredient2": "Nadolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295299/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Carteolol", "alternatives_b": "Naltrexone, Disulfiram, Levacetylmethadol, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 249494, "ingredient1": "Diamorphine", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295300/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 249495, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295301/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249496, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295302/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249497, "ingredient1": "Iodipamide", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.", "source": "DDInter", "management_text": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.  Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so.  The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity.  Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered.  Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy.  Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium.  It is important that patients be adequately hydrated with either saline or sodium bicarbonate.", "mechanism_text": "Synergism", "recommendation": "Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295304/", "reference_text": "[1] \"Product Information. Lasix (furosemide).\" sanofi-aventis  (2007):[2] Weinstein J-M, Heyman S, Brezis M \"Potential deleterious effect of furosemide in radiocontrast nephropathy.\" Nephron 62 (1992):  413-5[3] Solomon R, Werner C, Mann D, D'Elia J, Silva P \"Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents.\" N Engl J Med 331 (1994):  1416-20[4] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004):  302-12[5] Stevens MA, McCullough PA, Tobin KJ, et al. \"A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation.\" J Am Coll Cardiol 33 (1999):  403-11[6] Barrett BJ, Parfrey PS \"Clinical practice. Preventing nephropathy induced by contrast medium.\" N Engl J Med 354 (2006):  379-86[7] Briguori C, Marenzi G \"Contrast-induced nephropathy: Pharmacological prophylaxis.\" Kidney Int 69(S100) (2006):  S30-S38[8] Tepel M, Aspelin P, Lameire N \"Contrast-induced nephropathy: a clinical and evidence-based approach.\" Circulation 113 (2006):  1799-806[9] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G \"Facts and fallacies concerning the prevention of contrast medium-induced nephropathy.\" Crit Care Med 34 (2006):  2060-80[10] Stacul F, Adam A, Becker CR, et al. \"Strategies to reduce the risk of contrast-induced nephropathy.\" Am J Cardiol 98(6S1) (2006):  59-77[11] Ho KM, Sheridan DJ \"Meta-analysis of frusemide to prevent or treat acute renal failure.\" BMJ 333 (2006):  420[12] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC \"Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy.\" Ann Intern Med 148 (2008):  284-94[13] Venkataraman R \"Can we prevent acute kidney injury?\" Crit Care Med 36(4 Suppl) (2008):  S166-71[14] Fishman EK, Reddan D \"What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography.\" Acta Radiol 49 (2008):  310-20[15] Massicotte A \"Contrast medium-induced nephropathy: strategies for prevention.\" Pharmacotherapy 28 (2008):  1140-50", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 249498, "ingredient1": "Isoetharine", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics.", "source": "DDInter", "management_text": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.  Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer.  Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295305/", "reference_text": "[1] Lipworth BJ, McDevitt DG, Struthers AD \"Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol.\" Am J Med 86 (1989):  653-7[2] \"Product Information. Proventil (albuterol).\" Schering Corporation  (2002):[3] \"Product Information. Brethaire (terbutaline).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[5] \"Product Information. Brovana (arformoterol).\" Sepracor Inc  (2006):[6] \"Product Information. Arcapta Neohaler (indacaterol).\" Novartis Pharmaceuticals  (2011):[7] \"Product Information. Breo Ellipta (fluticasone-vilanterol).\" GlaxoSmithKline  (2013):[8] \"Product Information. Striverdi Respimat (olodaterol).\" Boehringer Ingelheim  (2014):", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249499, "ingredient1": "Bendroflumethiazide", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295306/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "updated_at": 1767369485}, {"id": 249500, "ingredient1": "Bendroflumethiazide", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295307/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Pimavanserin", "updated_at": 1767369485}, {"id": 249501, "ingredient1": "Bendroflumethiazide", "ingredient2": "Metocurine", "severity": "Moderate", "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.", "source": "DDInter", "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295308/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[3] Miller RD, Roderick LL \"Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine.\" Br J Anaesth 50 (1978): 541-4[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249502, "ingredient1": "Nadolol", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295310/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Pentobarbital, More", "alternatives_b": "Acebutolol, Sotalol, Acebutolol, Betaxolol, Pindolol, Sotalol", "updated_at": 1767369485}, {"id": 249503, "ingredient1": "Bendroflumethiazide", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295311/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Polythiazide, Hydroflumethiazide, Chlorothiazide, Trichlormethiazide, Methyclothiazide, Furosemide, Trichlormethiazide, Bumetanide, Metolazone, Tamsulosin, Tinidazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249504, "ingredient1": "Bendroflumethiazide", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295313/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Hydroflumethiazide, Chlorothiazide, Polythiazide, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "updated_at": 1767369485}, {"id": 249505, "ingredient1": "Bendroflumethiazide", "ingredient2": "Omadacycline", "severity": "Minor", "effect": "The coadministration of diuretics and tetracyclines may result in decreased renal function manifested by increases in serum creatinine and blood urea nitrogen (BUN).", "source": "DDInter", "management_text": "Usually, no clinical intervention is necessary, unless decreases in renal function occur.  If renal function deteriorates, discontinuation of one or both agents may be necessary.", "mechanism_text": "Synergism", "recommendation": "Usually, no clinical intervention is necessary, unless decreases in renal function occur.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295314/", "reference_text": "[1] Jick H, Slone D, Shapiro S, et al. \"Tetracycline and drug-attributed rises in blood urea nitrogen: a report from the Boston Collaborative Drug Surveillance Program.\" JAMA 220 (1972):  377-9[2] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980):  203-7[3] Tannenberg AM \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972):  713[4] Alexander MR \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972):  713-4", "alternatives_a": "Polythiazide, Hydroflumethiazide, Chlorothiazide, Trichlormethiazide, Methyclothiazide, Furosemide, Trichlormethiazide, Bumetanide, Metolazone, Tamsulosin, Tinidazole, More", "alternatives_b": "Sarecycline", "updated_at": 1767369485}, {"id": 249506, "ingredient1": "Bendroflumethiazide", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295315/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 249507, "ingredient1": "Bendroflumethiazide", "ingredient2": "Phenolphthalein", "severity": "Moderate", "effect": "The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics.  Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.", "source": "DDInter", "management_text": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.  During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia.  If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.", "mechanism_text": "Synergism", "recommendation": "In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295317/", "reference_text": "[1] Brinckmann J, Blumenthal M, eds., Goldberg A \"Herbal Medicine: Expanded Commission E Monographs.\" Newton, MA: Integrative Medicine Communications  (2000):[2] Chin RL \"Laxative-induced hypokalemia.\" Ann Emerg Med 32 (1998):  517-8[3] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[4] Muller-Lissner SA \"Adverse effects of laxatives: fact and fiction.\" Pharmacology 47 (1993):  138-45[5] Atsmon J, Dolev E \"Drug-induced hypomagnesaemia : scope and management.\" Drug Saf 28 (2005):  763-88", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, More", "updated_at": 1767369485}, {"id": 249508, "ingredient1": "Bendroflumethiazide", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states.  The risk may be increased in patients on dietary sodium restriction.  At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure.  Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination.", "source": "DDInter", "management_text": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure.  If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient's renal function and blood pressure.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295318/", "reference_text": "[1] Allan SG, Knox J, Kerr F \"Interaction between diuretics and indomethacin.\" Br Med J 283 (1981):  1611[2] McCarthy JT, Torres VE, Romero JC, et al. \"Acute intrinsic renal failure induced by indomethacin.\" Mayo Clin Proc 57 (1982):  289-96[3] Favre L, Glasson P, Vallotton MB \"Reversible acute renal failure from combined triamterene and indomethacin.\" Ann Intern Med 96 (1982):  317-20[4] Poe TE, Scott RB, Keith JF Jr \"Interaction of indomethacin with furosemide.\" J Fam Pract 16 (1983):  610-6[5] Ahmad S \"Indomethacin-bumetanide interaction: an alert.\" Am J Cardiol 54 (1984):  246-7[6] Dixey JJ, Noormohamed FH, Lant AF, Brewerton DA \"The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man.\" Br J Clin Pharmacol 23 (1987):  55-63[7] Brater DC, Fox WR, Chennavasin P \"Interaction studies with bumetanide and furosemide: effects of probenecid and of indomethacin on response to bumetanide in man.\" J Clin Pharmacol 21 (1981):  647-53[8] Smith DE, Brater DC, Lin ET, Benet LZ \"Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation.\" J Pharmacokinet Biopharm 7 (1979):  265-74[9] Mor R, Pitlik S, Rosenfeld JB \"Indomethacin- and Moduretic--induced hyperkalemia.\" Isr J Med Sci 19 (1983):  535-7[10] Kaufman J, Hamburger R, Matheson J, Flamenbaum W \"Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition.\" J Clin Pharmacol 21 (1981):  663-7[11] Favre L, Glasson P, Riondel A, Vallotton MB \"Interaction of diuretics and non-steroidal anti-inflammatory drugs in man.\" Clin Sci 64 (1983):  407-15[12] Pedrinelli R, Magagna A, Arzilli F, et al. \"Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension.\" Clin Pharmacol Ther 28 (1980):  722-31[13] Weinberg MS, Quigg RJ, Salant DJ, Bernard DB \"Anuric renal failure precipitated by indomethacin and triamterene.\" Nephron 40 (1985):  216-8[14] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988):  58-62[15] Gehr T, Sica DA, Steigler BW, Marshall C \"Interaction of triamterene-hydrochlorothiazide (T-H) and ibuprofen (I).\" Clin Pharmacol Ther 47 (1990):  200[16] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co., Inc  (2002):[17] Watkins J, Abbot EC, Hensby CN, Webster J, Dollery CT \"Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.\" Br Med J 281 (1980):  702-5[18] Ripley EB, Gehr TW, Wallace H, Wade J, Kish C, Sica DA \"The effect of nonsteroidal agents (NSAIDs) on the pharmacokinetics and pharmacodynamics of metolazone.\" Int J Clin Pharmacol Ther 32 (1994):  12-8[19] Desaulles E, Schwartz J \"A comparative study of the action of frusemide and methyclothiazide on renin release by rat kidney slices and the interaction with indomethacin.\" Br J Pharmacol 65 (1979):  193-6[20] Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV \"Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers.\" Eur J Clin Pharmacol 48 (1995):  247-51[21] Gurwitz JH, Everitt DE, Monane M, et al. \"The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons.\" J Gerontol A Biol Sci Med Sci 51 (1996):  m74-9[22] Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A \"NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.\" Arch Intern Med 158 (1998):  1108-12[23] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[24] Bennett WM \"Drug interactions and consequences of sodium restriction.\" Am J Clin Nutr 65 (1997):  S678-81[25] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006):  49-58[26] Perazella MA \"Drug-induced hyperkalemia: old culprits and new offenders.\" Am J Med 109 (2000):  307-14", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Acetylsalicylic acid, Misoprostol, Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 249509, "ingredient1": "Bendroflumethiazide", "ingredient2": "Pipecuronium", "severity": "Moderate", "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.", "source": "DDInter", "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295319/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[3] Miller RD, Roderick LL \"Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine.\" Br J Anaesth 50 (1978): 541-4[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 249510, "ingredient1": "Bendroflumethiazide", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Some neuroleptic agents may cause prolongation of the QT interval.  While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.  In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity.  Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy", "source": "DDInter", "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.  Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic.  Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295320/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, More", "alternatives_b": "Pimavanserin", "updated_at": 1767369485}, {"id": 249511, "ingredient1": "Bendroflumethiazide", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295321/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Suvorexant, Triazolam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, More", "updated_at": 1767369485}, {"id": 249512, "ingredient1": "Bendroflumethiazide", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295322/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Hydroflumethiazide, Chlorothiazide, Polythiazide, Furosemide, Bumetanide, Metolazone, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, More", "alternatives_b": "Desipramine, St. John's Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine", "updated_at": 1767369485}, {"id": 249513, "ingredient1": "Bendroflumethiazide", "ingredient2": "Rapacuronium", "severity": "Moderate", "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.", "source": "DDInter", "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295323/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[3] Miller RD, Roderick LL \"Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine.\" Br J Anaesth 50 (1978): 541-4[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249514, "ingredient1": "Remifentanil", "ingredient2": "Nadolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295325/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acebutolol, Sotalol, Acebutolol, Carvedilol, Esmolol, Betaxolol, Penbutolol, Carteolol, Sotalol, Pindolol", "alternatives_b": "Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Halothane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 249515, "ingredient1": "Bendroflumethiazide", "ingredient2": "Remifentanil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295326/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Polythiazide, Hydroflumethiazide, Chlorothiazide, Trichlormethiazide, Methyclothiazide, Furosemide, Trichlormethiazide, Bumetanide, Metolazone, Tinidazole, Ascorbic acid, More", "alternatives_b": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 249516, "ingredient1": "Bendroflumethiazide", "ingredient2": "Sufentanil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295327/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Polythiazide, Hydroflumethiazide, Chlorothiazide, Trichlormethiazide, Methyclothiazide, Metolazone, Trichlormethiazide, Bumetanide, Tinidazole, Ascorbic acid, Hydroflumethiazide, More", "alternatives_b": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 249517, "ingredient1": "Tigecycline", "ingredient2": "Bendroflumethiazide", "severity": "Minor", "effect": "The coadministration of diuretics and tetracyclines may result in decreased renal function manifested by increases in serum creatinine and blood urea nitrogen (BUN).", "source": "DDInter", "management_text": "Usually, no clinical intervention is necessary, unless decreases in renal function occur.  If renal function deteriorates, discontinuation of one or both agents may be necessary.", "mechanism_text": "Synergism", "recommendation": "Usually, no clinical intervention is necessary, unless decreases in renal function occur.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295329/", "reference_text": "[1] Jick H, Slone D, Shapiro S, et al. \"Tetracycline and drug-attributed rises in blood urea nitrogen: a report from the Boston Collaborative Drug Surveillance Program.\" JAMA 220 (1972):  377-9[2] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980):  203-7[3] Tannenberg AM \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972):  713[4] Alexander MR \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972):  713-4", "alternatives_a": "Polythiazide, Hydroflumethiazide, Chlorothiazide, Trichlormethiazide, Methyclothiazide, Metolazone, Trichlormethiazide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, More", "alternatives_b": "Sarecycline", "updated_at": 1767369485}, {"id": 249518, "ingredient1": "Triflupromazine", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Some neuroleptic agents may cause prolongation of the QT interval.  While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes.  In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity.  Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy", "source": "DDInter", "management_text": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.  Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic.  Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication.  Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295330/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, More", "alternatives_b": "Pimavanserin", "updated_at": 1767369485}, {"id": 249519, "ingredient1": "Alimemazine", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.  A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.  Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295331/", "reference_text": "[1] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985):  274[2] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986):  1833-4[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceuticals  (2001):[5] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994):  429-30[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[7] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[8] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Geodon (ziprasidone).\" Pfizer U.S. Pharmaceuticals  (2001):[10] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb  (2002):[11] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More", "alternatives_b": "Trichlormethiazide, Trichlormethiazide, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "updated_at": 1767369485}, {"id": 249520, "ingredient1": "Troglitazone", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295332/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, More", "alternatives_b": "Simvastatin, Guar gum, Rosuvastatin", "updated_at": 1767369485}, {"id": 249521, "ingredient1": "Tubocurarine", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.", "source": "DDInter", "management_text": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295333/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] \"Product Information. HydroDIURIL (hydrochlorothiazide).\" Merck & Co, Inc, West Point, PA.[3] Miller RD, Roderick LL \"Diuretic-induced hypokalemia, pancuronium neuromuscular blockade and its antagonism by neostigmine.\" Br J Anaesth 50 (1978): 541-4[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Trichlormethiazide, Trichlormethiazide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 249522, "ingredient1": "Abametapir (topical)", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450 3A4, CYP450 2B6, and CYP450 1A2 isoenzymes and increase their systemic concentrations.", "source": "DDInter", "management_text": "Use of CYP450 3A4, CYP450 2B6, and CYP450 1A2 substrates should generally be avoided within 2 weeks after topical application of abametapir lotion.  If this is not feasible, the manufacturer recommends avoiding use of abametapir lotion.  If abametapir is used, monitor for increased toxicity of the CYP450 3A4, CYP450 2B6, and/or CYP450 1A2 substrate.", "mechanism_text": "Metabolism", "recommendation": "Use of CYP450 3A4, CYP450 2B6, and CYP450 1A2 substrates should generally be avoided within 2 weeks after topical application of abametapir lotion.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295357/", "reference_text": "[1] \"Product Information. Xeglyze (abametapir topical).\" Dr. Reddy's Laboratories Inc  (2020):", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249523, "ingredient1": "Abiraterone", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295358/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Exemestane", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Etravirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 249524, "ingredient1": "Afatinib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295361/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Rilpivirine, Etravirine, More", "updated_at": 1767369485}, {"id": 249525, "ingredient1": "Alpelisib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295362/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 249526, "ingredient1": "Aluminum hydroxide", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295364/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249527, "ingredient1": "Aminoglutethimide", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295365/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Exemestane", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More", "updated_at": 1767369485}, {"id": 249528, "ingredient1": "Amiodarone", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295366/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lidocaine, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Elbasvir, More", "updated_at": 1767369485}, {"id": 249529, "ingredient1": "Amobarbital", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295367/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More", "updated_at": 1767369485}, {"id": 249530, "ingredient1": "Amprenavir", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295368/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Glecaprevir, Cabotegravir, Amprenavir, Zanamivir, Valaciclovir, Lenacapavir, Velpatasvir, Rilpivirine, Oseltamivir, Brincidofovir, Remdesivir, More", "updated_at": 1767369485}, {"id": 249531, "ingredient1": "Bictegravir", "ingredient2": "Apalutamide", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295369/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Exemestane", "alternatives_b": "Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Telaprevir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 249532, "ingredient1": "Bictegravir", "ingredient2": "Aprepitant", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295370/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Nabilone, Granisetron, Scopolamine, Dronabinol, Dolasetron, Ondansetron, Palonosetron", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249533, "ingredient1": "Bictegravir", "ingredient2": "Armodafinil", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295371/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249534, "ingredient1": "Bictegravir", "ingredient2": "Atazanavir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295373/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Cabotegravir, Amprenavir, Zanamivir, Velpatasvir, Rilpivirine, Oseltamivir, Cobicistat, Remdesivir, Famciclovir, Darunavir, Maribavir, More", "updated_at": 1767369485}, {"id": 249535, "ingredient1": "Bictegravir", "ingredient2": "Attapulgite", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295374/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Pectin, Activated charcoal", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249536, "ingredient1": "Bictegravir", "ingredient2": "Azithromycin", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295375/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Norfloxacin, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Levofloxacin, Ofloxacin, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 249537, "ingredient1": "Bictegravir", "ingredient2": "Bepridil", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295377/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249538, "ingredient1": "Bictegravir", "ingredient2": "Berotralstat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295378/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Hemin, Conestat alfa, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "Lamivudine, Cabotegravir, Simeprevir, Zanamivir, Valaciclovir, Telaprevir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 249539, "ingredient1": "Bictegravir", "ingredient2": "Bexarotene", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295380/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Famciclovir, More", "updated_at": 1767369485}, {"id": 249540, "ingredient1": "Boceprevir", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295381/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Lamivudine, Glecaprevir, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More", "updated_at": 1767369485}, {"id": 249541, "ingredient1": "Bosentan", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295382/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More", "alternatives_b": "Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, More", "updated_at": 1767369485}, {"id": 249542, "ingredient1": "Brigatinib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295383/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249543, "ingredient1": "Butabarbital", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295384/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More", "updated_at": 1767369485}, {"id": 249544, "ingredient1": "Butalbital", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295385/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More", "updated_at": 1767369485}, {"id": 249545, "ingredient1": "Cabozantinib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with cabozantinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter.  The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by cabozantinib.", "source": "DDInter", "management_text": "Caution is advised when cabozantinib is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cabozantinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism, Absorption, Excretion", "recommendation": "Caution is advised when cabozantinib is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295386/", "reference_text": "[1] \"Product Information. Cometriq (cabozantinib).\" Exelixis Inc  (2012):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Paritaprevir, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249546, "ingredient1": "Calcium acetate", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295387/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Promethazine, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249547, "ingredient1": "Calcium carbonate", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295388/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "updated_at": 1767369485}, {"id": 249548, "ingredient1": "Calcium citrate", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295389/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249549, "ingredient1": "Calcium glubionate anhydrous", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295390/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Calcium glucoheptonate, Calcium chloride", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249550, "ingredient1": "Calcium gluconate", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295391/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Minoxidil, Deoxycholic acid, Pimecrolimus, Glycopyrronium, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249551, "ingredient1": "Calcium glycerophosphate", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295392/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249552, "ingredient1": "Calcium lactate", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295393/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Calcium glucoheptonate, Calcium chloride", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249553, "ingredient1": "Calcium Phosphate", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295394/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249554, "ingredient1": "Capmatinib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters, such as digoxin and rosuvastatin.  The proposed mechanism is decreased clearance due to capmatinib-mediated inhibition of intestinal P-gp and/or BCRP efflux transport proteins.", "source": "DDInter", "management_text": "Coadministration of capmatinib with drugs that are substrates of P-gp and/or BCRP should generally be avoided.  However, if concomitant use is unavoidable, caution is advised, particularly with drugs that have a narrow therapeutic range.  Clinical and laboratory monitoring should be considered whenever capmatinib is added to or withdrawn from therapy with these drugs, and dosages adjusted as necessary.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Coadministration of capmatinib with drugs that are substrates of P-gp and/or BCRP should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295396/", "reference_text": "[1] \"Product Information. Tabrecta (capmatinib).\" Novartis Pharmaceuticals  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249555, "ingredient1": "Carbamazepine", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295397/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Paritaprevir, Zanamivir, Velpatasvir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, Pibrentasvir, Rimantadine, Telbivudine, Entecavir, More", "updated_at": 1767369485}, {"id": 249556, "ingredient1": "Iron", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295398/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Iron sucrose, Cyanocobalamin, Folic acid", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249557, "ingredient1": "Carvedilol", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295399/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Acebutolol, Labetalol, Nadolol, Propranolol, Metoprolol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, Carteolol, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 249558, "ingredient1": "Cenobamate", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295400/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 249559, "ingredient1": "Ceritinib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295401/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249560, "ingredient1": "Chloramphenicol", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295402/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249561, "ingredient1": "Ciprofloxacin", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295403/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Norfloxacin, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Levofloxacin, Ofloxacin, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, More", "updated_at": 1767369485}, {"id": 249562, "ingredient1": "Clarithromycin", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295404/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Lenacapavir, Velpatasvir, Voxilaprevir, Maribavir, Pibrentasvir, Rimantadine, Elvitegravir, Valganciclovir, More", "updated_at": 1767369485}, {"id": 249563, "ingredient1": "Clofarabine", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with bictegravir may increase the plasma concentrations of drugs that are substrates of organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE1).  The mechanism is inhibition of OCT2- and MATE1-mediated renal tubular secretion by bictegravir.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with drugs that are substrates of OCT2 or MATE1, particularly those with a narrow therapeutic range.  Close monitoring is particularly recommended in patients with moderate renal impairment (CrCl 30 to 59 mL/min) who are to be administered bictegravir and metformin, due to the increased risk of lactic acidosis.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever bictegravir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when bictegravir is used with drugs that are substrates of OCT2 or MATE1, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295405/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Methotrexate, Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, More", "alternatives_b": "Paritaprevir, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Etravirine, Oseltamivir, More", "updated_at": 1767369485}, {"id": 249564, "ingredient1": "Cobicistat", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295406/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Cabotegravir, Zanamivir, Lenacapavir, Valaciclovir, Telaprevir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, Remdesivir, Famciclovir, More", "updated_at": 1767369485}, {"id": 249565, "ingredient1": "Cobimetinib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295407/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249566, "ingredient1": "Conivaptan", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295408/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249567, "ingredient1": "Crizotinib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295409/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249568, "ingredient1": "Cyclosporine", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295410/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More", "updated_at": 1767369485}, {"id": 249569, "ingredient1": "Dabrafenib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295411/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249570, "ingredient1": "Daclatasvir", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with daclatasvir may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter.  The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by daclatasvir.", "source": "DDInter", "management_text": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever daclatasvir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when daclatasvir is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295412/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daklinza (daclatasvir).\" Bristol-Myers Squibb  (2015):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 249571, "ingredient1": "Dalfampridine", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors and/or substrates of organic cation transporter 2 (OCT2) may increase the plasma concentrations of dalfampridine.  In vitro studies have shown that OCT2 is the primary transporter responsible for the active tubular secretion of dalfampridine, which accounts for approximately 60% of its renal elimination--the major route of clearance for dalfampridine.", "source": "DDInter", "management_text": "Caution is advised when dalfampridine is used with OCT2 inhibitors and/or substrates.  The potential benefits of concomitant use should be considered against the risk of seizures.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when dalfampridine is used with OCT2 inhibitors and/or substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295413/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[5] \"Product Information. Ampyra (dalfampridine).\" Acorda Therapeutics  (2010):[6] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[7] Cerner Multum, Inc \"ANVISA Bulio Eletrico.\" O 0 (2015):", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Pitolisant, Amifampridine, Deutetrabenazine", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 249572, "ingredient1": "Darolutamide", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295414/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Exemestane", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Maraviroc, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, More", "updated_at": 1767369485}, {"id": 249573, "ingredient1": "Darunavir", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295415/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Lamivudine, Cabotegravir, Amprenavir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, Stavudine, Famciclovir, More", "updated_at": 1767369485}, {"id": 249574, "ingredient1": "Deferasirox", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295416/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Promethazine, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Lamivudine, Paritaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249575, "ingredient1": "Delavirdine", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295417/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249576, "ingredient1": "Dexamethasone", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295418/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Nedocromil, More", "alternatives_b": "Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, More", "updated_at": 1767369485}, {"id": 249577, "ingredient1": "Diltiazem", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295420/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lidocaine, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Triamcinolone, Nitroglycerin", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Brincidofovir, Stavudine, Remdesivir, Elbasvir, Voxilaprevir, More", "updated_at": 1767369485}, {"id": 249578, "ingredient1": "Dofetilide", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Coadministration with bictegravir may increase the plasma concentrations of dofetilide.  The proposed mechanism is inhibition of organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE1) by bictegravir, resulting in decreased renal tubular secretion of dofetilide.", "source": "DDInter", "management_text": "Given the risk for serious and/or life-threatening cardiovascular events associated with increased dofetilide plasma levels, concomitant use with bictegravir is considered contraindicated.", "mechanism_text": "Excretion", "recommendation": "Given the risk for serious and/or life-threatening cardiovascular events associated with increased dofetilide plasma levels, concomitant use with bictegravir is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295421/", "reference_text": "[1] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lidocaine, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Etravirine, Oseltamivir, More", "updated_at": 1767369485}, {"id": 249579, "ingredient1": "Dronedarone", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295422/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lidocaine, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249580, "ingredient1": "Duvelisib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295423/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249581, "ingredient1": "Echinacea", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4.  Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea.  In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.", "source": "DDInter", "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.  If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered.  Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295424/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004):  89-100[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249582, "ingredient1": "Efavirenz", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295425/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Paritaprevir, Cabotegravir, Zanamivir, Oseltamivir, Brincidofovir, Elbasvir, Voxilaprevir, Pibrentasvir, Rimantadine, Telbivudine, Efavirenz, More", "updated_at": 1767369485}, {"id": 249583, "ingredient1": "Elagolix", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295427/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "Lamivudine, Paritaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 249584, "ingredient1": "Eliglustat", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with eliglustat may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter.  The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by eliglustat.", "source": "DDInter", "management_text": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eliglustat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism, Absorption, Excretion", "recommendation": "Caution is advised when eliglustat is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295428/", "reference_text": "[1] \"Product Information. Cerdelga (eliglustat).\" Genzyme Corporation  (2014):", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Nitisinone, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 249585, "ingredient1": "Eltrombopag", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters.  The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295430/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline  (2008):[4] Kalliokoski A, Niemi M \"Impact of OATP transporters on pharmacokinetics.\" Br J Pharmacol 158 (2009):  693-705[5] Allred AJ, Bowen CJ, Park JW, et al. \"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.\" Br J Clin Pharmacol 72 (2011):  321-9", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249586, "ingredient1": "Enasidenib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Based on in vitro data, coadministration with enasidenib may increase the plasma concentrations of drugs that are substrates of the transporters, organic anion transporting polypeptides (OATP) 1B1/1B3 and breast cancer resistance protein (BCRP).  The proposed mechanism is decreased clearance due to enasidenib -mediated inhibition of OATP1B1/1B3 and BCRP transporters.", "source": "DDInter", "management_text": "Caution is advised when enasidenib is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever enasidenib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when enasidenib is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295431/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Idhifa (enasidenib).\" Celgene Corporation  (2017):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Maraviroc, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 249587, "ingredient1": "Encorafenib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with encorafenib may theoretically increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic cation transporter (OCT2), organic anion transporter (OAT1, OAT3), or organic anion transporting polypeptide (OATP1B1, OATP1B3).  The proposed mechanism is decreased clearance due to inhibition of the corresponding transporter by encorafenib.", "source": "DDInter", "management_text": "Caution is advised if encorafenib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever encorafenib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if encorafenib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295432/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc.  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Glecaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, Remdesivir, More", "updated_at": 1767369485}, {"id": 249588, "ingredient1": "Entrectinib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with entrectinib may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter.  The proposed mechanisms, based on in vitro data, is decreased clearance due to entrectinib-mediated inhibition of BCRP transport protein.", "source": "DDInter", "management_text": "Caution is advised when entrectinib is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, mitoxantrone, topotecan, and lapatinib.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever entrectinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when entrectinib is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, mitoxantrone, topotecan, and lapatinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295433/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Rozlytrek (entrectinib).\" Genentech  (2019):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, Elbasvir, More", "updated_at": 1767369485}, {"id": 249589, "ingredient1": "Enzalutamide", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295434/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Exemestane", "alternatives_b": "Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, Voxilaprevir, More", "updated_at": 1767369485}, {"id": 249590, "ingredient1": "Erdafitinib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter, resulting in increased toxicity of these drugs.", "source": "DDInter", "management_text": "Concomitant use of erdafitinib and P-gp substrates should generally be avoided.  If concomitant use is required, administer erdafitinib at least 6 hours before or after administration of P-gp substrates with narrow therapeutic ranges.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of erdafitinib and P-gp substrates should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295435/", "reference_text": "[1] \"Product Information. Balversa (erdafitinib).\" Janssen Products, LP  (2019):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 249591, "ingredient1": "Erythromycin", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295436/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Dirithromycin, Lincomycin, Clindamycin, Minocycline, Clindamycin, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Dapsone, Methylprednisolone, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Elbasvir, Famciclovir, Tipranavir, Voxilaprevir, Ribavirin, More", "updated_at": 1767369485}, {"id": 249592, "ingredient1": "Eslicarbazepine", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295437/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249593, "ingredient1": "Etravirine", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295438/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Etravirine, Oseltamivir, Acyclovir, Brincidofovir, Remdesivir, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 249594, "ingredient1": "Ezogabine", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295439/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 249595, "ingredient1": "Fedratinib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295440/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249596, "ingredient1": "Felbamate", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295441/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More", "updated_at": 1767369485}, {"id": 249597, "ingredient1": "Felodipine", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295442/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Amlodipine, Propranolol, Metoprolol, Nebivolol, Bisoprolol, Ivabradine, Sotalol, Acetylsalicylic acid, Atenolol, Amlodipine, Nisoldipine, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 249598, "ingredient1": "Bictegravir", "ingredient2": "Tetraferric tricitrate decahydrate", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295443/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Promethazine, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249599, "ingredient1": "Ferrous fumarate", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295445/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Iron sucrose, Cyanocobalamin, Folic acid", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249600, "ingredient1": "Ferrous gluconate", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295446/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Iron sucrose, Cyanocobalamin, Folic acid", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249601, "ingredient1": "Ferrous sulfate anhydrous", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295447/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249602, "ingredient1": "Flibanserin", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with flibanserin may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when flibanserin is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever flibanserin is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "Caution is advised when flibanserin is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295449/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals  (2015):", "alternatives_a": "Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Bromocriptine, Ibuprofen", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 249603, "ingredient1": "Fluconazole", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295450/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Norfloxacin, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Levofloxacin, Ofloxacin, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Brincidofovir, Elbasvir, Darunavir, More", "updated_at": 1767369485}, {"id": 249604, "ingredient1": "Fosamprenavir", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295451/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Glecaprevir, Cabotegravir, Amprenavir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Oseltamivir, Brincidofovir, Remdesivir, Famciclovir, More", "updated_at": 1767369485}, {"id": 249605, "ingredient1": "Fosaprepitant", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295452/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249606, "ingredient1": "Fosphenytoin", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295453/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 249607, "ingredient1": "Fostemsavir", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295454/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Lamivudine, Cabotegravir, Maraviroc, Zanamivir, Valaciclovir, Lenacapavir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, More", "updated_at": 1767369485}, {"id": 249608, "ingredient1": "Gefitinib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295456/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 249609, "ingredient1": "Gemfibrozil", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295457/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Ezetimibe, Niacin, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 249610, "ingredient1": "Gilteritinib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295458/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 249611, "ingredient1": "Glasdegib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with glasdegib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) efflux transporters.  In vitro data suggest that glasdegib may have the potential to inhibit P-gp (in the gastrointestinal (GI) tract) and BCRP (systemically and in the GI tract) at clinically relevant concentrations, which may result in decreased clearance of concomitantly administered P-gp and BCRP substrates.", "source": "DDInter", "management_text": "Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range.  Clinical and laboratory monitoring should be considered whenever glasdegib is added to or withdrawn from therapy with these drugs, and dosages adjusted as necessary.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295459/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daurismo (glasdegib).\" Pfizer U.S. Pharmaceuticals Group  (2018):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249612, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295460/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Nitisinone, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249613, "ingredient1": "Griseofulvin", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295461/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Terbinafine, Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Terbinafine, Econazole, Flucytosine, Tioconazole, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More", "updated_at": 1767369485}, {"id": 249614, "ingredient1": "Guanfacine", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with bictegravir may increase the plasma concentrations of drugs that are substrates of organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE1).  The mechanism is inhibition of OCT2- and MATE1-mediated renal tubular secretion by bictegravir.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with drugs that are substrates of OCT2 or MATE1, particularly those with a narrow therapeutic range.  Close monitoring is particularly recommended in patients with moderate renal impairment (CrCl 30 to 59 mL/min) who are to be administered bictegravir and metformin, due to the increased risk of lactic acidosis.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever bictegravir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when bictegravir is used with drugs that are substrates of OCT2 or MATE1, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295462/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Rauwolfia serpentina root, Clonidine, Methyldopa, Deserpidine", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Oseltamivir, More", "updated_at": 1767369485}, {"id": 249615, "ingredient1": "Idelalisib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295464/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Cabotegravir, Simeprevir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Famciclovir, Ribavirin, Tecovirimat, Maribavir, More", "updated_at": 1767369485}, {"id": 249616, "ingredient1": "Imatinib", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295465/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Elbasvir, More", "updated_at": 1767369485}, {"id": 249617, "ingredient1": "Indinavir", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295466/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Glecaprevir, Cabotegravir, Zanamivir, Lenacapavir, Valaciclovir, Telaprevir, Velpatasvir, Rilpivirine, Oseltamivir, Remdesivir, Famciclovir, More", "updated_at": 1767369485}, {"id": 249618, "ingredient1": "Iron protein succinylate", "ingredient2": "Bictegravir", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295469/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Iron sucrose, Cyanocobalamin, Folic acid", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249619, "ingredient1": "Isavuconazonium", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295470/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249620, "ingredient1": "Istradefylline", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter.  The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.", "source": "DDInter", "management_text": "Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295471/", "reference_text": "[1] \"Product Information. Nourianz (istradefylline).\" Kyowa Kirin, Inc  (2019):", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249621, "ingredient1": "Itraconazole", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295472/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Miconazole, Flucytosine, Anidulafungin", "alternatives_b": "Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Maribavir, More", "updated_at": 1767369485}, {"id": 249622, "ingredient1": "Ivacaftor", "ingredient2": "Bictegravir", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter.  The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.  The interaction has been studied with midazolam and digoxin, probe substrates for CYP450 3A4 ad P-gp, respectively.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295473/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals  (2012):", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249623, "ingredient1": "Bictegravir", "ingredient2": "Ivosidenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295474/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249624, "ingredient1": "Bictegravir", "ingredient2": "Kaolin", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295475/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Pectin, Activated charcoal", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249625, "ingredient1": "Bictegravir", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295476/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, More", "updated_at": 1767369485}, {"id": 249626, "ingredient1": "Bictegravir", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295477/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 249627, "ingredient1": "Bictegravir", "ingredient2": "Lasmiditan", "severity": "Moderate", "effect": "Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters.  The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan.", "source": "DDInter", "management_text": "Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible.  If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295478/", "reference_text": "[1] \"Product Information. Reyvow (lasmiditan).\" Lilly, Eli and Company  (2019):", "alternatives_a": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Clonidine, Naratriptan, More", "alternatives_b": "Lamivudine, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 249628, "ingredient1": "Bictegravir", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295479/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Fosfomycin, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249629, "ingredient1": "Bictegravir", "ingredient2": "Lesinurad", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295482/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Pegloticase, Febuxostat, Colchicine, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Velpatasvir, Etravirine, More", "updated_at": 1767369485}, {"id": 249630, "ingredient1": "Bictegravir", "ingredient2": "Lomitapide", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295484/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Ezetimibe, Niacin, More", "alternatives_b": "Paritaprevir, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Etravirine, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249631, "ingredient1": "Bictegravir", "ingredient2": "Lonafarnib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295485/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Nitisinone, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249632, "ingredient1": "Bictegravir", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295487/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Cabotegravir, Simeprevir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, Elbasvir, More", "updated_at": 1767369485}, {"id": 249633, "ingredient1": "Bictegravir", "ingredient2": "Magaldrate", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295488/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249634, "ingredient1": "Bictegravir", "ingredient2": "Magnesium carbonate", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295491/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Promethazine, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "updated_at": 1767369485}, {"id": 249635, "ingredient1": "Bictegravir", "ingredient2": "Magnesium chloride", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295492/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Sodium chloride, Sodium sulfate, Calcium chloride, Potassium chloride, Sodium acetate, Arginine, Sodium glycerophosphate, Zinc chloride, Tromethamine, Sodium phosphate, monobasic, Sodium bicarbonate, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249636, "ingredient1": "Bictegravir", "ingredient2": "Magnesium citrate", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295493/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Sorbitol, Sulfamethizole, Sodium citrate, Mannitol, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Sodium chloride, Sodium sulfate, Alvimopan, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249637, "ingredient1": "Bictegravir", "ingredient2": "Magnesium gluconate", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295494/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Sodium chloride, Sodium sulfate", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249638, "ingredient1": "Bictegravir", "ingredient2": "Magnesium glycinate", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295495/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249639, "ingredient1": "Bictegravir", "ingredient2": "Magnesium hydroxide", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295496/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "updated_at": 1767369485}, {"id": 249640, "ingredient1": "Bictegravir", "ingredient2": "Magnesium oxide", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295499/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Etravirine, More", "updated_at": 1767369485}, {"id": 249641, "ingredient1": "Bictegravir", "ingredient2": "Magnesium sulfate", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295501/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249642, "ingredient1": "Bictegravir", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295505/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More", "updated_at": 1767369485}, {"id": 249643, "ingredient1": "Bictegravir", "ingredient2": "Metformin", "severity": "Moderate", "effect": "Coadministration with bictegravir may increase the plasma concentrations of drugs that are substrates of organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE1).  The mechanism is inhibition of OCT2- and MATE1-mediated renal tubular secretion by bictegravir.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with drugs that are substrates of OCT2 or MATE1, particularly those with a narrow therapeutic range.  Close monitoring is particularly recommended in patients with moderate renal impairment (CrCl 30 to 59 mL/min) who are to be administered bictegravir and metformin, due to the increased risk of lactic acidosis.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever bictegravir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when bictegravir is used with drugs that are substrates of OCT2 or MATE1, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295506/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "Cabotegravir, Maraviroc, Zanamivir, Lenacapavir, Telaprevir, Rilpivirine, Etravirine, Cobicistat, Brincidofovir, Remdesivir, Doravirine, More", "updated_at": 1767369485}, {"id": 249644, "ingredient1": "Bictegravir", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295507/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Nitisinone, Levocarnitine, Laronidase, Imiglucerase, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 249645, "ingredient1": "Bictegravir", "ingredient2": "Midostaurin", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295509/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, More", "updated_at": 1767369485}, {"id": 249646, "ingredient1": "Bictegravir", "ingredient2": "Mifepristone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295510/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249647, "ingredient1": "Bictegravir", "ingredient2": "Mitotane", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295512/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Telaprevir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249648, "ingredient1": "Bictegravir", "ingredient2": "Modafinil", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295514/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Lamivudine, Paritaprevir, Cabotegravir, Simeprevir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, Elbasvir, More", "updated_at": 1767369485}, {"id": 249649, "ingredient1": "Bictegravir", "ingredient2": "Nafcillin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295519/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249650, "ingredient1": "Bictegravir", "ingredient2": "Naproxen", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295520/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Bromocriptine, Ibuprofen, Rabeprazole, Indomethacin, Tolazoline, Ketoprofen, Diclofenac, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 249651, "ingredient1": "Bictegravir", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295521/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Oseltamivir, Cobicistat, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249652, "ingredient1": "Bictegravir", "ingredient2": "Nelfinavir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295522/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, Oseltamivir, Brincidofovir, Remdesivir, More", "updated_at": 1767369485}, {"id": 249653, "ingredient1": "Bictegravir", "ingredient2": "Neratinib", "severity": "Moderate", "effect": "Coadministration with neratinib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter, such as dabigatran, rosuvastatin, sulfasazine, and topotecan.  The proposed mechanisms, based on in vitro data, is decreased clearance due to neratinib-mediated inhibition of BCRP transport protein.", "source": "DDInter", "management_text": "Caution is advised if neratinib is used concomitantly with drugs that are substrates of BCRP transport protein, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever neratinib is added to or withdrawn from therapy with these drugs.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if neratinib is used concomitantly with drugs that are substrates of BCRP transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295523/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 249654, "ingredient1": "Bictegravir", "ingredient2": "Nevirapine", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295524/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Tenofovir alafenamide, Cabotegravir, Zanamivir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, Telbivudine, More", "updated_at": 1767369485}, {"id": 249655, "ingredient1": "Bictegravir", "ingredient2": "Nifedipine", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295525/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Amlodipine, Nisoldipine, Nicardipine, Isradipine, Clevidipine, Levamlodipine, Celecoxib, Nimodipine, Amlodipine, Amlodipine, Propranolol, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Remdesivir, Elbasvir, Tipranavir, More", "updated_at": 1767369485}, {"id": 249656, "ingredient1": "Bictegravir", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295526/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249657, "ingredient1": "Bictegravir", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with olaparib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 (e.g., cisapride, ergot alkaloids, fentanyl, lovastatin, oral midazolam, pimozide, quetiapine, simvastatin, triazolam, vinca alkaloids), P-gp (e.g., colchicine, dabigatran, digoxin), breast cancer resistance protein (BCRP) (e.g., rosuvastatin), OATP1B1 (e.g., eluxadoline, glyburide, repaglinide, statins, valsartan), or organic cation transporter 1 or 2 (OCT1, OCT2) (e.g., metformin).  The proposed mechanism is decreased clearance due to inhibition of the corresponding metabolizing enzyme and/or efflux/uptake transporter by olaparib.", "source": "DDInter", "management_text": "Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever olaparib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if olaparib must be used concomitantly with drugs that are substrates of the affected enzymes or transporters, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295527/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 249658, "ingredient1": "Bictegravir", "ingredient2": "Oritavancin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295530/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Fosfomycin, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 249659, "ingredient1": "Bictegravir", "ingredient2": "Osimertinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295531/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 249660, "ingredient1": "Bictegravir", "ingredient2": "Oxcarbazepine", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295533/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Lamivudine, Paritaprevir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, Voxilaprevir, Tecovirimat, Pibrentasvir, More", "updated_at": 1767369485}, {"id": 249661, "ingredient1": "Bictegravir", "ingredient2": "Palbociclib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295535/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 249662, "ingredient1": "Bictegravir", "ingredient2": "Pazopanib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295536/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249663, "ingredient1": "Bictegravir", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295537/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More", "updated_at": 1767369485}, {"id": 249664, "ingredient1": "Bictegravir", "ingredient2": "Pexidartinib", "severity": "Moderate", "effect": "Coadministration with pexidartinib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4.  The proposed mechanism is increased clearance due to pexidartinib-mediated induction of CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Concomitant administration of pexidartinib with drugs that are substrates of CYP450 3A4 should generally be avoided, particularly those with a narrow therapeutic range.  The potential for diminished therapeutic effects should be considered when pexidartinib is prescribed in combination with drugs that are substrates of CYP450 3A4.  Dosage adjustments as well as clinical and laboratory monitoring of the CYP450 3A4 substrate drug should be considered whenever pexidartinib is added to or withdrawn from therapy with these drugs.", "mechanism_text": "Metabolism", "recommendation": "Concomitant administration of pexidartinib with drugs that are substrates of CYP450 3A4 should generally be avoided, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295538/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc.  (2019):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Elbasvir, Famciclovir, Ribavirin, Tecovirimat, Pibrentasvir, Rimantadine, More", "updated_at": 1767369485}, {"id": 249665, "ingredient1": "Bictegravir", "ingredient2": "Phenobarbital", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295539/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Lamivudine, Paritaprevir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 249666, "ingredient1": "Bictegravir", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295540/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acetylsalicylic acid, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, Glucosamine, More", "alternatives_b": "Lamivudine, Paritaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249667, "ingredient1": "Bictegravir", "ingredient2": "Phenytoin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295541/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Paritaprevir, Zanamivir, Velpatasvir, Brincidofovir, Elbasvir, Famciclovir, Voxilaprevir, Tecovirimat, Pibrentasvir, Rimantadine, Valganciclovir, More", "updated_at": 1767369485}, {"id": 249668, "ingredient1": "Bictegravir", "ingredient2": "Pioglitazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295542/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "Tenofovir alafenamide, Cabotegravir, Maraviroc, Zanamivir, Telaprevir, Rilpivirine, Dolutegravir, Cobicistat, Brincidofovir, Famciclovir, Doravirine, More", "updated_at": 1767369485}, {"id": 249669, "ingredient1": "Bictegravir", "ingredient2": "Ponatinib", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with ponatinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter.  The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by ponatinib.", "source": "DDInter", "management_text": "Caution is advised when ponatinib is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ponatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism, Absorption, Excretion", "recommendation": "Caution is advised when ponatinib is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295544/", "reference_text": "[1] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc  (2012):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 249670, "ingredient1": "Bictegravir", "ingredient2": "Posaconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295545/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Miconazole, Flucytosine, Anidulafungin", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Famciclovir, Tipranavir, Darunavir, More", "updated_at": 1767369485}, {"id": 249671, "ingredient1": "Bictegravir", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295546/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Stavudine, Remdesivir, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 249672, "ingredient1": "Bictegravir", "ingredient2": "Prednisolone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295547/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Mometasone furoate, Amcinonide, Budesonide, Fluocinolone acetonide, Hydrocortisone butyrate, Hydrocortisone, Fluticasone, Fluocinonide, Methylprednisolone, Betamethasone, Fluorometholone, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249673, "ingredient1": "Bictegravir", "ingredient2": "Prednisone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295548/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Budesonide, Hydrocortisone, Cromoglicic acid, Olsalazine, Sulfasalazine, Betamethasone, Balsalazide, Beclomethasone dipropionate, Mesalazine, Fludrocortisone, Cortisone, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249674, "ingredient1": "Bictegravir", "ingredient2": "Primidone", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295549/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 249675, "ingredient1": "Bictegravir", "ingredient2": "Propafenone", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295550/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lidocaine, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 249676, "ingredient1": "Bictegravir", "ingredient2": "Quinidine", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295551/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lidocaine, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Cabotegravir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Stavudine, Remdesivir, More", "updated_at": 1767369485}, {"id": 249677, "ingredient1": "Bictegravir", "ingredient2": "Quinine", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295552/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, More", "updated_at": 1767369485}, {"id": 249678, "ingredient1": "Bictegravir", "ingredient2": "Ranolazine", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295553/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Ivabradine, Adenosine, Regadenoson", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249679, "ingredient1": "Bictegravir", "ingredient2": "Regorafenib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295554/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 249680, "ingredient1": "Bictegravir", "ingredient2": "Reserpine", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295555/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Prazosin, Rauwolfia serpentina root, Hydralazine, Clonidine, Guanethidine, Deserpidine, Rauwolfia serpentina root, Clonidine, Methyldopa, Deserpidine", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249681, "ingredient1": "Bictegravir", "ingredient2": "Ribociclib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295556/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249682, "ingredient1": "Bictegravir", "ingredient2": "Rifabutin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295557/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Lamivudine, Paritaprevir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, Elbasvir, More", "updated_at": 1767369485}, {"id": 249683, "ingredient1": "Bictegravir", "ingredient2": "Rifampicin", "severity": "Major", "effect": "Coadministration with rifampin may significantly decrease the plasma concentrations of bictegravir.  The proposed mechanism is rifampin induction of bictegravir metabolism via CYP450 3A4 and uridine diphosphate glucuronosyltransferase (UGT) 1A1.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with rifampin is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with rifampin is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295558/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Paritaprevir, Zanamivir, Velpatasvir, Elbasvir, Famciclovir, Tecovirimat, Pibrentasvir, Rimantadine, Valganciclovir, Telbivudine, Entecavir, More", "updated_at": 1767369485}, {"id": 249684, "ingredient1": "Bictegravir", "ingredient2": "Rifapentine", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295559/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Lamivudine, Paritaprevir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, Famciclovir, More", "updated_at": 1767369485}, {"id": 249685, "ingredient1": "Bictegravir", "ingredient2": "Ritonavir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295560/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Paritaprevir, Cabotegravir, Zanamivir, Velpatasvir, Rilpivirine, Oseltamivir, Darunavir, Maribavir, Rimantadine, Elvitegravir, Telbivudine, More", "updated_at": 1767369485}, {"id": 249686, "ingredient1": "Bictegravir", "ingredient2": "Rofecoxib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295561/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, Glucosamine, Oxaprozin, More", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 249687, "ingredient1": "Bictegravir", "ingredient2": "Rolapitant", "severity": "Moderate", "effect": "Coadministration with rolapitant may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter.", "source": "DDInter", "management_text": "Concomitant use of rolapitant with drugs that are P-gp substrates should generally be avoided.  If concomitant administration is unavoidable, caution is advised, particularly with drugs that have a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever rolapitant is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "Concomitant use of rolapitant with drugs that are P-gp substrates should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295562/", "reference_text": "[1] \"Product Information. Varubi (rolapitant).\" Tesaro Inc.  (2015):", "alternatives_a": "Nabilone, Granisetron, Scopolamine, Dronabinol, Dolasetron, Ondansetron, Palonosetron", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 249688, "ingredient1": "Bictegravir", "ingredient2": "Rucaparib", "severity": "Moderate", "effect": "Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 3A4.  The proposed mechanism is decreased clearance due to rucaparib-mediated inhibition of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295563/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249689, "ingredient1": "Bictegravir", "ingredient2": "Rufinamide", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295564/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, Etravirine, More", "updated_at": 1767369485}, {"id": 249690, "ingredient1": "Bictegravir", "ingredient2": "Safinamide", "severity": "Moderate", "effect": "Coadministration with safinamide may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter.  The proposed mechanism is decreased clearance due to intestinal BCRP-inhibition by safinamide.", "source": "DDInter", "management_text": "Caution is advised when safinamide is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, topotecan, and irinotecan.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever safinamide is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when safinamide is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range such as methotrexate, topotecan, and irinotecan.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295565/", "reference_text": "[1] \"Product Information. Xadago (safinamide).\" US WorldMeds LLC  (2017):", "alternatives_a": "Apomorphine, Ropinirole, Opicapone, Cabergoline, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, Pergolide, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249691, "ingredient1": "Bictegravir", "ingredient2": "Saquinavir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295566/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Glecaprevir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Oseltamivir, Remdesivir, Famciclovir, Maribavir, Pibrentasvir, More", "updated_at": 1767369485}, {"id": 249692, "ingredient1": "Bictegravir", "ingredient2": "Sarecycline", "severity": "Moderate", "effect": "Coadministration with sarecycline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter.  The proposed mechanism is decreased clearance in the intestine, kidney, and/or liver due to inhibition of P-gp-mediated efflux by sarecycline.", "source": "DDInter", "management_text": "Caution is advised when sarecycline is used concurrently with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever sarecycline is added to or withdrawn from therapy.", "mechanism_text": "Metabolism, Absorption, Excretion", "recommendation": "Caution is advised when sarecycline is used concurrently with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295567/", "reference_text": "[1] \"Product Information. Seysara (sarecycline).\" Allergan Inc  (2018):", "alternatives_a": "Tetracycline, Minocycline, Oxytetracycline, Doxycycline, Omadacycline, Eravacycline, Demeclocycline, Tigecycline", "alternatives_b": "Lamivudine, Glecaprevir, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 249693, "ingredient1": "Bictegravir", "ingredient2": "Secobarbital", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295568/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Cobicistat, Acyclovir, More", "updated_at": 1767369485}, {"id": 249694, "ingredient1": "Bictegravir", "ingredient2": "Simeprevir", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295569/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 249695, "ingredient1": "Bictegravir", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295570/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 249696, "ingredient1": "Bictegravir", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295571/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "updated_at": 1767369485}, {"id": 249697, "ingredient1": "Bictegravir", "ingredient2": "Somatotropin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295572/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "updated_at": 1767369485}, {"id": 249698, "ingredient1": "Bictegravir", "ingredient2": "Sonidegib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295573/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 249699, "ingredient1": "Bictegravir", "ingredient2": "Sorafenib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295574/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 249700, "ingredient1": "Bictegravir", "ingredient2": "Spironolactone", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295576/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Eplerenone, Amiloride, Triamterene, Finerenone", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 249701, "ingredient1": "Bictegravir", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may significantly decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers, such as St. John's wort, should generally be avoided.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of bictegravir with potent CYP450 3A4 inducers, such as St.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295577/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, More", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More", "updated_at": 1767369485}, {"id": 249702, "ingredient1": "Bictegravir", "ingredient2": "Stiripentol", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295578/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Brivaracetam, Topiramate, Lamotrigine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Perampanel, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 249703, "ingredient1": "Bictegravir", "ingredient2": "Sucralfate", "severity": "Major", "effect": "Concurrent administration of medications or oral supplements containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of bictegravir.", "source": "DDInter", "management_text": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.  Routine administration of bictegravir simultaneously with, or 2 hours after, antacids containing aluminum, magnesium or calcium is not recommended.  When used with supplements containing calcium or iron, bictegravir and the supplements may be taken together with food.  Routine administration of bictegravir under fasting conditions simultaneously with, or 2 hours after, supplements containing calcium or iron is not recommended.", "mechanism_text": "Absorption", "recommendation": "When used with antacids containing aluminum, magnesium or calcium, bictegravir may be taken under fasting conditions 2 hours before the antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295579/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, Rabeprazole, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Famotidine, Cimetidine, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More", "updated_at": 1767369485}, {"id": 249704, "ingredient1": "Bictegravir", "ingredient2": "Sulfinpyrazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295580/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Pegloticase, Febuxostat, Colchicine, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, More", "updated_at": 1767369485}, {"id": 249705, "ingredient1": "Bictegravir", "ingredient2": "Suvorexant", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295581/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 249706, "ingredient1": "Bictegravir", "ingredient2": "Tacrolimus", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295582/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Minoxidil, Deoxycholic acid, Pimecrolimus, Glycopyrronium, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, Dupilumab, More", "alternatives_b": "Cabotegravir, Maraviroc, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Brincidofovir, Elbasvir, Voxilaprevir, Pibrentasvir, Rimantadine, More", "updated_at": 1767369485}, {"id": 249707, "ingredient1": "Bictegravir", "ingredient2": "Tafamidis", "severity": "Moderate", "effect": "Based on in vitro data, coadministration with tafamidis may increase the plasma concentrations and the risk of toxicity of drugs that are substrates of the transport protein breast cancer resistance protein (BCRP) (e.g., methotrexate, rosuvastatin, imatinib), uridine diphosphate glucuronosyltransferase (UGT) 1A1 (e.g., bictegravir, irinotecan, raltegravir), and/or uptake transporters OAT1 and OAT3 (organic anion transporters) (e.g., bumetanide, furosemide, lamivudine, methotrexate, oseltamivir, tenofovir, ganciclovir, adefovir, cidofovir, zidovudine, zalcitabine) at clinically relevant concentrations.  The proposed mechanism is decreased clearance due to tafamidis-mediated inhibition of the corresponding transport protein.", "source": "DDInter", "management_text": "Caution is advised if tafamidis is used concomitantly with drugs that are substrates of these transport proteins, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever tafamidis is added to or withdrawn from therapy with these drugs.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism, Excretion", "recommendation": "Caution is advised if tafamidis is used concomitantly with drugs that are substrates of these transport proteins, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295583/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[3] \"Product Information. Vyndaqel (tafamidis).\" Pfizer U.S. Pharmaceuticals Group  (2019):", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Pitolisant, Amifampridine, Deutetrabenazine", "alternatives_b": "Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 249708, "ingredient1": "Bictegravir", "ingredient2": "Tamoxifen", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295584/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, Nilutamide, Exemestane", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Telaprevir, Velpatasvir, Dolutegravir, More", "updated_at": 1767369485}, {"id": 249709, "ingredient1": "Bictegravir", "ingredient2": "Tedizolid", "severity": "Moderate", "effect": "Coadministration with oral tedizolid may increase the plasma concentrations and the risk of adverse effects of orally administered drugs that are substrates of the breast cancer resistance protein (BCRP) transporter.  The proposed mechanism is decreased clearance due to inhibition of BCRP-mediated intestinal efflux by tedizolid.", "source": "DDInter", "management_text": "Consider temporarily interrupting treatment with the BCRP substrate during treatment with tedizolid, especially for BCRP substrates with a narrow therapeutic index.  If coadministration cannot be avoided, monitor for adverse reactions related to concomitantly administered BCRP substrate.", "mechanism_text": "Metabolism", "recommendation": "Consider temporarily interrupting treatment with the BCRP substrate during treatment with tedizolid, especially for BCRP substrates with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295586/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Sivextro (tedizolid).\" Cubist Pharmaceuticals Inc  (2014):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Fosfomycin, More", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249710, "ingredient1": "Bictegravir", "ingredient2": "Telaprevir", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295587/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, Dolutegravir, More", "alternatives_b": "Lamivudine, Glecaprevir, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, Oseltamivir, Cobicistat, More", "updated_at": 1767369485}, {"id": 249711, "ingredient1": "Bictegravir", "ingredient2": "Telithromycin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295588/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Dirithromycin, Lincomycin, Clindamycin", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Lenacapavir, Velpatasvir, Stavudine, Famciclovir, Tipranavir, More", "updated_at": 1767369485}, {"id": 249712, "ingredient1": "Bictegravir", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295589/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Cobicistat, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249713, "ingredient1": "Bictegravir", "ingredient2": "Teriflunomide", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295591/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More", "alternatives_b": "Glecaprevir, Cabotegravir, Amprenavir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Velpatasvir, Dolutegravir, Oseltamivir, Cobicistat, More", "updated_at": 1767369485}, {"id": 249714, "ingredient1": "Bictegravir", "ingredient2": "Ticagrelor", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295592/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Betrixaban, Clopidogrel, Cilostazol, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249715, "ingredient1": "Bictegravir", "ingredient2": "Tivozanib", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295593/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 249716, "ingredient1": "Bictegravir", "ingredient2": "Tolvaptan", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295594/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249717, "ingredient1": "Bictegravir", "ingredient2": "Troglitazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295596/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "Lamivudine, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Cobicistat, Acyclovir, Brincidofovir, Stavudine, Famciclovir, More", "updated_at": 1767369485}, {"id": 249718, "ingredient1": "Bictegravir", "ingredient2": "Troleandomycin", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295597/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Dirithromycin, Lincomycin, Clindamycin", "alternatives_b": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 249719, "ingredient1": "Bictegravir", "ingredient2": "Tucatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295598/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Glecaprevir, Cabotegravir, Amprenavir, Zanamivir, Valaciclovir, Lenacapavir, Telaprevir, Velpatasvir, Dolutegravir, Oseltamivir, More", "updated_at": 1767369485}, {"id": 249720, "ingredient1": "Bictegravir", "ingredient2": "Ulipristal", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with ulipristal may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter.  The proposed mechanism is decreased clearance in the intestine, liver, and/or kidney due to inhibition of P-glycoprotein-mediated drug efflux by ulipristal.", "source": "DDInter", "management_text": "Caution is advised when ulipristal is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ulipristal is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ulipristal is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295599/", "reference_text": "[1] \"Product Information. Ella (ulipristal).\" Afaxys Inc.  (2022):", "alternatives_a": "Norelgestromin, Norethisterone, Etonogestrel, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 249721, "ingredient1": "Bictegravir", "ingredient2": "Valbenazine", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both P-gp and BCRP; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.  If concomitant use is required, caution and close clinical and laboratory monitoring, including renal function, are recommended.  Dosage adjustments may be required whenever a P-gp and/or BCRP inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The use of bictegravir with P-gp and/or BCRP inhibitors should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295600/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Dextromethorphan, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Pitolisant, Amifampridine, Deutetrabenazine", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 249722, "ingredient1": "Bictegravir", "ingredient2": "Vandetanib", "severity": "Moderate", "effect": "Coadministration with vandetanib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein transporter, such as digoxin and dabigatran.  The mechanism involves increased absorption and/or decreased clearance due to inhibition of drug efflux mediated by intestinal and renal/hepatic P-glycoprotein, respectively.  Vandetanib is a weak P-glycoprotein inhibitor.", "source": "DDInter", "management_text": "Caution is advised if vandetanib must be used concomitantly with medications that are substrates of P-glycoprotein, particularly those with a narrow therapeutic range such as digoxin.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever vandetanib is added to or withdrawn from therapy.", "mechanism_text": "Absorption, Excretion", "recommendation": "Caution is advised if vandetanib must be used concomitantly with medications that are substrates of P-glycoprotein, particularly those with a narrow therapeutic range such as digoxin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295601/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Vandetanib (vandetanib).\" Astra-Zeneca Pharmaceuticals  (2011):", "alternatives_a": "Acalabrutinib, Dacomitinib, Larotrectinib, Avapritinib, Bosutinib, Selumetinib, Ibrutinib, Zanubrutinib, Axitinib, Sunitinib, Ripretinib, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 249723, "ingredient1": "Bictegravir", "ingredient2": "Varenicline", "severity": "Moderate", "effect": "Coadministration with bictegravir may increase the plasma concentrations of drugs that are substrates of organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE1).  The mechanism is inhibition of OCT2- and MATE1-mediated renal tubular secretion by bictegravir.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with drugs that are substrates of OCT2 or MATE1, particularly those with a narrow therapeutic range.  Close monitoring is particularly recommended in patients with moderate renal impairment (CrCl 30 to 59 mL/min) who are to be administered bictegravir and metformin, due to the increased risk of lactic acidosis.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever bictegravir is added to or withdrawn from therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when bictegravir is used with drugs that are substrates of OCT2 or MATE1, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295602/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Naltrexone, Disulfiram, Methadone, Levacetylmethadol, Nalmefene, Nicotine, Buprenorphine", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 249724, "ingredient1": "Bictegravir", "ingredient2": "Vemurafenib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295603/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More", "alternatives_b": "Lamivudine, Paritaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, More", "updated_at": 1767369485}, {"id": 249725, "ingredient1": "Bictegravir", "ingredient2": "Verapamil", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295604/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Enalapril, Amlodipine, Moexipril, Ramipril, Hydrochlorothiazide, Lisinopril, Perindopril, Bisoprolol, Benazepril, Quinapril, Trandolapril, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Velpatasvir, Brincidofovir, Remdesivir, Elbasvir, Voxilaprevir, Maribavir, More", "updated_at": 1767369485}, {"id": 249726, "ingredient1": "Bictegravir", "ingredient2": "Voriconazole", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295606/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Miconazole, Flucytosine, Anidulafungin", "alternatives_b": "Glecaprevir, Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Stavudine, Famciclovir, Darunavir, More", "updated_at": 1767369485}, {"id": 249727, "ingredient1": "Bictegravir", "ingredient2": "Voxelotor", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or uridine diphosphate glucuronosyltransferase (UGT) 1A1 may increase the plasma concentrations of bictegravir.  According to the product labeling, bictegravir is a substrate of both CYP450 3A4 and UGT1A1; however, the extent to which each enzymatic pathway contributes to the metabolic clearance of bictegravir has not been reported.", "source": "DDInter", "management_text": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.  Patients should be monitored for increased adverse effects such as diarrhea, nausea, and vomiting.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when bictegravir is used with CYP450 3A4 and UGT1A1 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295607/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):", "alternatives_a": "Hemin, Conestat alfa, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Dolutegravir, Oseltamivir, Acyclovir, More", "updated_at": 1767369485}, {"id": 249728, "ingredient1": "Bictegravir", "ingredient2": "Zinc acetate", "severity": "Major", "effect": "Coadministration with medications or supplements containing polyvalent cations such as zinc may decrease the plasma concentrations of integrase strand transfer inhibitors (INSTIs).  The proposed mechanism involves chelation of the INSTI by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI at least 2 hours before or 6 hours after products containing polyvalent cations such as zinc.", "mechanism_text": "Absorption", "recommendation": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI at least 2 hours before or 6 hours after products containing polyvalent cations such as zinc.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295608/", "reference_text": "[1] \"Product Information. Tivicay (dolutegravir).\" ViiV Healthcare  (2013):[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):[3] US National Library of Medicine \"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.  https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/287/insti-drug-interactions\"   (2019):", "alternatives_a": "Lidocaine, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Triamcinolone, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249729, "ingredient1": "Bictegravir", "ingredient2": "Zinc gluconate", "severity": "Major", "effect": "Coadministration with medications or supplements containing polyvalent cations such as zinc may decrease the plasma concentrations of integrase strand transfer inhibitors (INSTIs).  The proposed mechanism involves chelation of the INSTI by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI at least 2 hours before or 6 hours after products containing polyvalent cations such as zinc.", "mechanism_text": "Absorption", "recommendation": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI at least 2 hours before or 6 hours after products containing polyvalent cations such as zinc.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295609/", "reference_text": "[1] \"Product Information. Tivicay (dolutegravir).\" ViiV Healthcare  (2013):[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):[3] US National Library of Medicine \"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.  https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/287/insti-drug-interactions\"   (2019):", "alternatives_a": "Lidocaine, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Triamcinolone, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249730, "ingredient1": "Bictegravir", "ingredient2": "Zinc sulfate", "severity": "Major", "effect": "Coadministration with medications or supplements containing polyvalent cations such as zinc may decrease the plasma concentrations of integrase strand transfer inhibitors (INSTIs).  The proposed mechanism involves chelation of the INSTI by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI at least 2 hours before or 6 hours after products containing polyvalent cations such as zinc.", "mechanism_text": "Absorption", "recommendation": "If concomitant use is required, monitor for virologic efficacy and administer the INSTI at least 2 hours before or 6 hours after products containing polyvalent cations such as zinc.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295610/", "reference_text": "[1] \"Product Information. Tivicay (dolutegravir).\" ViiV Healthcare  (2013):[2] \"Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir).\" Gilead Sciences  (2018):[3] US National Library of Medicine \"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.  https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/287/insti-drug-interactions\"   (2019):", "alternatives_a": "Lidocaine, Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Triamcinolone, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 249731, "ingredient1": "Hydralazine", "ingredient2": "Amobarbital", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295611/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More", "alternatives_b": "Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine", "updated_at": 1767369485}, {"id": 249732, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Amobarbital", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295612/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More", "alternatives_b": "Isosorbide mononitrate, Nesiritide, Nitroglycerin, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, More", "updated_at": 1767369485}, {"id": 249733, "ingredient1": "Hydralazine", "ingredient2": "Brentuximab vedotin", "severity": "Moderate", "effect": "Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.  Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness.  Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295613/", "reference_text": "[1] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995):  201[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979):  663-6[3] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online.  http://www.appco.com.au/appguide/default.asp\"   (2006):[4] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[5] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):[6] \"Product Information. Danyelza (naxitamab).\" Y-mAbs Therapeutics  (2020):", "alternatives_a": "Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 249734, "ingredient1": "Hydralazine", "ingredient2": "Chlorphenesin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295614/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, Flucytosine, Tioconazole, Clotrimazole", "alternatives_b": "Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Guanethidine, Deserpidine", "updated_at": 1767369485}, {"id": 249735, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Chlorphenesin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295615/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Ciclopirox, Griseofulvin, Terbinafine, Econazole, Flucytosine, Tioconazole", "alternatives_b": "Isosorbide mononitrate, Nesiritide, Nitroglycerin, Vericiguat, Lidocaine, Zinc sulfate, Diltiazem, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, More", "updated_at": 1767369485}, {"id": 249736, "ingredient1": "Hydralazine", "ingredient2": "Chlorzoxazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295616/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Chlormezanone", "alternatives_b": "Minoxidil, Nitroprusside, Diazoxide, Guanethidine", "updated_at": 1767369485}, {"id": 249737, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Chlorzoxazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295617/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Chlormezanone", "alternatives_b": "Isosorbide mononitrate, Nesiritide, Nitroglycerin, Vericiguat, Lidocaine, Zinc sulfate, Diltiazem, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, More", "updated_at": 1767369485}, {"id": 249738, "ingredient1": "Hydralazine", "ingredient2": "Cyclobenzaprine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295618/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Chlormezanone", "alternatives_b": "Nitroprusside, Diazoxide, Prazosin, Deserpidine", "updated_at": 1767369485}, {"id": 249739, "ingredient1": "Hydralazine", "ingredient2": "Ethanol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295619/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Methionine, More", "alternatives_b": "Minoxidil, Nitroprusside, Diazoxide, Guanethidine", "updated_at": 1767369485}, {"id": 249740, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Ethanol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295620/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Methionine, More", "alternatives_b": "Isosorbide mononitrate, Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Diltiazem, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, More", "updated_at": 1767369485}, {"id": 249741, "ingredient1": "Hydralazine", "ingredient2": "Diamorphine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295621/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Rauwolfia serpentina root, Deserpidine", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Levacetylmethadol, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 249742, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Diamorphine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295622/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More", "alternatives_b": "Acamprosate, Naltrexone, Disulfiram, Levacetylmethadol, Nalmefene", "updated_at": 1767369485}, {"id": 249743, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295623/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Isosorbide mononitrate, Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249744, "ingredient1": "Hydralazine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295624/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Minoxidil", "alternatives_b": "Duloxetine, Desipramine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "updated_at": 1767369485}, {"id": 249745, "ingredient1": "Hydralazine", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295625/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Minoxidil, Nitroprusside, Diazoxide, Prazosin", "alternatives_b": "Duloxetine, Desipramine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John's Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "updated_at": 1767369485}, {"id": 249746, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295626/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Isosorbide mononitrate, Nesiritide, Nitroglycerin, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, More", "alternatives_b": "Desipramine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More", "updated_at": 1767369485}, {"id": 249747, "ingredient1": "Hydralazine", "ingredient2": "Remifentanil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295627/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Guanethidine, Deserpidine", "alternatives_b": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 249748, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Remifentanil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295628/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Isosorbide mononitrate, Nesiritide, Nitroglycerin, Vericiguat, Tetracaine, Zinc sulfate, Diltiazem, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, More", "alternatives_b": "Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Halothane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 249749, "ingredient1": "Hydralazine", "ingredient2": "Sufentanil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295629/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Guanethidine, Deserpidine", "alternatives_b": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 249750, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Sufentanil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295630/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Isosorbide mononitrate, Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, More", "alternatives_b": "Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Halothane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 249751, "ingredient1": "Hydralazine", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295632/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Minoxidil, Nitroprusside, Diazoxide, Prazosin, Guanethidine", "alternatives_b": "Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More", "updated_at": 1767369485}, {"id": 249752, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Bacampicillin", "severity": "Moderate", "effect": "Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Antagonism", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295633/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics.  https://www.florajen.com/products/florajen-women\"   (2020):", "alternatives_a": "Sulbactam, Piperacillin, Meticillin, Carbenicillin, Ticarcillin, Mezlocillin, Tazobactam, Nafcillin, Benzylpenicillin, Procaine benzylpenicillin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249753, "ingredient1": "Brentuximab vedotin", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.  It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed unless benefits are anticipated to outweigh the potential risk of infection.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295634/", "reference_text": "[1] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004):  62-9[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002):  1155-60[3] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999):  1159-60[4] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998):  887-8[5] Saxelin M, Chuang NH, Chassy B, et al. \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996):  564-6[6] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997):  1048-55[7] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998):  325-6[8] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999):  290-2[9] Borriello SP, Hammes WP, Holzapfel W, et al. \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003):  775-80[10] Lolis N, Veldekis D, Moraitou H, et al. \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008):  epub[11] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006):  1256-64", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249754, "ingredient1": "Brentuximab vedotin", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.  It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed unless benefits are anticipated to outweigh the potential risk of infection.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295635/", "reference_text": "[1] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004):  62-9[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002):  1155-60[3] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999):  1159-60[4] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998):  887-8[5] Saxelin M, Chuang NH, Chassy B, et al. \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996):  564-6[6] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997):  1048-55[7] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998):  325-6[8] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999):  290-2[9] Borriello SP, Hammes WP, Holzapfel W, et al. \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003):  775-80[10] Lolis N, Veldekis D, Moraitou H, et al. \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008):  epub[11] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006):  1256-64", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249755, "ingredient1": "Cloxacillin", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Antagonism", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295636/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics.  https://www.florajen.com/products/florajen-women\"   (2020):", "alternatives_a": "Sulbactam, Piperacillin, Meticillin, Carbenicillin, Ticarcillin, Mezlocillin, Tazobactam, Nafcillin, Benzylpenicillin, Procaine benzylpenicillin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249756, "ingredient1": "Enoxacin", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Antagonism", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295638/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics.  https://www.florajen.com/products/florajen-women\"   (2020):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249757, "ingredient1": "Gemtuzumab ozogamicin", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.  It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed unless benefits are anticipated to outweigh the potential risk of infection.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295639/", "reference_text": "[1] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004):  62-9[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002):  1155-60[3] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999):  1159-60[4] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998):  887-8[5] Saxelin M, Chuang NH, Chassy B, et al. \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996):  564-6[6] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997):  1048-55[7] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998):  325-6[8] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999):  290-2[9] Borriello SP, Hammes WP, Holzapfel W, et al. \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003):  775-80[10] Lolis N, Veldekis D, Moraitou H, et al. \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008):  epub[11] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006):  1256-64", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249758, "ingredient1": "Gemtuzumab ozogamicin", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.  It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed unless benefits are anticipated to outweigh the potential risk of infection.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295640/", "reference_text": "[1] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004):  62-9[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002):  1155-60[3] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999):  1159-60[4] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998):  887-8[5] Saxelin M, Chuang NH, Chassy B, et al. \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996):  564-6[6] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997):  1048-55[7] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998):  325-6[8] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999):  290-2[9] Borriello SP, Hammes WP, Holzapfel W, et al. \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003):  775-80[10] Lolis N, Veldekis D, Moraitou H, et al. \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008):  epub[11] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006):  1256-64", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249759, "ingredient1": "Grepafloxacin", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Antagonism", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295641/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics.  https://www.florajen.com/products/florajen-women\"   (2020):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249760, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.  It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed unless benefits are anticipated to outweigh the potential risk of infection.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295642/", "reference_text": "[1] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004):  62-9[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002):  1155-60[3] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999):  1159-60[4] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998):  887-8[5] Saxelin M, Chuang NH, Chassy B, et al. \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996):  564-6[6] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997):  1048-55[7] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998):  325-6[8] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999):  290-2[9] Borriello SP, Hammes WP, Holzapfel W, et al. \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003):  775-80[10] Lolis N, Veldekis D, Moraitou H, et al. \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008):  epub[11] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006):  1256-64", "alternatives_a": "Iodide I-131", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249761, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.  It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed unless benefits are anticipated to outweigh the potential risk of infection.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295643/", "reference_text": "[1] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004):  62-9[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002):  1155-60[3] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999):  1159-60[4] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998):  887-8[5] Saxelin M, Chuang NH, Chassy B, et al. \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996):  564-6[6] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997):  1048-55[7] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998):  325-6[8] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999):  290-2[9] Borriello SP, Hammes WP, Holzapfel W, et al. \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003):  775-80[10] Lolis N, Veldekis D, Moraitou H, et al. \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008):  epub[11] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006):  1256-64", "alternatives_a": "Iodide I-131", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249762, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Antagonism", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295644/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics.  https://www.florajen.com/products/florajen-women\"   (2020):", "alternatives_a": "Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Famciclovir, Tobramycin, Benzylpenicillin, Gentamicin, Amikacin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249763, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Loracarbef", "severity": "Moderate", "effect": "Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Antagonism", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295645/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics.  https://www.florajen.com/products/florajen-women\"   (2020):", "alternatives_a": "Cefepime, Imipenem, Aztreonam, Ceftazidime, Cefiderocol, Cefapirin, Cefoxitin, Cefonicid, Cefoperazone, Meropenem, Cefalotin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249764, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Sulfadoxine", "severity": "Moderate", "effect": "Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Antagonism", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295646/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics.  https://www.florajen.com/products/florajen-women\"   (2020):", "alternatives_a": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249765, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Sulfamethizole", "severity": "Moderate", "effect": "Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Antagonism", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295647/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics.  https://www.florajen.com/products/florajen-women\"   (2020):", "alternatives_a": "Sorbitol, Sodium citrate, Magnesium citrate, Mannitol, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Neomycin, Tamsulosin, Tinidazole, Ascorbic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249766, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Tositumomab", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.  It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed unless benefits are anticipated to outweigh the potential risk of infection.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295648/", "reference_text": "[1] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004):  62-9[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002):  1155-60[3] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999):  1159-60[4] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998):  887-8[5] Saxelin M, Chuang NH, Chassy B, et al. \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996):  564-6[6] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997):  1048-55[7] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998):  325-6[8] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999):  290-2[9] Borriello SP, Hammes WP, Holzapfel W, et al. \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003):  775-80[10] Lolis N, Veldekis D, Moraitou H, et al. \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008):  epub[11] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006):  1256-64", "alternatives_a": "Iodide I-131", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249767, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Troleandomycin", "severity": "Moderate", "effect": "Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic.  It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations.", "source": "DDInter", "management_text": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "mechanism_text": "Antagonism", "recommendation": "Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295649/", "reference_text": "[1] Clarion Brands, Inc. \"Florajen Probiotics.  https://www.florajen.com/products/florajen-women\"   (2020):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249768, "ingredient1": "Bifidobacterium longum infantis", "ingredient2": "Uracil mustard", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.  It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed unless benefits are anticipated to outweigh the potential risk of infection.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295651/", "reference_text": "[1] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004):  62-9[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002):  1155-60[3] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999):  1159-60[4] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998):  887-8[5] Saxelin M, Chuang NH, Chassy B, et al. \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996):  564-6[6] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997):  1048-55[7] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998):  325-6[8] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999):  290-2[9] Borriello SP, Hammes WP, Holzapfel W, et al. \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003):  775-80[10] Lolis N, Veldekis D, Moraitou H, et al. \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008):  epub[11] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006):  1256-64", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249769, "ingredient1": "Brentuximab vedotin", "ingredient2": "Progesterone", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.  In vitro, MMAE was found to be a substrate of the P-gp efflux transporter.", "source": "DDInter", "management_text": "Caution is advised when brentuximab is used with P-gp inhibitors.  Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when brentuximab is used with P-gp inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295887/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):", "alternatives_a": "Norethisterone, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, Dienogest, Norgestrel, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 249770, "ingredient1": "Somapacitan", "ingredient2": "Progesterone", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295889/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dienogest, Etynodiol, Dienogest, Etynodiol", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 249771, "ingredient1": "St. John's Wort", "ingredient2": "Progesterone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins.  Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.  The interaction has been reported primarily with oral contraceptives.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.  For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers.  Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).  Individual product labeling should be consulted for specific time frames.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Patients should be advised to notify their physician if they experience inadequate control of symptoms associated with estrogen deficiency (e.g., nocturnal sweating, vasomotor disturbances, atrophic vaginitis) or changes in the uterine bleeding profile.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295890/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[3] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[4] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984):  1125-6[5] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986):  384[6] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990):  124-5[7] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[8] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[9] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990):  101-5[10] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990):  241-7[11] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[12] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[13] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[14] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[15] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[16] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[17] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[19] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[20] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[21] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[22] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984):  1125-6[23] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[24] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[25] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[26] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[27] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[28] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories  (2001):[30] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[31] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[32] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[33] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[34] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[35] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[36] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[37] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[38] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000):  598-604[39] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[40] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[41] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[42] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003):  112-113[43] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003):  683-90[44] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003):  525-35[45] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002):  P25[46] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001):  A25[47] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249772, "ingredient1": "Telotristat ethyl", "ingredient2": "Progesterone", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes.  The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295891/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc.  (2017):", "alternatives_a": "Dienogest, Drospirenone, Etynodiol, Dienogest, Etynodiol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249773, "ingredient1": "Brentuximab vedotin", "ingredient2": "Metronidazole", "severity": "Moderate", "effect": "Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.  Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness.  Patients experiencing new, worsening, or recurrent neuropathy may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The potential for increased risk and/or severity of peripheral neuropathy should be considered when brentuximab vedotin is used with other drugs that are also associated with peripheral neuropathy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295893/", "reference_text": "[1] Carrion C, Espinosa E, Herrero A, Garcia B \"Possible vincristine-isoniazid interaction.\" Ann Pharmacother 29 (1995):  201[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979):  663-6[3] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online.  http://www.appco.com.au/appguide/default.asp\"   (2006):[4] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[5] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):[6] \"Product Information. Danyelza (naxitamab).\" Y-mAbs Therapeutics  (2020):", "alternatives_a": "Pantoprazole, Tetracycline, Rabeprazole, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Famotidine, Rifabutin, Cimetidine, Esomeprazole, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 249774, "ingredient1": "Isosorbide", "ingredient2": "Tetracycline", "severity": "Minor", "effect": "The coadministration of diuretics and tetracyclines may result in decreased renal function manifested by increases in serum creatinine and blood urea nitrogen (BUN).", "source": "DDInter", "management_text": "Usually, no clinical intervention is necessary, unless decreases in renal function occur.  If renal function deteriorates, discontinuation of one or both agents may be necessary.", "mechanism_text": "Synergism", "recommendation": "Usually, no clinical intervention is necessary, unless decreases in renal function occur.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295895/", "reference_text": "[1] Jick H, Slone D, Shapiro S, et al. \"Tetracycline and drug-attributed rises in blood urea nitrogen: a report from the Boston Collaborative Drug Surveillance Program.\" JAMA 220 (1972):  377-9[2] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980):  203-7[3] Tannenberg AM \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972):  713[4] Alexander MR \"Tetracycline and rises in urea nitrogen.\" JAMA 221 (1972):  713-4", "alternatives_a": "Rifamycin, Miconazole, Polymyxin B, Ciprofloxacin, Chloramphenicol, Gentamicin, Chlorhexidine, Neomycin, Ofloxacin, Tinidazole, Dexlansoprazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249775, "ingredient1": "Tetracycline", "ingredient2": "Ketoconazole", "severity": "Major", "effect": "Use of hepatotoxic drugs together with ketoconazole or levoketoconazole may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The use of ketoconazole or levoketoconazole with other potentially hepatotoxic agents should be avoided.  Patients treated with levoketoconazole or ketoconazole should have liver tests performed prior to and during treatment.  Levoketoconazole manufacturer recommends interrupting treatment immediately if signs of hepatotoxicity occur.  Refer to levoketoconazole labeling for specific instructions on management of hepatotoxicity.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The use of ketoconazole or levoketoconazole with other potentially hepatotoxic agents should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295896/", "reference_text": "[1] \"Product Information. Ketoconazole (ketoconazole).\" Mylan Pharmaceuticals Inc  (2019):[2] \"Product Information. Recorlev (levoketoconazole).\" Xeris Pharmaceuticals Inc  (2022):[3] Auchus R, Pivonello R, Fleseriu M, et al. \"Levoketoconazole: a novel treatment for endogenous Cushing's syndrome.  https://www.tandfonline.com/doi/pdf/10.1080/17446651.2021.1945440\"   (2022):", "alternatives_a": "Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Mitapivat, Amphotericin B, Ciclopirox, Vemurafenib, Darunavir, Probenecid, Tioconazole, More", "alternatives_b": "Rifamycin, Polymyxin B, Chloramphenicol, Gentamicin, Chlorhexidine, Neomycin, Tinidazole, Misoprostol, Bismuth subcitrate potassium, Amoxicillin, Epinephrine, More", "updated_at": 1767369485}, {"id": 249776, "ingredient1": "Amobarbital", "ingredient2": "Bisoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295899/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Zopiclone, More", "alternatives_b": "Acetylsalicylic acid, Sotalol, Sotalol, Pindolol, Betaxolol, Carteolol, Sotalol, Indapamide, Ramipril", "updated_at": 1767369485}, {"id": 249777, "ingredient1": "Gadoxetic acid", "ingredient2": "Bisoprolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295900/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Enalapril, Moexipril, Ramipril, Hydrochlorothiazide, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, More", "alternatives_b": "Ferumoxsil", "updated_at": 1767369485}, {"id": 249778, "ingredient1": "Diamorphine", "ingredient2": "Bisoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295901/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Levacetylmethadol, Nalmefene", "updated_at": 1767369485}, {"id": 249779, "ingredient1": "Bisoprolol", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295902/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Felodipine, Ivabradine, Sotalol, Acebutolol, Sotalol, Acebutolol, Betaxolol, Pindolol, Sotalol, Felodipine", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Zopiclone, More", "updated_at": 1767369485}, {"id": 249780, "ingredient1": "Bisoprolol", "ingredient2": "Patiromer", "severity": "Moderate", "effect": "Patiromer can bind to some orally administered drugs, which may decrease their gastrointestinal absorption and reduce their effectiveness.  According to the manufacturer, in vitro studies observed potentially clinically significant binding between patiromer and telmisartan, bisoprolol, carvedilol, nebivolol, mycophenolate mofetil, quinidine, and thiamine.", "source": "DDInter", "management_text": "Patiromer should be administered at least 3 hours before or 3 hours after other oral medications, particularly ciprofloxacin, levothyroxine, metformin, telmisartan, bisoprolol, carvedilol, nebivolol, mycophenolate mofetil, quinidine, and thiamine.  Alternatives to patiromer or the other medications should be considered if adequate dosing separation is not possible.  Otherwise, clinical response and/or blood levels should be monitored where possible.", "mechanism_text": "Absorption", "recommendation": "Patiromer should be administered at least 3 hours before or 3 hours after other oral medications, particularly ciprofloxacin, levothyroxine, metformin, telmisartan, bisoprolol, carvedilol, nebivolol, mycophenolate mofetil, quinidine, and thiamine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295903/", "reference_text": "[1] \"Product Information. Veltassa (patiromer).\" Relypsa, Inc.  (2015):[2] \"Product Information. Veltassa (patiromer).\" Vifor Pharma Pty Ltd  (2023):[3] \"Product Information. Veltassa (patiromer).\" Vifor Fresenius Medical Care Renal Pharma UK Ltd  (2022):", "alternatives_a": "Felodipine, Amlodipine, Propranolol, Metoprolol, Carvedilol, Nifedipine, Ivabradine, Sotalol, Acetylsalicylic acid, Atenolol, Acebutolol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249781, "ingredient1": "Bisoprolol", "ingredient2": "Remifentanil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295905/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Felodipine, Carvedilol, Nifedipine, Ivabradine, Sotalol, Acetylsalicylic acid, Acebutolol, Sotalol, Acebutolol, Carvedilol, Esmolol, More", "alternatives_b": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 249782, "ingredient1": "Diamorphine", "ingredient2": "Brimonidine (ophthalmic)", "severity": "Moderate", "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.  Additive hypotensive effects and orthostasis may also occur with some CNS depressants and other agents that have these effects, particularly during initial dosing and/or parenteral administration.", "source": "DDInter", "management_text": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295907/", "reference_text": "[1] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[2] \"Product Information. Alphagan (brimonidine ophthalmic).\" Allergan Inc  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Pekdemir M, Yanturali S, Karakus G \"More than just an ocular solution.\" Emerg Med J 22 (2005):  753-4[5] \"Product Information. Mirvaso (brimonidine topical).\" Galderma Laboratories Inc  (2013):", "alternatives_a": "Tacrolimus, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, More", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 249783, "ingredient1": "Brimonidine (ophthalmic)", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects such as hypotension and bradycardia.  The possibility for an additive or potentiating effect on blood pressure and heart rate should be considered when used with other medications that affect these parameters, such as ophthalmic and systemic beta blockers, vasodilators, cardiac glycosides, and antihypertensive agents.", "source": "DDInter", "management_text": "Blood pressure and pulse rate should be monitored regularly when topical alpha-2 adrenergic receptor agonists are prescribed in combination with cardiovascular drugs.  Patients should be advised to notify their physician if they experience slow pulse, irregular heartbeat, dizziness, lightheadedness, or syncope.", "mechanism_text": "Synergism", "recommendation": "Blood pressure and pulse rate should be monitored regularly when topical alpha-2 adrenergic receptor agonists are prescribed in combination with cardiovascular drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295908/", "reference_text": "[1] King MH, Richards DW \"Near syncope and chest tightness after administration of apraclonidine before argon laser iridotomy.\" Am J Ophthalmol 110 (1990):  308-9[2] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[3] Nordlund JR, Pasquale LR, Robin AL, Rudikoff MT, Ordman J, Chen KS, Walt J \"The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine.\" Arch Ophthalmol 113 (1995):  77-83[4] \"Product Information. Alphagan (brimonidine ophthalmic).\" Allergan Inc  (2001):[5] Walters TR \"Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.\" Surv Ophthalmol 41 ( Suppl (1996):  s19-26[6] Pekdemir M, Yanturali S, Karakus G \"More than just an ocular solution.\" Emerg Med J 22 (2005):  753-4[7] \"Product Information. Mirvaso (brimonidine topical).\" Galderma Laboratories Inc  (2013):", "alternatives_a": "Tacrolimus, Minoxidil, Deoxycholic acid, Magnesium sulfate, Glycopyrronium, Calcium gluconate, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249784, "ingredient1": "Brimonidine (ophthalmic)", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.  Additive hypotensive effects and orthostasis may also occur with some CNS depressants and other agents that have these effects, particularly during initial dosing and/or parenteral administration.", "source": "DDInter", "management_text": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295911/", "reference_text": "[1] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[2] \"Product Information. Alphagan (brimonidine ophthalmic).\" Allergan Inc  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Pekdemir M, Yanturali S, Karakus G \"More than just an ocular solution.\" Emerg Med J 22 (2005):  753-4[5] \"Product Information. Mirvaso (brimonidine topical).\" Galderma Laboratories Inc  (2013):", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, More", "alternatives_b": "Citalopram, Duloxetine, Vilazodone, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More", "updated_at": 1767369485}, {"id": 249785, "ingredient1": "Gadoxetic acid", "ingredient2": "Timolol (ophthalmic)", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295912/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "alternatives_b": "Ferumoxsil", "updated_at": 1767369485}, {"id": 249786, "ingredient1": "Somapacitan", "ingredient2": "Relugolix", "severity": "Minor", "effect": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.", "source": "DDInter", "management_text": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.  Relugolix is also a substrate for intestinal P-gp.  When relugolix was coadministered with rifampin, a combined P-gp and potent CYP450 3A inducer, relugolix peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 23% and 55%, respectively.  By contrast, no clinically significant differences in the pharmacokinetics of relugolix were observed when coadministered with enzalutamide, a strong CYP450 3A inducer that is not known to induce P-gp.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295915/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc.  (2021):", "alternatives_a": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 249787, "ingredient1": "St. John's Wort", "ingredient2": "Relugolix", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of relugolix.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.  Relugolix is also a substrate for intestinal P-gp.", "source": "DDInter", "management_text": "Concomitant use of relugolix with combined P-gp and potent CYP450 3A inducers should generally be avoided.  However, when relugolix is used as monotherapy for the treatment of prostate cancer and coadministration is required, the manufacturer recommends increasing the relugolix dosage to 240 mg once daily.  Therapeutic response and tolerance should be monitored more frequently.  Following discontinuation of the P-gp/CYP450 3A inducer, treatment with relugolix should be resumed at the normally recommended dosage of 120 mg once daily.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Concomitant use of relugolix with combined P-gp and potent CYP450 3A inducers should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295916/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc.  (2021):", "alternatives_a": "Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, More", "alternatives_b": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Paroxetine, Desvenlafaxine, Nefazodone, Isocarboxazid, Oxitriptan, Viloxazine, Vortioxetine, More", "updated_at": 1767369485}, {"id": 249788, "ingredient1": "Telotristat ethyl", "ingredient2": "Relugolix", "severity": "Minor", "effect": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.", "source": "DDInter", "management_text": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.  In vitro, relugolix is metabolized primarily by CYP450 3A and, to a lesser extent, by CYP450 2C8.  Relugolix is also a substrate for intestinal P-gp.  When relugolix was coadministered with rifampin, a combined P-gp and potent CYP450 3A inducer, relugolix peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 23% and 55%, respectively.  By contrast, no clinically significant differences in the pharmacokinetics of relugolix were observed when coadministered with enzalutamide, a strong CYP450 3A inducer that is not known to induce P-gp.", "mechanism_text": "Metabolism, Absorption", "recommendation": "Coadministration with lone inducers of CYP450 3A4 is unlikely to decrease the plasma concentrations of relugolix to a clinically significant extent.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295918/", "reference_text": "[1] \"Product Information. Orgovyx (relugolix).\" Myovant Sciences, Inc.  (2021):", "alternatives_a": "Nafarelin, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Aminoglutethimide, Fulvestrant, Abarelix, Flutamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249789, "ingredient1": "Abametapir (topical)", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450 3A4, CYP450 2B6, and CYP450 1A2 isoenzymes and increase their systemic concentrations.", "source": "DDInter", "management_text": "Use of CYP450 3A4, CYP450 2B6, and CYP450 1A2 substrates should generally be avoided within 2 weeks after topical application of abametapir lotion.  If this is not feasible, the manufacturer recommends avoiding use of abametapir lotion.  If abametapir is used, monitor for increased toxicity of the CYP450 3A4, CYP450 2B6, and/or CYP450 1A2 substrate.", "mechanism_text": "Metabolism", "recommendation": "Use of CYP450 3A4, CYP450 2B6, and CYP450 1A2 substrates should generally be avoided within 2 weeks after topical application of abametapir lotion.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295920/", "reference_text": "[1] \"Product Information. Xeglyze (abametapir topical).\" Dr. Reddy's Laboratories Inc  (2020):", "alternatives_a": "Dienogest, Estetrol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249790, "ingredient1": "Adalimumab", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295922/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249791, "ingredient1": "Alefacept", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295923/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249792, "ingredient1": "Aminoglutethimide", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins.  Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.  The interaction has been reported primarily with oral contraceptives.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.  For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers.  Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).  Individual product labeling should be consulted for specific time frames.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Patients should be advised to notify their physician if they experience inadequate control of symptoms associated with estrogen deficiency (e.g., nocturnal sweating, vasomotor disturbances, atrophic vaginitis) or changes in the uterine bleeding profile.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295924/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[3] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[4] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984):  1125-6[5] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986):  384[6] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990):  124-5[7] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[8] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[9] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990):  101-5[10] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990):  241-7[11] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[12] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[13] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[14] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[15] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[16] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[17] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[19] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[20] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[21] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[22] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984):  1125-6[23] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[24] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[25] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[26] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[27] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[28] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories  (2001):[30] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[31] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[32] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[33] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[34] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[35] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[36] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[37] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[38] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000):  598-604[39] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[40] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[41] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[42] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003):  112-113[43] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003):  683-90[44] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003):  525-35[45] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002):  P25[46] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001):  A25[47] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "alternatives_b": "Dienogest, Estetrol", "updated_at": 1767369485}, {"id": 249793, "ingredient1": "Aminophylline", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "The coadministration with contraceptive steroids may increase the plasma concentrations of theophylline and other methylxanthines.  The proposed mechanism is inhibition of methylxanthine metabolism via hepatic microsomal enzymes, of which estrogens and progestins are also substrates.", "source": "DDInter", "management_text": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives.  Serum theophylline levels and pharmacologic response should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their theophylline regimen.  Patients should be advised to notify their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, and irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295925/", "reference_text": "[1] Tornatore KM, Kanarkowski R, McCarthy TL, et al. \"Effect of chronic oral contraceptive steroids on theophylline disposition.\" Eur J Clin Pharmacol 23 (1982):  129-34[2] Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R \"Effects of tobacco smoking and oral contraceptive use on theophylline disposition.\" Br J Clin Pharmacol 16 (1983):  271-80[3] Roberts RK, Grice J, McGuffie, Heilbronn L \"Oral contraceptive steroids impair the elimination of theophylline.\" J Lab Clin Med 101 (1983):  821-25", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Megestrol acetate, Ulipristal, Estetrol, Medroxyprogesterone acetate", "updated_at": 1767369485}, {"id": 249794, "ingredient1": "Amobarbital", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with a barbiturate may reduce the efficacy of contraceptive hormones.The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and enhancement of hormone-binding globulin capacity by phenobarbital.  Since all barbiturates are believed to possess enzyme-inducing capabilities, the interaction should be expected with agents in the class other than phenobarbital.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates.  Alternative or additional methods of birth control should be used during and for at least one week after short-term and 4 weeks after long-term (greater than 4 weeks) barbiturate therapy.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by barbiturates.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295926/", "reference_text": "[1] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[2] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[3] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[4] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[5] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[6] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[7] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[8] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[10] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[11] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[13] Kleier DJ, Tucker JE \"Oral contraceptive failure secondary to dentally prescribed drugs: fact or fiction?\" J Colo Dent Assoc 66 (1987):  5-6[14] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[15] Shane-McWorter L, Cerveny JD, MacFarlane LL, Osborn C \"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.\" Pharmacotherapy 18 (1998):  1360-4[16] Haukkamaa M \"Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.\" Contraception 33 (1986):  559-65[17] \"Product Information. Norplant System (levonorgestrel).\" Wyeth-Ayerst Laboratories  (2001):[18] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[19] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[20] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249795, "ingredient1": "Amprenavir", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with some hormonal contraceptives may decrease the plasma concentrations of amprenavir.  The mechanism of interaction is unknown.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, alternative (i.e., nonhormonal) methods of birth control should be considered in patients treated with amprenavir.", "mechanism_text": "Others", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, alternative (i.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295927/", "reference_text": "[1] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[2] Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P \"Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.\" Aids 14 (2000):  1333-9[3] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Ulipristal, Megestrol acetate, Estradiol, Dienogest, Estetrol", "updated_at": 1767369485}, {"id": 249796, "ingredient1": "Anakinra", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295928/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249797, "ingredient1": "Norelgestromin", "ingredient2": "Apalutamide", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins.  Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.  The interaction has been reported primarily with oral contraceptives.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.  For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers.  Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).  Individual product labeling should be consulted for specific time frames.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Patients should be advised to notify their physician if they experience inadequate control of symptoms associated with estrogen deficiency (e.g., nocturnal sweating, vasomotor disturbances, atrophic vaginitis) or changes in the uterine bleeding profile.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295929/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[3] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[4] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984):  1125-6[5] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986):  384[6] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990):  124-5[7] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[8] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[9] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990):  101-5[10] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990):  241-7[11] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[12] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[13] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[14] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[15] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[16] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[17] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[19] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[20] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[21] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[22] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984):  1125-6[23] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[24] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[25] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[26] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[27] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[28] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories  (2001):[30] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[31] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[32] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[33] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[34] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[35] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[36] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[37] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[38] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000):  598-604[39] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[40] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[41] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[42] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003):  112-113[43] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003):  683-90[44] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003):  525-35[45] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002):  P25[46] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001):  A25[47] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249798, "ingredient1": "Norelgestromin", "ingredient2": "Aprepitant", "severity": "Moderate", "effect": "Aprepitant and its prodrug, fosaprepitant, may reduce the efficacy of low-dose hormonal contraceptives during and for up to 28 days after treatment.  The proposed mechanism is aprepitant induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of contraceptive hormones.", "source": "DDInter", "management_text": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with aprepitant or fosaprepitant.  Alternative or additional methods of birth control is recommended during treatment with aprepitant and for one month following the last dose of aprepitant.  Data are not available for single-dosing of aprepitant 40 mg.  However, since the timing of aprepitant administration relative to ovulation could cause contraceptive failure, the same precaution as for the 125 mg/80 mg regimen should be observed.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with aprepitant or fosaprepitant.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295930/", "reference_text": "[1] \"Product Information. Emend (aprepitant).\" Merck & Co., Inc  (2003):[2] \"Product Information. Emend for Injection (fosaprepitant).\" Merck & Co., Inc  (2008):[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Nabilone, Granisetron, Scopolamine, Dronabinol, Rolapitant, Dolasetron, Ondansetron, Palonosetron", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249799, "ingredient1": "Norelgestromin", "ingredient2": "Armodafinil", "severity": "Moderate", "effect": "Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of ethinyl estradiol and other contraceptive hormones.  The mechanism involves induction of CYP450 3A4-mediated metabolism by modafinil and armodafinil.", "source": "DDInter", "management_text": "Women using hormonal contraceptives (including depot and implantable contraceptives) should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with modafinil or armodafinil.  Alternative or additional methods of birth control are recommended during and for one month after treatment with modafinil or armodafinil.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives (including depot and implantable contraceptives) should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with modafinil or armodafinil.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295931/", "reference_text": "[1] \"Product Information. Provigil (modafinil).\" Cephalon, Inc  (2001):[2] Robertson P, Decory HH, Madan A, Parkinson A \"In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.\" Drug Metab Dispos 28 (2000):  664-71[3] Robertson P Jr, Hellriegel ET, Arora S, Nelson M \"Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers.\" Clin Pharmacol Ther 71 (2002):  46-56[4] \"Product Information. Nuvigil (armodafinil).\" Cephalon Inc  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249800, "ingredient1": "Norelgestromin", "ingredient2": "Atazanavir", "severity": "Moderate", "effect": "Coadministration with atazanavir may increase the plasma concentrations of ethinyl estradiol and norethindrone and possibly other contraceptive hormones.  The mechanism is atazanavir inhibition of CYP450 3A4 and UGT1A1, the enzymes responsible for the metabolic clearance of contraceptive hormones.", "source": "DDInter", "management_text": "The manufacturer recommends alternate methods of nonhormonal contraception during atazanavir or atazanavir-ritonavir therapy.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends alternate methods of nonhormonal contraception during atazanavir or atazanavir-ritonavir therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295933/", "reference_text": "[1] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Megestrol acetate, Estetrol, Estradiol", "updated_at": 1767369485}, {"id": 249801, "ingredient1": "Atorvastatin", "ingredient2": "Norelgestromin", "severity": "Minor", "effect": "Coadministration with atorvastatin may increase the plasma concentrations of estrogens and progestins.  The exact mechanism of interaction is unknown but may be related to competitive inhibition of CYP450 3A4, the isoenzyme responsible for the metabolism of atorvastatin, estrogens, some (if not all) progestins, and other steroids.", "source": "DDInter", "management_text": "The clinical significance of these alterations is unknown but should be considered when selecting oral contraceptive and hormone replacement doses.", "mechanism_text": "Metabolism", "recommendation": "The clinical significance of these alterations is unknown but should be considered when selecting oral contraceptive and hormone replacement doses.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295934/", "reference_text": "[1] \"Product Information. Lipitor (atorvastatin).\" Parke-Davis  (2001):", "alternatives_a": "Amlodipine, Ramipril, Valsartan, Simvastatin, Lovastatin, Lisinopril, Perindopril, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, More", "alternatives_b": "Megestrol acetate, Ulipristal, Estetrol", "updated_at": 1767369485}, {"id": 249802, "ingredient1": "Berotralstat", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.", "source": "DDInter", "management_text": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.  Clinical and laboratory monitoring are recommended following the initiation of berotralstat, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295937/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Orladeyo (berotralstat).\" BioCryst Pharmaceuticals Inc  (2021):", "alternatives_a": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249803, "ingredient1": "Bexarotene", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "There are no data concerning the potential effect of bexarotene on hormonal contraceptives.  Presumably, coadministration with bexarotene may decrease the efficacy of contraceptives containing low-dose estrogens and progestins due to its induction of CYP450 3A4, the isoenzyme that is primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with bexarotene.  Because use of bexarotene is likely associated with major birth defects, it is particularly important that patients not become pregnant during treatment.  Therefore, hormonal contraceptives should not be used as the sole method of birth control in women of childbearing potential treated with bexarotene.  Product labeling recommends that two reliable forms of contraception, one non-hormonal, be used simultaneously during bexarotene therapy and for at least one month following discontinuation of therapy.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Metabolism", "recommendation": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with bexarotene.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295938/", "reference_text": "[1] \"Product Information. Targretin (bexarotene).\" Ligand Pharmaceuticals  (2001):[2] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249804, "ingredient1": "Boceprevir", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, may decrease the plasma concentrations and efficacy of hormonal contraceptives.  The mechanism involves induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Systemic hormonal contraceptives may be continued, but may not be as effective, during and for up to two weeks following treatment with boceprevir or telaprevir.  Because HCV NS3/4A protease inhibitors must be used in combination with peginterferon alfa and ribavirin, and use of ribavirin has been associated with significant birth defects and fetal death, it is particularly important that patients not become pregnant during treatment.  Therefore, systemic hormonal contraceptives should not be relied upon as an effective method of birth control in women of childbearing potential treated with HCV NS3/4A protease inhibitors.  Two alternative, effective methods of contraception, which may include intrauterine devices and barrier methods, should be used during HCV NS3/4A protease inhibitor treatment in combination with peginterferon alfa and ribavirin.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Two weeks after completion of HCV NS3/4A protease inhibitor treatment, hormonal contraceptives are again appropriate as one of the two required effective methods of birth control for patients receiving peginterferon alfa and ribavirin.", "mechanism_text": "Metabolism", "recommendation": "Systemic hormonal contraceptives may be continued, but may not be as effective, during and for up to two weeks following treatment with boceprevir or telaprevir.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295939/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Ulipristal, Estetrol", "updated_at": 1767369485}, {"id": 249805, "ingredient1": "Bosentan", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with bosentan may decrease the plasma concentrations and efficacy of contraceptive hormones.  The mechanism is bosentan induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with bosentan.  Because use of bosentan is likely associated with major birth defects, it is particularly important that patients not become pregnant during treatment.  Therefore, hormonal contraceptives should not be used as the sole method of birth control in women of childbearing potential treated with bosentan.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Metabolism", "recommendation": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with bosentan.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295940/", "reference_text": "[1] \"Product Information. Tracleer (bosentan).\" Actelion Pharmaceuticals US Inc  (2001):[2] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249806, "ingredient1": "Brigatinib", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with brigatinib may decrease the plasma concentrations of contraceptive hormones.  Brigatinib has been shown in vitro to induce CYP450 3A4 at clinically relevant plasma concentrations.  Since contraceptive hormones are known substrates of the isoenzyme, decreased concentrations and therapeutic failure may potentially occur.", "source": "DDInter", "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with brigatinib.  Because use of brigatinib may cause fetal harm, it is particularly important that patients not become pregnant during treatment.  Alternative or additional methods of birth control (i.e., non-hormonal) are recommended during and for at least 4 months after the final dose of brigatinib.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Metabolism", "recommendation": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with brigatinib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295941/", "reference_text": "[1] \"Product Information. Alunbrig (brigatinib).\" Ariad Pharmaceuticals Inc  (2017):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Ulipristal, Estetrol", "updated_at": 1767369485}, {"id": 249807, "ingredient1": "Brivaracetam", "ingredient2": "Norelgestromin", "severity": "Minor", "effect": "Coadministration with brivaracetam at higher than recommended dosages may decrease the plasma concentrations of contraceptive hormones.  The mechanism may involve weak induction of CYP450 3A4 metabolism by brivaracetam.", "source": "DDInter", "management_text": "Based on existing data, the interaction is not expected to be clinically relevant, and no particular precaution appears necessary when brivaracetam is used with oral contraceptives.", "mechanism_text": "Metabolism", "recommendation": "Based on existing data, the interaction is not expected to be clinically relevant, and no particular precaution appears necessary when brivaracetam is used with oral contraceptives.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295942/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Stockis A, Watanabe S, Fauchoux N \"Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study.\" Epilepsia 55 (2014):  e27-31[3] Stockis A, Rolan P \"Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics  of a combination oral contraceptive in healthy women.\" J Clin Pharmacol 53 (2013):  1313-21[4] \"Product Information. Briviact (brivaracetam).\" UCB Pharma Inc  (2016):", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249808, "ingredient1": "Butabarbital", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with a barbiturate may reduce the efficacy of contraceptive hormones.The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and enhancement of hormone-binding globulin capacity by phenobarbital.  Since all barbiturates are believed to possess enzyme-inducing capabilities, the interaction should be expected with agents in the class other than phenobarbital.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates.  Alternative or additional methods of birth control should be used during and for at least one week after short-term and 4 weeks after long-term (greater than 4 weeks) barbiturate therapy.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by barbiturates.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295943/", "reference_text": "[1] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[2] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[3] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[4] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[5] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[6] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[7] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[8] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[10] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[11] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[13] Kleier DJ, Tucker JE \"Oral contraceptive failure secondary to dentally prescribed drugs: fact or fiction?\" J Colo Dent Assoc 66 (1987):  5-6[14] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[15] Shane-McWorter L, Cerveny JD, MacFarlane LL, Osborn C \"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.\" Pharmacotherapy 18 (1998):  1360-4[16] Haukkamaa M \"Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.\" Contraception 33 (1986):  559-65[17] \"Product Information. Norplant System (levonorgestrel).\" Wyeth-Ayerst Laboratories  (2001):[18] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[19] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[20] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249809, "ingredient1": "Butalbital", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with a barbiturate may reduce the efficacy of contraceptive hormones.The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and enhancement of hormone-binding globulin capacity by phenobarbital.  Since all barbiturates are believed to possess enzyme-inducing capabilities, the interaction should be expected with agents in the class other than phenobarbital.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates.  Alternative or additional methods of birth control should be used during and for at least one week after short-term and 4 weeks after long-term (greater than 4 weeks) barbiturate therapy.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by barbiturates.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295944/", "reference_text": "[1] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[2] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[3] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[4] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[5] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[6] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[7] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[8] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[10] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[11] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[13] Kleier DJ, Tucker JE \"Oral contraceptive failure secondary to dentally prescribed drugs: fact or fiction?\" J Colo Dent Assoc 66 (1987):  5-6[14] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[15] Shane-McWorter L, Cerveny JD, MacFarlane LL, Osborn C \"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.\" Pharmacotherapy 18 (1998):  1360-4[16] Haukkamaa M \"Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.\" Contraception 33 (1986):  559-65[17] \"Product Information. Norplant System (levonorgestrel).\" Wyeth-Ayerst Laboratories  (2001):[18] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[19] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[20] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249810, "ingredient1": "Canakinumab", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295945/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249811, "ingredient1": "Carbamazepine", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.  Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) anticonvulsant therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be considered.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable.  If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).  However, there are no data on efficacy, compliance, or side effects of this regimen.  For women with the etonogestrel subdermal implant, the addition of a barrier method is recommended during concomitant use and for 28 days after discontinuation of hepatic enzyme inducing drugs.  It is recommended to remove the implant and to prescribe a nonhormonal method in women who require long-term treatment with hepatic enzyme inducing drugs.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.", "mechanism_text": "Antagonism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295946/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Odlind V, Olsson SE \"Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with norplant implants.\" Contraception 33 (1986):  257-61[3] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[4] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[5] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[6] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[7] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[8] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[9] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[10] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[11] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[12] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[13] Diamond MP, Greene JW, Thompson JM, VanHooydonk JE, Wentz AC \"Interaction of anticonvulsants and oral contraceptives in epileptic adolescents.\" Contraception 31 (1985):  623-32[14] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[15] Rapport DJ, Calabrese JR \"Interactions between carbamazepine and birth control pills.\" Psychosomatics 30 (1989):  462-4[16] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[17] Saano V, Glue P, Banfield CR \"Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive.\" Clin Pharmacol Ther 58 (1995):  523-31[18] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[19] Shane-McWorter L, Cerveny JD, MacFarlane LL, Osborn C \"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.\" Pharmacotherapy 18 (1998):  1360-4[20] Haukkamaa M \"Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.\" Contraception 33 (1986):  559-65[21] Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E \"Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women.\" Epilepsia 40 (1999):  783-7[22] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[23] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[24] \"Product Information. Norplant System (levonorgestrel).\" Wyeth-Ayerst Laboratories  (2001):[25] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[26] Kenyon IE \"Unplanned pregnancy in an epileptic. (Letter to the editor).\" Br Med J 1 (1972):  686[27] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[28] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[29] Schindlbeck C, Janni W, Friese K \"Failure of Implanon contraception in a patient taking carbamazepin for epilepsia.\" Arch Gynecol Obstet 273 (2006):  255-6[30] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[31] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[32] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc  (2013):[33] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249812, "ingredient1": "Carfilzomib", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have occurred during treatment with carfilzomib, and concurrent use of hormonal contraception also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "Hormonal contraception associated with a risk of thrombosis should generally be avoided during use of carfilzomib.  Advise female and male patients of reproductive potential to use effective contraception or abstain from sexual activity during treatment with carfilzomib for at least 30 and 90 days, respectively, following completion of therapy.  Advise the patient to contact their physician immediately if pregnancy does occur during these times.", "mechanism_text": "Synergism", "recommendation": "Hormonal contraception associated with a risk of thrombosis should generally be avoided during use of carfilzomib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295947/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, More", "alternatives_b": "Megestrol acetate, Ulipristal", "updated_at": 1767369485}, {"id": 249813, "ingredient1": "Cenobamate", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins.  Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.  The interaction has been reported primarily with oral contraceptives.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.  For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers.  Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).  Individual product labeling should be consulted for specific time frames.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Patients should be advised to notify their physician if they experience inadequate control of symptoms associated with estrogen deficiency (e.g., nocturnal sweating, vasomotor disturbances, atrophic vaginitis) or changes in the uterine bleeding profile.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295948/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[3] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[4] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984):  1125-6[5] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986):  384[6] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990):  124-5[7] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[8] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[9] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990):  101-5[10] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990):  241-7[11] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[12] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[13] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[14] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[15] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[16] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[17] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[19] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[20] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[21] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[22] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984):  1125-6[23] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[24] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[25] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[26] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[27] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[28] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories  (2001):[30] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[31] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[32] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[33] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[34] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[35] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[36] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[37] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[38] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000):  598-604[39] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[40] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[41] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[42] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003):  112-113[43] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003):  683-90[44] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003):  525-35[45] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002):  P25[46] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001):  A25[47] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Megestrol acetate, Estetrol", "updated_at": 1767369485}, {"id": 249814, "ingredient1": "Certolizumab pegol", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295949/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249815, "ingredient1": "Cholestyramine", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with bile-acid binding resins such as cholestyramine may decrease the plasma concentrations and therapeutic effects of estrogens and progestins.  The proposed mechanism involves delaying or reducing the absorption of concomitant orally administered drugs by cholestyramine.", "source": "DDInter", "management_text": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam.  Patients receiving this combination should be advised to closely follow dosing schedules to prevent loss of therapeutic effects.", "mechanism_text": "Absorption", "recommendation": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295950/", "reference_text": "[1] \"Product Information. Questran (cholestyramine).\" Par Pharmaceutical Inc  (2002):[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[5] Underhill KL, Rotter BA, Thompson BK, Prelusky DB, Trenholm HL \"Effectiveness of cholestyramine in the detoxification of zearalenone as determined in mice.\" Bull Environ Contam Toxicol 54 (1995):  128-34[6] Arts CJM, Govers CARL, van den Berg H, Wolters MGE, van Leeuwen P, Thijssen JHH \"In vitro binding of estrogens by dietary fiber and the in vivo apparent digestibility tested in pigs.\" J Steroid Biochem Mol Biol 38 (1991):  621-8[7] \"Product Information. Nextstellis (drospirenone-estetrol).\" Mayne Pharma  (2021):", "alternatives_a": "Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Lomitapide, Ezetimibe, Niacin, Colesevelam, More", "alternatives_b": "Ulipristal", "updated_at": 1767369485}, {"id": 249816, "ingredient1": "Cladribine", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with cladribine may reduce the efficacy of hormonal contraceptives.", "source": "DDInter", "management_text": "Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm.  Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course.  Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle.  In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course.", "mechanism_text": "Antagonism", "recommendation": "Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295951/", "reference_text": "[1] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249817, "ingredient1": "Clarithromycin", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents.", "source": "DDInter", "management_text": "During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Others", "recommendation": "During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295952/", "reference_text": "[1] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories  (2001):[2] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical  (2001):[3] \"Product Information. Yasmin (drospirenone-ethinyl estradiol).\" Berlex Laboratories  (2001):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories  (2005):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249818, "ingredient1": "Clobazam", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with clobazam, a weak inducer of CYP450 3A4, may decrease the plasma concentrations of contraceptive hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with clobazam.  Additional, nonhormonal forms of contraception should be used during and for 28 days after discontinuing clobazam treatment to ensure contraceptive reliability.  A significant interaction with hormone-releasing intrauterine systems is not anticipated due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with clobazam.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295953/", "reference_text": "[1] \"Product Information. Onfi (clobazam).\" Lundbeck Inc  (2011):[2] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Meprobamate, Alprazolam, Diazepam, Lorazepam, Chlordiazepoxide, Halazepam, Clorazepic acid, Buspirone, Hydroxyzine, Oxazepam", "alternatives_b": "Ulipristal, Megestrol acetate, Estradiol, Medroxyprogesterone acetate, Dienogest, Estetrol", "updated_at": 1767369485}, {"id": 249819, "ingredient1": "Clotrimazole", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins.  The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295954/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990):  s327-33[2] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993):  436[3] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989):  851-9[4] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998):  300-4[5] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals  (2002):", "alternatives_a": "Salicylic acid, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Terbinafine, Econazole, Flucytosine, Tioconazole, Chlorphenesin, Tetracycline, More", "alternatives_b": "Megestrol acetate, Estetrol", "updated_at": 1767369485}, {"id": 249820, "ingredient1": "Clozapine", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Limited data suggest that coadministration with contraceptive hormones may increase the plasma concentrations of clozapine.  The exact mechanism of interaction is unknown but may involve inhibition of clozapine metabolism via CYP450 1A2, 2C19 and/or 3A4.", "source": "DDInter", "management_text": "Patients treated concomitantly with hormonal contraceptives may require a lower dosage of clozapine to control psychotic symptoms.  Pharmacologic response to clozapine should be monitored more closely whenever an oral contraceptive is added to or withdrawn from therapy in patients stabilized on their existing antipsychotic regimen, and the clozapine dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Patients treated concomitantly with hormonal contraceptives may require a lower dosage of clozapine to control psychotic symptoms.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295955/", "reference_text": "[1] Gabbay V, O'Dowd MA, Mamamtavrishvili M, Asnis GM \"Clozapine and Oral Contraceptives: A Possible Drug Interaction.\" J Clin Psychopharmacol 22 (2002):  621-622", "alternatives_a": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Lumateperone, Pimozide, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249821, "ingredient1": "Cobicistat", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with cobicistat and elvitegravir may alter the plasma concentrations of contraceptive hormones.  The exact mechanism of interaction has not been described.", "source": "DDInter", "management_text": "The potential risks and benefits of using norgestimate-containing contraceptives in combination with cobicistat and elvitegravir should be considered, particularly in women who have risk factors for insulin resistance, dyslipidemia, acne, and venous thrombosis.  Coadministration of cobicistat and elvitegravir with other hormonal contraceptives (e.g., contraceptive patch, contraceptive vaginal ring, or injectable contraceptives), oral contraceptives containing progestogens other than norgestimate, or less than 25 mcg of ethinyl estradiol has not been studied and is not recommended.  Some authorities recommend that hormonal contraceptives containing at least 30 mcg of ethinyl estradiol with norgestimate should be used in combination with the multi-ingredient antiretroviral formulations containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.  However, the long term effects of increased progesterone exposure are not known.  Alternative, nonhormonal methods of contraception may be considered.", "mechanism_text": "Others", "recommendation": "The potential risks and benefits of using norgestimate-containing contraceptives in combination with cobicistat and elvitegravir should be considered, particularly in women who have risk factors for insulin resistance, dyslipidemia, acne, and venous thrombosis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295956/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences  (2012):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Megestrol acetate, Ulipristal, Estetrol", "updated_at": 1767369485}, {"id": 249822, "ingredient1": "Colestipol", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with bile-acid binding resins such as cholestyramine may decrease the plasma concentrations and therapeutic effects of estrogens and progestins.  The proposed mechanism involves delaying or reducing the absorption of concomitant orally administered drugs by cholestyramine.", "source": "DDInter", "management_text": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam.  Patients receiving this combination should be advised to closely follow dosing schedules to prevent loss of therapeutic effects.", "mechanism_text": "Absorption", "recommendation": "Estrogens and/or progestin-containing oral medications should be administered at least one hour before or four to six hours after bile-acid binding resins such as cholestyramine, colestipol, and colesevelam.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295957/", "reference_text": "[1] \"Product Information. Questran (cholestyramine).\" Par Pharmaceutical Inc  (2002):[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[4] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[5] Underhill KL, Rotter BA, Thompson BK, Prelusky DB, Trenholm HL \"Effectiveness of cholestyramine in the detoxification of zearalenone as determined in mice.\" Bull Environ Contam Toxicol 54 (1995):  128-34[6] Arts CJM, Govers CARL, van den Berg H, Wolters MGE, van Leeuwen P, Thijssen JHH \"In vitro binding of estrogens by dietary fiber and the in vivo apparent digestibility tested in pigs.\" J Steroid Biochem Mol Biol 38 (1991):  621-8[7] \"Product Information. Nextstellis (drospirenone-estetrol).\" Mayne Pharma  (2021):", "alternatives_a": "Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Lomitapide, Ezetimibe, Niacin, Colesevelam, More", "alternatives_b": "Ulipristal", "updated_at": 1767369485}, {"id": 249823, "ingredient1": "Conivaptan", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with conivaptan may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by conivaptan.", "source": "DDInter", "management_text": "Caution is advised if conivaptan must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever conivaptan is added to or withdrawn from therapy, or the combination avoided altogether.  If a clinical decision is made to discontinue concomitant medications at recommended doses, clinicians should allow an appropriate amount of time following the end of conivaptan administration before resuming these medications.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if conivaptan must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295958/", "reference_text": "[1] \"Product Information. Vaprisol (conivaptan).\" Cumberland Pharmaceuticals Inc  (2006):", "alternatives_a": "Tolvaptan", "alternatives_b": "Dienogest, Estetrol, Etynodiol", "updated_at": 1767369485}, {"id": 249824, "ingredient1": "Cyclosporine", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with some estrogens or progestins may increase the plasma concentrations of cyclosporine.  The risk of cyclosporine-induced nephrotoxicity, hepatotoxicity, and neurotoxicity may be increased.  The proposed mechanism is competitive inhibition of cyclosporine metabolism via CYP450 3A4, of which estrogens and progestins are also substrates.", "source": "DDInter", "management_text": "Caution is advised during concomitant therapy with cyclosporine.  Cyclosporine blood levels as well as renal and hepatic function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their cyclosporine regimen.  Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity (e.g., fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, jaundice) or neurotoxicity (e.g., tremor, convulsions).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant therapy with cyclosporine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295959/", "reference_text": "[1] Maurer G \"Metabolism of cyclosporine.\" Transplant Proc 17 (1985):  19-26[2] Deray G, Le Hoang P, Cacoub P, et al. \"Oral contraceptive interaction with cyclosporin.\" Lancet 1 (1987):  158-9", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249825, "ingredient1": "Dabrafenib", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with dabrafenib may decrease the plasma concentrations and efficacy of contraceptive hormones.  The mechanism is dabrafenib induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib.  Because use of dabrafenib may cause fetal harm, it is particularly important that patients not become pregnant during treatment.  Female patients of reproductive potential should use a highly effective, non-hormonal method of contraception during treatment and for 4 weeks after treatment.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Metabolism", "recommendation": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295960/", "reference_text": "[1] \"Product Information. Tafinlar (dabrafenib).\" GlaxoSmithKline  (2013):[2] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249826, "ingredient1": "Darunavir", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with darunavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by darunavir.", "source": "DDInter", "management_text": "Caution is advised if darunavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever darunavir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if darunavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295961/", "reference_text": "[1] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Dienogest, Estetrol, Ethinylestradiol, Etynodiol", "updated_at": 1767369485}, {"id": 249827, "ingredient1": "Dasatinib", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with dasatinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dasatinib, which is a time-dependent inhibitor of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if dasatinib must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dasatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dasatinib must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295962/", "reference_text": "[1] \"Product Information. Sprycel (dasatinib).\" Bristol-Myers Squibb  (2006):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Ulipristal, Megestrol acetate, Etynodiol, Desogestrel, Dienogest, Estetrol", "updated_at": 1767369485}, {"id": 249828, "ingredient1": "Deferasirox", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with deferasirox may decrease the plasma concentrations of contraceptive hormones.  The proposed mechanism is deferasirox induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Hormonal contraceptives agents may not be reliable when used with deferasirox.  Female patients of reproductive potential receiving hormonal contraceptives should be counseled to use alternative or additional methods of birth control during treatment with deferasirox.", "mechanism_text": "Metabolism", "recommendation": "Hormonal contraceptives agents may not be reliable when used with deferasirox.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295963/", "reference_text": "[1] \"Product Information. Desferal (deferoxamine).\" Novartis Pharmaceuticals  (2001):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Promethazine, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249829, "ingredient1": "Valproic acid", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "A case report suggests that estrogens or progestins may decrease the serum concentrations and pharmacologic effects of valproic acid (VPA).  The proposed mechanism is induction of hepatic glucuronidation by sex hormones.", "source": "DDInter", "management_text": "Pharmacologic response and serum valproic levels should be monitored more closely whenever estrogen- and/or progestin-containing drugs are added to or withdrawn from therapy, and the valproic acid dosage adjusted as necessary.  Patients should be advised to contact their physician if they experience loss of seizure control or symptoms of valproic acid toxicity such as tremors, ataxia, nystagmus, increased seizures, and changes in mental status.  In patients receiving oral contraceptives, gradual transient increases in valproic acid levels will likely occur during the pill-free week for women not also taking an enzyme-inducing drug (e.g., carbamazepine, phenytoin, phenobarbital, primidone, rifampin).  The increase in valproic acid levels will be greater if the dose of valproic acid is increased in the few days before or during the pill-free week.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response and serum valproic levels should be monitored more closely whenever estrogen- and/or progestin-containing drugs are added to or withdrawn from therapy, and the valproic acid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295964/", "reference_text": "[1] \"Product Information. Depakene (valproic acid).\" Abbott Pharmaceutical  (2001):[2] \"Product Information. Depakote (divalproex sodium).\" Abbott Pharmaceutical  (2001):[3] Crawford P, Chadwick D, Cleland P, Tjia J, Cowie A, Back DJ, Orme ML \"The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids.\" Contraception 33 (1986):  23-9[4] \"Product Information. Depacon (valproic acid).\" Abbott Pharmaceutical  (2001):[5] Herzog AG, Farina EL, Blum AS \"Serum valproate levels with oral contraceptive use.\" Epilepsia 46 (2005):  970-1", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Ulipristal", "updated_at": 1767369485}, {"id": 249830, "ingredient1": "Dronedarone", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with dronedarone may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme, CYP450 3A4 isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter.  The mechanism is decreased clearance via these routes due to inhibition by dronedarone.", "source": "DDInter", "management_text": "Caution is advised when dronedarone is used concomitantly with drugs that are substrates of CYP450 2D6, CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dronedarone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dronedarone is used concomitantly with drugs that are substrates of CYP450 2D6, CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295965/", "reference_text": "[1] \"Product Information. Multaq (dronedarone).\" sanofi-aventis  (2009):", "alternatives_a": "Quinidine, Amiodarone, Lidocaine, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, More", "alternatives_b": "Dienogest, Estetrol, Etynodiol", "updated_at": 1767369485}, {"id": 249831, "ingredient1": "Duvelisib", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with duvelisib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  The mechanism is reduced clearance due to inhibition of CYP450 3A4 by duvelisib.", "source": "DDInter", "management_text": "Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vinca alkaloids).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever duvelisib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295966/", "reference_text": "[1] \"Product Information. Copiktra (duvelisib).\" Verastem, Inc.  (2018):[2] \"Product Information. Copiktra (duvelisib).\" Verastem, Inc.  (2021):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Dienogest, Estetrol, Etynodiol", "updated_at": 1767369485}, {"id": 249832, "ingredient1": "Echinacea", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4.  Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea.  In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.", "source": "DDInter", "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.  If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered.  Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295967/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004):  89-100[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Drospirenone, Etynodiol, Desogestrel, Dienogest, Estetrol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249833, "ingredient1": "Efavirenz", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "There are limited data concerning the potential effect of efavirenz on hormonal contraceptives.  Presumably, coadministration with efavirenz may decrease the efficacy of contraceptives containing low-dose estrogens and progestins due to its induction of CYP450 3A4, the isoenzyme that is primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Because the potential interaction between efavirenz and contraceptive hormones has not been fully characterized, and use of efavirenz has been associated with fetal malformations in animal studies, the manufacturer recommends that women avoid pregnancy during efavirenz treatment and that a barrier form of contraception be used in addition to hormonal contraceptives.  Alternative or additional methods of birth control should be used during and for at least 4 weeks after efavirenz therapy.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Metabolism", "recommendation": "Because the potential interaction between efavirenz and contraceptive hormones has not been fully characterized, and use of efavirenz has been associated with fetal malformations in animal studies, the manufacturer recommends that women avoid pregnancy during efavirenz treatment and that a barrier form of contraception be used in addition to hormonal contraceptives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295968/", "reference_text": "[1] \"Product Information. Sustiva (efavirenz).\" DuPont Pharmaceuticals  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Lakhi N, Govind A \"Implanon failure in patients on antiretroviral medication: the importance of disclosure.\" J Fam Plann Reprod Health Care 36 (2010):  181-2[4] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249834, "ingredient1": "Elagolix", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins.  Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.  The interaction has been reported primarily with oral contraceptives.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.  For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers.  Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).  Individual product labeling should be consulted for specific time frames.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Patients should be advised to notify their physician if they experience inadequate control of symptoms associated with estrogen deficiency (e.g., nocturnal sweating, vasomotor disturbances, atrophic vaginitis) or changes in the uterine bleeding profile.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295969/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[3] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[4] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984):  1125-6[5] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986):  384[6] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990):  124-5[7] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[8] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[9] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990):  101-5[10] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990):  241-7[11] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[12] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[13] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[14] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[15] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[16] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[17] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[19] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[20] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[21] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[22] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984):  1125-6[23] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[24] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[25] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[26] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[27] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[28] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories  (2001):[30] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[31] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[32] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[33] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[34] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[35] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[36] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[37] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[38] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000):  598-604[39] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[40] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[41] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[42] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003):  112-113[43] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003):  683-90[44] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003):  525-35[45] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002):  P25[46] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001):  A25[47] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Norethisterone, Nafarelin, Octreotide, Cetrorelix, Pasireotide, Estradiol, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249835, "ingredient1": "Elvitegravir", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with cobicistat and elvitegravir may alter the plasma concentrations of contraceptive hormones.  The exact mechanism of interaction has not been described.", "source": "DDInter", "management_text": "The potential risks and benefits of using norgestimate-containing contraceptives in combination with cobicistat and elvitegravir should be considered, particularly in women who have risk factors for insulin resistance, dyslipidemia, acne, and venous thrombosis.  Coadministration of cobicistat and elvitegravir with other hormonal contraceptives (e.g., contraceptive patch, contraceptive vaginal ring, or injectable contraceptives), oral contraceptives containing progestogens other than norgestimate, or less than 25 mcg of ethinyl estradiol has not been studied and is not recommended.  Some authorities recommend that hormonal contraceptives containing at least 30 mcg of ethinyl estradiol with norgestimate should be used in combination with the multi-ingredient antiretroviral formulations containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.  However, the long term effects of increased progesterone exposure are not known.  Alternative, nonhormonal methods of contraception may be considered.", "mechanism_text": "Others", "recommendation": "The potential risks and benefits of using norgestimate-containing contraceptives in combination with cobicistat and elvitegravir should be considered, particularly in women who have risk factors for insulin resistance, dyslipidemia, acne, and venous thrombosis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295970/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov).\" Gilead Sciences  (2012):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Megestrol acetate, Ulipristal, Estetrol", "updated_at": 1767369485}, {"id": 249836, "ingredient1": "Emapalumab", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295971/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249837, "ingredient1": "Enasidenib", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with enasidenib may alter the plasma concentrations of hormonal contraceptives.  In vitro, enasidenib has been found to both inhibit and induce CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of contraceptive hormones.", "source": "DDInter", "management_text": "Because use of enasidenib may be associated with fetal harm, it is important that patients not become pregnant during treatment.  It may be advisable to monitor patients for potentially altered effects of their hormonal contraceptive during and after treatment with enasidenib.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Metabolism", "recommendation": "Because use of enasidenib may be associated with fetal harm, it is important that patients not become pregnant during treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295972/", "reference_text": "[1] \"Product Information. Idhifa (enasidenib).\" Celgene Corporation  (2017):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249838, "ingredient1": "Encorafenib", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with encorafenib may decrease the plasma concentrations and efficacy of contraceptive hormones.  The proposed mechanism is induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with encorafenib.  Because encorafenib can cause fetal harm, it is particularly important that patients not become pregnant during treatment.  Therefore, females of reproductive potential should use an effective, nonhormonal method of contraception during treatment and for 2 weeks after the final dose of encorafenib.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Metabolism", "recommendation": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with encorafenib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295973/", "reference_text": "[1] \"Product Information. Braftovi (encorafenib).\" Array BioPharma Inc.  (2018):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249839, "ingredient1": "Entrectinib", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with entrectinib may render systemic hormonal contraceptives ineffective.  The mechanism for the potential interaction has not been established and there are no clinical data regarding the use of entrectinib with hormonal contraceptives.", "source": "DDInter", "management_text": "Until further data are available, females of reproductive potential should be advised to use effective non-hormonal contraception during treatment and for 5 weeks after the final dose.  In addition, men receiving entrectinib should use highly effective contraceptive methods during treatment and for 3 months after the final dose.", "mechanism_text": "Others", "recommendation": "Until further data are available, females of reproductive potential should be advised to use effective non-hormonal contraception during treatment and for 5 weeks after the final dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295974/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Rozlytrek (entrectinib).\" Genentech  (2019):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Megestrol acetate, Estetrol, Estradiol", "updated_at": 1767369485}, {"id": 249840, "ingredient1": "Enzalutamide", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins.  Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.  The interaction has been reported primarily with oral contraceptives.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.  For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers.  Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).  Individual product labeling should be consulted for specific time frames.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Patients should be advised to notify their physician if they experience inadequate control of symptoms associated with estrogen deficiency (e.g., nocturnal sweating, vasomotor disturbances, atrophic vaginitis) or changes in the uterine bleeding profile.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295975/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[3] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[4] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984):  1125-6[5] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986):  384[6] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990):  124-5[7] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[8] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[9] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990):  101-5[10] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990):  241-7[11] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[12] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[13] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[14] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[15] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[16] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[17] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[19] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[20] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[21] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[22] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984):  1125-6[23] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[24] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[25] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[26] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[27] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[28] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories  (2001):[30] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[31] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[32] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[33] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[34] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[35] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[36] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[37] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[38] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000):  598-604[39] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[40] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[41] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[42] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003):  112-113[43] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003):  683-90[44] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003):  525-35[45] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002):  P25[46] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001):  A25[47] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249841, "ingredient1": "Erythromycin", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents.", "source": "DDInter", "management_text": "During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Others", "recommendation": "During concomitant therapy with erythromycin or clarithromycin, patients should be observed for increased or altered pharmacologic response to estrogens and progestogens, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295976/", "reference_text": "[1] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories  (2001):[2] \"Product Information. Ortho-Est (estropipate).\" Ortho McNeil Pharmaceutical  (2001):[3] \"Product Information. Yasmin (drospirenone-ethinyl estradiol).\" Berlex Laboratories  (2001):[4] \"Product Information. Angeliq (drospirenone-estradiol).\" Berlex Laboratories  (2005):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Clindamycin, Troleandomycin, Dirithromycin, Azithromycin, Lincomycin, Minocycline, Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249842, "ingredient1": "Eslicarbazepine", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.  Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) anticonvulsant therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be considered.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable.  If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).  However, there are no data on efficacy, compliance, or side effects of this regimen.  For women with the etonogestrel subdermal implant, the addition of a barrier method is recommended during concomitant use and for 28 days after discontinuation of hepatic enzyme inducing drugs.  It is recommended to remove the implant and to prescribe a nonhormonal method in women who require long-term treatment with hepatic enzyme inducing drugs.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.", "mechanism_text": "Antagonism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295977/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Odlind V, Olsson SE \"Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with norplant implants.\" Contraception 33 (1986):  257-61[3] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[4] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[5] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[6] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[7] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[8] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[9] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[10] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[11] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[12] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[13] Diamond MP, Greene JW, Thompson JM, VanHooydonk JE, Wentz AC \"Interaction of anticonvulsants and oral contraceptives in epileptic adolescents.\" Contraception 31 (1985):  623-32[14] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[15] Rapport DJ, Calabrese JR \"Interactions between carbamazepine and birth control pills.\" Psychosomatics 30 (1989):  462-4[16] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[17] Saano V, Glue P, Banfield CR \"Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive.\" Clin Pharmacol Ther 58 (1995):  523-31[18] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[19] Shane-McWorter L, Cerveny JD, MacFarlane LL, Osborn C \"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.\" Pharmacotherapy 18 (1998):  1360-4[20] Haukkamaa M \"Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.\" Contraception 33 (1986):  559-65[21] Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E \"Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women.\" Epilepsia 40 (1999):  783-7[22] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[23] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[24] \"Product Information. Norplant System (levonorgestrel).\" Wyeth-Ayerst Laboratories  (2001):[25] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[26] Kenyon IE \"Unplanned pregnancy in an epileptic. (Letter to the editor).\" Br Med J 1 (1972):  686[27] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[28] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[29] Schindlbeck C, Janni W, Friese K \"Failure of Implanon contraception in a patient taking carbamazepin for epilepsia.\" Arch Gynecol Obstet 273 (2006):  255-6[30] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[31] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[32] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc  (2013):[33] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249843, "ingredient1": "Etanercept", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295978/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249844, "ingredient1": "Etravirine", "ingredient2": "Norelgestromin", "severity": "Minor", "effect": "Coadministration with etravirine may slightly increase the plasma concentrations of ethinyl estradiol.  The mechanism of interaction has not been described.", "source": "DDInter", "management_text": "Etravirine and ethinyl estradiol-norethindrone may be coadministered without any dosage adjustments.", "mechanism_text": "Others", "recommendation": "Etravirine and ethinyl estradiol-norethindrone may be coadministered without any dosage adjustments.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295979/", "reference_text": "[1] \"Product Information. Intelence (etravirine).\" Ortho Biotech Inc  (2008):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Dienogest, Estetrol", "updated_at": 1767369485}, {"id": 249845, "ingredient1": "Fedratinib", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with fedratinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4, 2C19, and/or 2D6 isoenzymes.", "source": "DDInter", "management_text": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, and/or 2D6.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, and/or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295980/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation  (2019):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Dienogest, Estetrol, Etynodiol", "updated_at": 1767369485}, {"id": 249846, "ingredient1": "Felbamate", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.  Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) anticonvulsant therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be considered.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable.  If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).  However, there are no data on efficacy, compliance, or side effects of this regimen.  For women with the etonogestrel subdermal implant, the addition of a barrier method is recommended during concomitant use and for 28 days after discontinuation of hepatic enzyme inducing drugs.  It is recommended to remove the implant and to prescribe a nonhormonal method in women who require long-term treatment with hepatic enzyme inducing drugs.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.", "mechanism_text": "Antagonism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295981/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Odlind V, Olsson SE \"Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with norplant implants.\" Contraception 33 (1986):  257-61[3] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[4] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[5] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[6] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[7] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[8] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[9] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[10] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[11] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[12] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[13] Diamond MP, Greene JW, Thompson JM, VanHooydonk JE, Wentz AC \"Interaction of anticonvulsants and oral contraceptives in epileptic adolescents.\" Contraception 31 (1985):  623-32[14] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[15] Rapport DJ, Calabrese JR \"Interactions between carbamazepine and birth control pills.\" Psychosomatics 30 (1989):  462-4[16] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[17] Saano V, Glue P, Banfield CR \"Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive.\" Clin Pharmacol Ther 58 (1995):  523-31[18] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[19] Shane-McWorter L, Cerveny JD, MacFarlane LL, Osborn C \"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.\" Pharmacotherapy 18 (1998):  1360-4[20] Haukkamaa M \"Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.\" Contraception 33 (1986):  559-65[21] Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E \"Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women.\" Epilepsia 40 (1999):  783-7[22] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[23] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[24] \"Product Information. Norplant System (levonorgestrel).\" Wyeth-Ayerst Laboratories  (2001):[25] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[26] Kenyon IE \"Unplanned pregnancy in an epileptic. (Letter to the editor).\" Br Med J 1 (1972):  686[27] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[28] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[29] Schindlbeck C, Janni W, Friese K \"Failure of Implanon contraception in a patient taking carbamazepin for epilepsia.\" Arch Gynecol Obstet 273 (2006):  255-6[30] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[31] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[32] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc  (2013):[33] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249847, "ingredient1": "Flibanserin", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Concomitant use of hormonal contraceptives has been associated with increased adverse effects of flibanserin.  The mechanism of interaction has not been established, but may partially involve inhibition of flibanserin metabolism.  Flibanserin is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C19.  Some oral contraceptives are considered weak inhibitors of these isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when flibanserin is used with hormonal contraceptives.  Patients should be monitored for signs and symptoms of hypotension, syncope, and central nervous system depression.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when flibanserin is used with hormonal contraceptives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295983/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals  (2015):", "alternatives_a": "Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249848, "ingredient1": "Fluconazole", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins.  The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295984/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990):  s327-33[2] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993):  436[3] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989):  851-9[4] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998):  300-4[5] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals  (2002):", "alternatives_a": "Tinidazole, Tetracycline, Cefepime, Norfloxacin, Ciprofloxacin, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, More", "alternatives_b": "Megestrol acetate, Estetrol", "updated_at": 1767369485}, {"id": 249849, "ingredient1": "Fosamprenavir", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Some hormonal contraceptives may decrease the plasma concentrations of amprenavir from fosamprenavir when it is administered in the absence of low-dose ritonavir as a pharmacokinetic booster.  In contrast, fosamprenavir in combination with ritonavir may reduce the plasma levels of certain contraceptive hormones, and there is also an increased risk of transaminase elevations when these agents are used together.  The mechanism of interaction has not been described.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, alternative (i.e., nonhormonal) methods of birth control should be considered in patients treated with fosamprenavir.", "mechanism_text": "Others", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, alternative (i.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295985/", "reference_text": "[1] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Megestrol acetate, Estetrol, Estradiol", "updated_at": 1767369485}, {"id": 249850, "ingredient1": "Fosaprepitant", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Aprepitant and its prodrug, fosaprepitant, may reduce the efficacy of low-dose hormonal contraceptives during and for up to 28 days after treatment.  The proposed mechanism is aprepitant induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of contraceptive hormones.", "source": "DDInter", "management_text": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with aprepitant or fosaprepitant.  Alternative or additional methods of birth control is recommended during treatment with aprepitant and for one month following the last dose of aprepitant.  Data are not available for single-dosing of aprepitant 40 mg.  However, since the timing of aprepitant administration relative to ovulation could cause contraceptive failure, the same precaution as for the 125 mg/80 mg regimen should be observed.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with aprepitant or fosaprepitant.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295986/", "reference_text": "[1] \"Product Information. Emend (aprepitant).\" Merck & Co., Inc  (2003):[2] \"Product Information. Emend for Injection (fosaprepitant).\" Merck & Co., Inc  (2008):[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Estetrol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249851, "ingredient1": "Fosphenytoin", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.  Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) anticonvulsant therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be considered.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable.  If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).  However, there are no data on efficacy, compliance, or side effects of this regimen.  For women with the etonogestrel subdermal implant, the addition of a barrier method is recommended during concomitant use and for 28 days after discontinuation of hepatic enzyme inducing drugs.  It is recommended to remove the implant and to prescribe a nonhormonal method in women who require long-term treatment with hepatic enzyme inducing drugs.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.", "mechanism_text": "Antagonism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295987/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Odlind V, Olsson SE \"Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with norplant implants.\" Contraception 33 (1986):  257-61[3] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[4] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[5] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[6] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[7] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[8] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[9] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[10] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[11] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[12] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[13] Diamond MP, Greene JW, Thompson JM, VanHooydonk JE, Wentz AC \"Interaction of anticonvulsants and oral contraceptives in epileptic adolescents.\" Contraception 31 (1985):  623-32[14] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[15] Rapport DJ, Calabrese JR \"Interactions between carbamazepine and birth control pills.\" Psychosomatics 30 (1989):  462-4[16] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[17] Saano V, Glue P, Banfield CR \"Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive.\" Clin Pharmacol Ther 58 (1995):  523-31[18] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[19] Shane-McWorter L, Cerveny JD, MacFarlane LL, Osborn C \"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.\" Pharmacotherapy 18 (1998):  1360-4[20] Haukkamaa M \"Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.\" Contraception 33 (1986):  559-65[21] Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E \"Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women.\" Epilepsia 40 (1999):  783-7[22] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[23] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[24] \"Product Information. Norplant System (levonorgestrel).\" Wyeth-Ayerst Laboratories  (2001):[25] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[26] Kenyon IE \"Unplanned pregnancy in an epileptic. (Letter to the editor).\" Br Med J 1 (1972):  686[27] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[28] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[29] Schindlbeck C, Janni W, Friese K \"Failure of Implanon contraception in a patient taking carbamazepin for epilepsia.\" Arch Gynecol Obstet 273 (2006):  255-6[30] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[31] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[32] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc  (2013):[33] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249852, "ingredient1": "Fostamatinib", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter.  The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.", "source": "DDInter", "management_text": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295988/", "reference_text": "[1] \"Product Information. Tavalisse (fostamatinib).\" Rigel Pharmaceuticals  (2018):", "alternatives_a": "Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Dienogest, Estetrol, Etynodiol", "updated_at": 1767369485}, {"id": 249853, "ingredient1": "Frovatriptan", "ingredient2": "Norelgestromin", "severity": "Minor", "effect": "The concurrent use of oral contraceptives may increase the plasma concentrations of frovatriptan.The mechanism of interaction has not been established, and it is not known if hormonal contraceptives delivered by other routes (intravaginal, transdermal) may similarly affect the pharmacokinetics of frovatriptan.", "source": "DDInter", "management_text": "The concurrent use of oral contraceptives may increase the plasma concentrations of frovatriptan.  According to the manufacturer, retrospective analysis of pharmacokinetic data from females across trials indicated that the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of frovatriptan are 30% higher in oral contraceptive users compared to non-users.  The mechanism of interaction has not been established, and it is not known if hormonal contraceptives delivered by other routes (intravaginal, transdermal) may similarly affect the pharmacokinetics of frovatriptan.  Regardless, this interaction is unlikely to be of clinical significance.", "mechanism_text": "Others", "recommendation": "The concurrent use of oral contraceptives may increase the plasma concentrations of frovatriptan.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295989/", "reference_text": "[1] \"Product Information. Frova (frovatriptan).\" Endo Laboratories LLC  (2001):", "alternatives_a": "Rimegepant, Dihydroergotamine, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Clonidine, Naratriptan, More", "alternatives_b": "Ulipristal, Megestrol acetate, Estradiol, Medroxyprogesterone acetate, Dienogest, Estetrol", "updated_at": 1767369485}, {"id": 249854, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with glycerol phenylbutyrate may decrease the systemic exposure to and therapeutic efficacy of drugs that are substrates of CYP450 3A4.  Glycerol phenylbutyrate, its active moiety phenylbutyrate, and active metabolite phenylacetic acid are considered weak CYP450 3A4 inducers in vivo.", "source": "DDInter", "management_text": "Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.g., oral midazolam) or CYP450 3A4 substrates with a narrow therapeutic index (e.g., alfentanil, oral contraceptives, quinidine, and cyclosporine) should be done with caution and monitoring for reduced efficacy.  Dosage adjustment as well as clinical and laboratory monitoring may be appropriate whenever glycerol phenylbutyrate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295990/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Megestrol acetate, Estetrol, Etynodiol, Norgestrel", "updated_at": 1767369485}, {"id": 249855, "ingredient1": "Golimumab", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295991/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249856, "ingredient1": "Griseofulvin", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Limited clinical data suggest that griseofulvin may reduce the efficacy of contraceptive hormones.The proposed mechanism is accelerated clearance of the hormones due to induction of hepatic CYP450 enzymes by griseofulvin.", "source": "DDInter", "management_text": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with griseofulvin.  Because griseofulvin has been shown to be teratogenic in animal studies and is capable of inducing aneuploidy (abnormal segregation of chromosomes following cell division) in mammalian cells in vitro and in vivo, it is particularly important that patients not become pregnant during treatment.  Therefore, additional methods of birth control should be used during and for one month after griseofulvin therapy.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Metabolism", "recommendation": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with griseofulvin.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295992/", "reference_text": "[1] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984):  1125-6[2] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986):  384[3] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990):  124-5[4] \"Product Information. Grifulvin V (griseofulvin).\" Ortho McNeil Pharmaceutical[5] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984):  1125-6[6] Bollen M \"Use of antibiotics when taking the oral contraceptive pill.\" Aust Fam Physician 24 (1995):  928-9[7] Helms SE, Bredle DL, Zajic J, Jarjoura D, Brodell RT, Krishnarao I \"Oral contraceptive failure rates and oral antibiotics.\" J Am Acad Dermatol 36 (1997):  705-10[8] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[9] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[10] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[11] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[12] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[13] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Terbinafine, Salicylic acid, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Terbinafine, Econazole, Flucytosine, Tioconazole, Chlorphenesin", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249857, "ingredient1": "Guselkumab", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295993/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249858, "ingredient1": "Indinavir", "ingredient2": "Norelgestromin", "severity": "Minor", "effect": "Coadministration with indinavir may increase the plasma concentrations of estrogens and progestins.  The proposed mechanism is indinavir inhibition of CYP450 3A4, the isoenzyme involved in the metabolism of estrogens, some (if not all) progestins, and other steroids.", "source": "DDInter", "management_text": "Coadministration with indinavir may increase the plasma concentrations of estrogens and progestins.  The proposed mechanism is indinavir inhibition of CYP450 3A4, the isoenzyme involved in the metabolism of estrogens, some (if not all) progestins, and other steroids.  According to product labeling, indinavir (800 mg every 8 hours) increased the area under the plasma concentration-time curve (AUC) of ethinyl estradiol and norethindrone (administered as Ortho-Novum 1/35 once daily) by approximately 25% each after one week.  The clinical significance of these alterations is unknown but should be considered when selecting oral contraceptive and hormone replacement doses.", "mechanism_text": "Metabolism", "recommendation": "Coadministration with indinavir may increase the plasma concentrations of estrogens and progestins.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295994/", "reference_text": "[1] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Megestrol acetate, Estetrol", "updated_at": 1767369485}, {"id": 249859, "ingredient1": "Infliximab", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295995/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249860, "ingredient1": "Isavuconazonium", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp).  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295996/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc  (2015):", "alternatives_a": "Ulipristal, Estetrol, Etynodiol, Dienogest", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249861, "ingredient1": "Itraconazole", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins.  The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295997/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990):  s327-33[2] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993):  436[3] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989):  851-9[4] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998):  300-4[5] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals  (2002):", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Megestrol acetate, Estetrol", "updated_at": 1767369485}, {"id": 249862, "ingredient1": "Norelgestromin", "ingredient2": "Ivosidenib", "severity": "Moderate", "effect": "Coadministration with ivosidenib may decrease the plasma concentrations of contraceptive hormones.  The interaction has not been evaluated in pharmacokinetic studies.  However, ivosidenib is an inducer of CYP450 3A4 and induces its own metabolism following multiple dosing.", "source": "DDInter", "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when used with ivosidenib.  Female patients of reproductive potential receiving hormonal contraceptives should consider alternative or additional methods of contraception during treatment with ivosidenib.", "mechanism_text": "Metabolism", "recommendation": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when used with ivosidenib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295998/", "reference_text": "[1] \"Product Information. Tibsovo (ivosidenib).\" Agios Pharmaceuticals, Inc.  (2018):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249863, "ingredient1": "Norelgestromin", "ingredient2": "Ixekizumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/295999/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249864, "ingredient1": "Norelgestromin", "ingredient2": "Ketoconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins.  The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296000/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990):  s327-33[2] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993):  436[3] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989):  851-9[4] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998):  300-4[5] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals  (2002):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More", "alternatives_b": "Megestrol acetate, Estetrol", "updated_at": 1767369485}, {"id": 249865, "ingredient1": "Norelgestromin", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Coadministration with estrogens or progestins may decrease the plasma concentrations and pharmacologic effects of lamotrigine due to induction of lamotrigine glucuronidation.", "source": "DDInter", "management_text": "Pharmacologic response and plasma lamotrigine levels should be monitored more closely whenever estrogen- and/or progestin-containing drugs are added to or withdrawn from therapy, and the lamotrigine dosage adjusted as necessary.  The manufacturer's labeling should be consulted for detailed dosage recommendations.  Patients should be advised to contact their physician if they experience loss of seizure control or symptoms of lamotrigine toxicity such as ataxia, nystagmus, increased seizures, irregular heartbeat, and changes in mental status.  In patients receiving oral contraceptives, gradual transient increases in lamotrigine levels will occur during the pill-free week for women not also taking an enzyme-inducing drug (e.g., carbamazepine, phenytoin, phenobarbital, primidone, rifampin).  The increase in lamotrigine levels will be greater if the dose of lamotrigine is increased in the few days before or during the pill-free week.  Although diminished contraceptive efficacy has not been reported, the possibility should be considered.  Patients should be instructed to promptly report changes in their menstrual pattern.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response and plasma lamotrigine levels should be monitored more closely whenever estrogen- and/or progestin-containing drugs are added to or withdrawn from therapy, and the lamotrigine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296001/", "reference_text": "[1] \"Product Information. Lamictal (lamotrigine).\" Glaxo Wellcome  (2001):[2] Tomson T, Ohman I, Vitols S \"Lamotrigine in pregnancy and lactation: A case report.\" Epilepsia 38 (1997):  1039-41[3] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[4] Sabers A, Buchholt JM, Uldall P, Hansen EL \"Lamotrigine plasma levels reduced by oral contraceptives.\" Epilepsy Res 47 (2001):  151-4[5] Miners JO, Mackenzie PI \"Drug glucuronidation in humans.\" Pharmacol Ther 51 (1991):  347-69[6] Ohman I, Vitols S, Tomson T \"Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation.\" Epilepsia 41 (2000):  706-13[7] Holdich T, Whiteman P, Orme M, Back D, Ward S \"Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill.\" Epilepsia 32(Suppl) (1991):  96[8] Hussein Z, Posner J \"Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data.\" Br J Clin Pharmacol 43 (1997):  457-65[9] Sabers A, Ohman I, Christensen J, Tomson T \"Oral contraceptives reduce lamotrigine plasma levels.\" Neurology 61 (2003):  570-1[10] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[11] \"Product Information. Nextstellis (drospirenone-estetrol).\" Mayne Pharma  (2021):", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Megestrol acetate, Ulipristal, Dienogest", "updated_at": 1767369485}, {"id": 249866, "ingredient1": "Norelgestromin", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with lapatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter.  The mechanism is decreased clearance via these routes due to inhibition by lapatinib.", "source": "DDInter", "management_text": "Caution is advised if lapatinib must be used concurrently with medications that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or P-gp efflux transporter, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lapatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lapatinib must be used concurrently with medications that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or P-gp efflux transporter, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296002/", "reference_text": "[1] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals  (2007):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249867, "ingredient1": "Norelgestromin", "ingredient2": "Larotrectinib", "severity": "Moderate", "effect": "Coadministration with larotrectinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever larotrectinib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  Some authorities recommend avoiding concomitant use of larotrectinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.  These drugs include, but are not limited to:  alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296003/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Vitrakvi (larotrectinib).\" Bayer Pharmaceutical Inc  (2018):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Dienogest, Estetrol, Etynodiol", "updated_at": 1767369485}, {"id": 249868, "ingredient1": "Norelgestromin", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296004/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More", "alternatives_b": "Dienogest, Estetrol, Etynodiol", "updated_at": 1767369485}, {"id": 249869, "ingredient1": "Norelgestromin", "ingredient2": "Lesinurad", "severity": "Moderate", "effect": "Coadministration with lesinurad may decrease the plasma concentrations of contraceptive hormones and reduce their effectiveness.  The interaction has not been evaluated in pharmacokinetic studies.  However, lesinurad is a weak inducer of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of contraceptive hormones.  Lesinurad has been shown to induce the metabolism of other CYP450 3A4 substrates in interaction studies.", "source": "DDInter", "management_text": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when used with lesinurad.  Female patients of reproductive potential receiving hormonal contraceptives should practice additional methods of contraception during treatment with lesinurad.", "mechanism_text": "Metabolism", "recommendation": "Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when used with lesinurad.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296006/", "reference_text": "[1] \"Product Information. Zurampic (lesinurad).\" Astra-Zeneca Pharmaceuticals  (2015):", "alternatives_a": "Pegloticase, Febuxostat, Colchicine, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Megestrol acetate, Estetrol, Estradiol", "updated_at": 1767369485}, {"id": 249870, "ingredient1": "Norelgestromin", "ingredient2": "Letermovir", "severity": "Moderate", "effect": "Coadministration with letermovir may increase the plasma concentrations of drugs that are substrates of CYP450 3A4.  In vitro and in vivo studies have shown that both estrogens and progestins are partially metabolized by CYP450 3A4.", "source": "DDInter", "management_text": "Monitor estrogen/progestin therapy for altered pharmacologic response and adjust dosage(s) accordingly whenever letermovir is added to or withdrawn from therapy.  When choosing an oral contraceptive, consider choosing an ethinyl estradiol-levonorgestrel product as this combination has been studied with letermovir and no clinically significant interaction has been found.", "mechanism_text": "Metabolism", "recommendation": "Monitor estrogen/progestin therapy for altered pharmacologic response and adjust dosage(s) accordingly whenever letermovir is added to or withdrawn from therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296007/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Prevymis (letermovir).\" Merck & Co., Inc  (2017):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Ulipristal, Estetrol, Levonorgestrel, Ethinylestradiol", "updated_at": 1767369485}, {"id": 249871, "ingredient1": "Norelgestromin", "ingredient2": "Linaclotide", "severity": "Moderate", "effect": "The absorption and efficacy of oral contraceptives may be reduced if severe diarrhea occurs with linaclotide treatment.  Linaclotide has been associated with severe and prolonged diarrhea.", "source": "DDInter", "management_text": "In patients who develop severe diarrhea during treatment with linaclotide, European labeling recommends use of an additional contraceptive method to prevent possible failure of oral contraception.", "mechanism_text": "Absorption", "recommendation": "In patients who develop severe diarrhea during treatment with linaclotide, European labeling recommends use of an additional contraceptive method to prevent possible failure of oral contraception.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296009/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[3] \"Product Information. Linzess (linaclotide).\" Forest Pharmaceuticals  (2012):", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, More", "alternatives_b": "Ulipristal, Megestrol acetate, Norgestimate, Drospirenone, Estradiol, Medroxyprogesterone acetate, Estetrol", "updated_at": 1767369485}, {"id": 249872, "ingredient1": "Norelgestromin", "ingredient2": "Lonafarnib", "severity": "Moderate", "effect": "Coadministration with lonafarnib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  Lonafarnib is a potent CYP450 3A time-dependent and mechanism-based inhibitor in vitro.", "source": "DDInter", "management_text": "Caution is advised when lonafarnib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lonafarnib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information recommends avoiding concomitant use of lonafarnib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges when possible.  These drugs include, but are not limited to:  alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when lonafarnib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296010/", "reference_text": "[1] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals  (2020):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Dienogest, Estetrol, Etynodiol", "updated_at": 1767369485}, {"id": 249873, "ingredient1": "Norelgestromin", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins.  Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.  The interaction has been reported primarily with oral contraceptives.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.  For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers.  Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).  Individual product labeling should be consulted for specific time frames.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Patients should be advised to notify their physician if they experience inadequate control of symptoms associated with estrogen deficiency (e.g., nocturnal sweating, vasomotor disturbances, atrophic vaginitis) or changes in the uterine bleeding profile.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296012/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[3] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[4] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984):  1125-6[5] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986):  384[6] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990):  124-5[7] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[8] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[9] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990):  101-5[10] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990):  241-7[11] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[12] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[13] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[14] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[15] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[16] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[17] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[19] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[20] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[21] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[22] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984):  1125-6[23] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[24] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[25] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[26] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[27] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[28] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories  (2001):[30] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[31] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[32] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[33] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[34] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[35] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[36] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[37] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[38] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000):  598-604[39] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[40] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[41] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[42] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003):  112-113[43] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003):  683-90[44] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003):  525-35[45] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002):  P25[46] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001):  A25[47] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249874, "ingredient1": "Norelgestromin", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Coadministration with a barbiturate may reduce the efficacy of contraceptive hormones.The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and enhancement of hormone-binding globulin capacity by phenobarbital.  Since all barbiturates are believed to possess enzyme-inducing capabilities, the interaction should be expected with agents in the class other than phenobarbital.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates.  Alternative or additional methods of birth control should be used during and for at least one week after short-term and 4 weeks after long-term (greater than 4 weeks) barbiturate therapy.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by barbiturates.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296014/", "reference_text": "[1] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[2] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[3] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[4] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[5] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[6] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[7] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[8] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[10] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[11] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[13] Kleier DJ, Tucker JE \"Oral contraceptive failure secondary to dentally prescribed drugs: fact or fiction?\" J Colo Dent Assoc 66 (1987):  5-6[14] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[15] Shane-McWorter L, Cerveny JD, MacFarlane LL, Osborn C \"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.\" Pharmacotherapy 18 (1998):  1360-4[16] Haukkamaa M \"Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.\" Contraception 33 (1986):  559-65[17] \"Product Information. Norplant System (levonorgestrel).\" Wyeth-Ayerst Laboratories  (2001):[18] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[19] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[20] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249875, "ingredient1": "Norelgestromin", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Treatment with metreleptin, a recombinant analog of human leptin, may affect the pharmacokinetics of drugs that are primarily metabolized by CYP450 isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin.  Clinical and laboratory monitoring are recommended following the initiation, discontinuation or change of dosage of metreleptin, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when metreleptin is prescribed to patients receiving drugs with a narrow therapeutic index that are substrates of CYP450 isoenzymes, such as macrolide immunosuppressants, oral contraceptives, cyclosporine, theophylline, and warfarin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296015/", "reference_text": "[1] \"Product Information. Myalept (metreleptin).\" Bristol-Myers Squibb  (2014):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Megestrol acetate, Estetrol, Estradiol", "updated_at": 1767369485}, {"id": 249876, "ingredient1": "Norelgestromin", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins.  The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296016/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990):  s327-33[2] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993):  436[3] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989):  851-9[4] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998):  300-4[5] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals  (2002):", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "Megestrol acetate, Dienogest, Estetrol", "updated_at": 1767369485}, {"id": 249877, "ingredient1": "Norelgestromin", "ingredient2": "Mifepristone", "severity": "Moderate", "effect": "Mifepristone is a progesterone-receptor antagonist and will interfere with the effectiveness of hormonal contraceptives.", "source": "DDInter", "management_text": "When mifepristone is prescribed daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, only nonhormonal contraceptive methods should be used.  Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).", "mechanism_text": "Antagonism", "recommendation": "When mifepristone is prescribed daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, only nonhormonal contraceptive methods should be used.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296017/", "reference_text": "[1] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated  (2012):", "alternatives_a": "Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Ulipristal, Estetrol", "updated_at": 1767369485}, {"id": 249878, "ingredient1": "Norelgestromin", "ingredient2": "Mitotane", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins.  Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.  The interaction has been reported primarily with oral contraceptives.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.  For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers.  Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).  Individual product labeling should be consulted for specific time frames.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Patients should be advised to notify their physician if they experience inadequate control of symptoms associated with estrogen deficiency (e.g., nocturnal sweating, vasomotor disturbances, atrophic vaginitis) or changes in the uterine bleeding profile.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296019/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[3] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[4] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984):  1125-6[5] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986):  384[6] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990):  124-5[7] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[8] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[9] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990):  101-5[10] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990):  241-7[11] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[12] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[13] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[14] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[15] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[16] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[17] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[19] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[20] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[21] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[22] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984):  1125-6[23] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[24] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[25] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[26] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[27] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[28] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories  (2001):[30] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[31] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[32] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[33] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[34] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[35] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[36] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[37] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[38] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000):  598-604[39] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[40] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[41] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[42] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003):  112-113[43] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003):  683-90[44] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003):  525-35[45] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002):  P25[46] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001):  A25[47] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249879, "ingredient1": "Norelgestromin", "ingredient2": "Modafinil", "severity": "Moderate", "effect": "Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of ethinyl estradiol and other contraceptive hormones.  The mechanism involves induction of CYP450 3A4-mediated metabolism by modafinil and armodafinil.", "source": "DDInter", "management_text": "Women using hormonal contraceptives (including depot and implantable contraceptives) should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with modafinil or armodafinil.  Alternative or additional methods of birth control are recommended during and for one month after treatment with modafinil or armodafinil.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives (including depot and implantable contraceptives) should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with modafinil or armodafinil.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296021/", "reference_text": "[1] \"Product Information. Provigil (modafinil).\" Cephalon, Inc  (2001):[2] Robertson P, Decory HH, Madan A, Parkinson A \"In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.\" Drug Metab Dispos 28 (2000):  664-71[3] Robertson P Jr, Hellriegel ET, Arora S, Nelson M \"Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers.\" Clin Pharmacol Ther 71 (2002):  46-56[4] \"Product Information. Nuvigil (armodafinil).\" Cephalon Inc  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249880, "ingredient1": "Norelgestromin", "ingredient2": "Morphine", "severity": "Minor", "effect": "Oral contraceptives induce glucuronidation and may decrease plasma concentrations of morphine, diamorphine, and other opioids.", "source": "DDInter", "management_text": "Oral contraceptives may influence opioid analgesic effects and opioid dosage may need to be adjusted.", "mechanism_text": "Metabolism", "recommendation": "Oral contraceptives may influence opioid analgesic effects and opioid dosage may need to be adjusted.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296022/", "reference_text": "[1] Shenfield GM, Griffin JM \"Clinical pharmacokinetics of contraceptive steroids: an update.\" Clin Pharmacokinet 20 (1991):  15-37[2] \"Product Information. NuvaRing (ethinyl estradiol-etonogestrel).\" Organon  (2001):[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. VyLibra (ethinyl estradiol-norgestimate).\" Afaxys Inc.  (2022):[5] Ribeiro-Dasilva MC, Shinal RM, Glover T, Williams RS, Staud R, Riley JL 3rd, Fillingim RB \"Evaluation of menstrual cycle effects on morphine and pentazocine analgesia\" Pain 152 (2011):  614-622", "alternatives_a": "Diphenoxylate, Opium, Eluxadoline, Difenoxin, Loperamide, Naltrexone, Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, More", "alternatives_b": "Megestrol acetate, Estetrol", "updated_at": 1767369485}, {"id": 249881, "ingredient1": "Norelgestromin", "ingredient2": "Mycophenolate mofetil", "severity": "Major", "effect": "Coadministration with mycophenolic acid may decrease the plasma concentrations and, theoretically, the efficacy of contraceptive hormones.  The mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although clinical significance of the interaction is unknown, caution is advised when mycophenolic acid is prescribed in combination with hormonal contraceptives, including all oral, injectable, transdermal, vaginal, and implantable forms.  Because use of mycophenolic acid is associated with an increased risk of pregnancy loss in the first trimester and congenital malformations, it is particularly important that female patients not become pregnant during treatment.  An acceptable barrier method (e.g., diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male condom, female condom) should be used in addition to the hormonal contraceptive of choice during the entire duration of mycophenolic acid therapy and for 6 weeks after discontinuation.  Input from a gynecologist or similar expert on adequate contraception should be sought as needed.  Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Others", "recommendation": "Although clinical significance of the interaction is unknown, caution is advised when mycophenolic acid is prescribed in combination with hormonal contraceptives, including all oral, injectable, transdermal, vaginal, and implantable forms.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296023/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories  (2001):[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals  (2004):", "alternatives_a": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249882, "ingredient1": "Norelgestromin", "ingredient2": "Mycophenolic acid", "severity": "Major", "effect": "Coadministration with mycophenolic acid may decrease the plasma concentrations and, theoretically, the efficacy of contraceptive hormones.  The mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Although clinical significance of the interaction is unknown, caution is advised when mycophenolic acid is prescribed in combination with hormonal contraceptives, including all oral, injectable, transdermal, vaginal, and implantable forms.  Because use of mycophenolic acid is associated with an increased risk of pregnancy loss in the first trimester and congenital malformations, it is particularly important that female patients not become pregnant during treatment.  An acceptable barrier method (e.g., diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male condom, female condom) should be used in addition to the hormonal contraceptive of choice during the entire duration of mycophenolic acid therapy and for 6 weeks after discontinuation.  Input from a gynecologist or similar expert on adequate contraception should be sought as needed.  Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Others", "recommendation": "Although clinical significance of the interaction is unknown, caution is advised when mycophenolic acid is prescribed in combination with hormonal contraceptives, including all oral, injectable, transdermal, vaginal, and implantable forms.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296024/", "reference_text": "[1] \"Product Information. CellCept (mycophenolate mofetil).\" Roche Laboratories  (2001):[2] \"Product Information. Myfortic (mycophenolic acid).\" Novartis Pharmaceuticals  (2004):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249883, "ingredient1": "Norelgestromin", "ingredient2": "Nafcillin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins.  Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.  The interaction has been reported primarily with oral contraceptives.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.  For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers.  Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).  Individual product labeling should be consulted for specific time frames.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Patients should be advised to notify their physician if they experience inadequate control of symptoms associated with estrogen deficiency (e.g., nocturnal sweating, vasomotor disturbances, atrophic vaginitis) or changes in the uterine bleeding profile.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296025/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[3] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[4] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984):  1125-6[5] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986):  384[6] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990):  124-5[7] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[8] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[9] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990):  101-5[10] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990):  241-7[11] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[12] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[13] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[14] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[15] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[16] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[17] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[19] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[20] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[21] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[22] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984):  1125-6[23] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[24] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[25] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[26] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[27] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[28] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories  (2001):[30] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[31] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[32] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[33] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[34] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[35] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[36] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[37] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[38] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000):  598-604[39] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[40] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[41] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[42] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003):  112-113[43] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003):  683-90[44] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003):  525-35[45] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002):  P25[46] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001):  A25[47] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249884, "ingredient1": "Norelgestromin", "ingredient2": "Nelfinavir", "severity": "Moderate", "effect": "Nelfinavir may decrease the plasma concentrations of contraceptive hormones during chronic coadministration.  The proposed mechanism is nelfinavir induction of the hepatic metabolism of sex hormones.", "source": "DDInter", "management_text": "When using Nelfinavir and birth control pills together, we recommend additional contraception.", "mechanism_text": "Metabolism", "recommendation": "When using Nelfinavir and birth control pills together, we recommend additional contraception.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296026/", "reference_text": "[1] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[2] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Megestrol acetate, Estetrol", "updated_at": 1767369485}, {"id": 249885, "ingredient1": "Norelgestromin", "ingredient2": "Neratinib", "severity": "Moderate", "effect": "Coadministration with neratinib may reduce the efficacy of hormonal contraceptives.  The mechanism for the potential interaction has not been established.", "source": "DDInter", "management_text": "Although the clinical significance of this interaction is unknown, caution is advised when neratinib is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm.  Women should avoid becoming pregnant during treatment with neratinib and for up to 1 month after discontinuing treatment.  Women using hormonal contraceptives should add a barrier method.  In addition, men receiving neratinib should use a barrier method of contraception during treatment and for 3 months after discontinuing treatment.", "mechanism_text": "Others", "recommendation": "Although the clinical significance of this interaction is unknown, caution is advised when neratinib is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296027/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249886, "ingredient1": "Norelgestromin", "ingredient2": "Nevirapine", "severity": "Moderate", "effect": "Coadministration with nevirapine may decrease the plasma concentrations of contraceptive hormones.  The proposed mechanism is nevirapine induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of sex hormones and other steroids.", "source": "DDInter", "management_text": "ADDITIONAL CONTRACEPTION RECOMMENDED:  Coadministration with nevirapine may decrease the plasma concentrations of contraceptive hormones.  The proposed mechanism is nevirapine induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of sex hormones and other steroids.  In ten HIV-positive subjects, nevirapine (200 mg once a day for 2 weeks followed by 200 mg twice a day for 2 weeks) decreased the area under the plasma concentration-time curve (AUC) of ethinyl estradiol (administered as ethinyl estradiol-norethindrone 0.035 mg-1 mg) by 20% compared to administration of the oral contraceptive alone.  The AUC and peak plasma concentration (Cmax) of norethindrone decreased by 19% and 16%, respectively.", "mechanism_text": "Metabolism", "recommendation": "ADDITIONAL CONTRACEPTION RECOMMENDED:  Coadministration with nevirapine may decrease the plasma concentrations of contraceptive hormones.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296028/", "reference_text": "[1] \"Product Information. Viramune (nevirapine).\" Boehringer-Ingelheim  (2001):[2] Back D, Gibbons S, Khoo S \"Pharmacokinetic drug interactions with nevirapine.\" J Acquir Immune Defic Syndr 34 Suppl 1 (2003):  S8-14[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249887, "ingredient1": "Norelgestromin", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with nilotinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter and/or CYP450 2D6, CYP450 3A4, or UGT1A1 isoenzymes.  The mechanism is decreased clearance via these routes due to inhibition by nilotinib.", "source": "DDInter", "management_text": "Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nilotinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296029/", "reference_text": "[1] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals  (2007):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Dienogest, Estetrol, Etynodiol", "updated_at": 1767369485}, {"id": 249888, "ingredient1": "Olaparib", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with olaparib may decrease the plasma concentrations and efficacy of contraceptive hormones.  The proposed mechanism is olaparib induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Some authorities recommend that women avoid pregnancy during olaparib treatment due to its potential teratogenic effects.  In women of childbearing potential, alternative or additional non-hormonal methods of birth control should be considered during treatment and for one month after receiving the last dose of olaparib.  Regular pregnancy tests are also recommended.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Some authorities recommend that women avoid pregnancy during olaparib treatment due to its potential teratogenic effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296030/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, More", "alternatives_b": "Ulipristal, Megestrol acetate, Estradiol, Medroxyprogesterone acetate, Estetrol", "updated_at": 1767369485}, {"id": 249889, "ingredient1": "Osilodrostat", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296032/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Dienogest, Estetrol, Etynodiol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249890, "ingredient1": "Oxcarbazepine", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.  Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) anticonvulsant therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be considered.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable.  If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).  However, there are no data on efficacy, compliance, or side effects of this regimen.  For women with the etonogestrel subdermal implant, the addition of a barrier method is recommended during concomitant use and for 28 days after discontinuation of hepatic enzyme inducing drugs.  It is recommended to remove the implant and to prescribe a nonhormonal method in women who require long-term treatment with hepatic enzyme inducing drugs.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.", "mechanism_text": "Antagonism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296033/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Odlind V, Olsson SE \"Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with norplant implants.\" Contraception 33 (1986):  257-61[3] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[4] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[5] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[6] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[7] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[8] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[9] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[10] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[11] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[12] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[13] Diamond MP, Greene JW, Thompson JM, VanHooydonk JE, Wentz AC \"Interaction of anticonvulsants and oral contraceptives in epileptic adolescents.\" Contraception 31 (1985):  623-32[14] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[15] Rapport DJ, Calabrese JR \"Interactions between carbamazepine and birth control pills.\" Psychosomatics 30 (1989):  462-4[16] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[17] Saano V, Glue P, Banfield CR \"Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive.\" Clin Pharmacol Ther 58 (1995):  523-31[18] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[19] Shane-McWorter L, Cerveny JD, MacFarlane LL, Osborn C \"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.\" Pharmacotherapy 18 (1998):  1360-4[20] Haukkamaa M \"Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.\" Contraception 33 (1986):  559-65[21] Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E \"Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women.\" Epilepsia 40 (1999):  783-7[22] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[23] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[24] \"Product Information. Norplant System (levonorgestrel).\" Wyeth-Ayerst Laboratories  (2001):[25] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[26] Kenyon IE \"Unplanned pregnancy in an epileptic. (Letter to the editor).\" Br Med J 1 (1972):  686[27] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[28] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[29] Schindlbeck C, Janni W, Friese K \"Failure of Implanon contraception in a patient taking carbamazepin for epilepsia.\" Arch Gynecol Obstet 273 (2006):  255-6[30] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[31] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[32] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc  (2013):[33] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249891, "ingredient1": "Oxtriphylline", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "The coadministration with contraceptive steroids may increase the plasma concentrations of theophylline and other methylxanthines.  The proposed mechanism is inhibition of methylxanthine metabolism via hepatic microsomal enzymes, of which estrogens and progestins are also substrates.", "source": "DDInter", "management_text": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives.  Serum theophylline levels and pharmacologic response should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their theophylline regimen.  Patients should be advised to notify their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, and irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296034/", "reference_text": "[1] Tornatore KM, Kanarkowski R, McCarthy TL, et al. \"Effect of chronic oral contraceptive steroids on theophylline disposition.\" Eur J Clin Pharmacol 23 (1982):  129-34[2] Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R \"Effects of tobacco smoking and oral contraceptive use on theophylline disposition.\" Br J Clin Pharmacol 16 (1983):  271-80[3] Roberts RK, Grice J, McGuffie, Heilbronn L \"Oral contraceptive steroids impair the elimination of theophylline.\" J Lab Clin Med 101 (1983):  821-25", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Megestrol acetate, Ulipristal, Estetrol, Medroxyprogesterone acetate", "updated_at": 1767369485}, {"id": 249892, "ingredient1": "Pentobarbital", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with a barbiturate may reduce the efficacy of contraceptive hormones.The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and enhancement of hormone-binding globulin capacity by phenobarbital.  Since all barbiturates are believed to possess enzyme-inducing capabilities, the interaction should be expected with agents in the class other than phenobarbital.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates.  Alternative or additional methods of birth control should be used during and for at least one week after short-term and 4 weeks after long-term (greater than 4 weeks) barbiturate therapy.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by barbiturates.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296036/", "reference_text": "[1] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[2] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[3] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[4] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[5] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[6] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[7] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[8] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[10] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[11] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[13] Kleier DJ, Tucker JE \"Oral contraceptive failure secondary to dentally prescribed drugs: fact or fiction?\" J Colo Dent Assoc 66 (1987):  5-6[14] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[15] Shane-McWorter L, Cerveny JD, MacFarlane LL, Osborn C \"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.\" Pharmacotherapy 18 (1998):  1360-4[16] Haukkamaa M \"Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.\" Contraception 33 (1986):  559-65[17] \"Product Information. Norplant System (levonorgestrel).\" Wyeth-Ayerst Laboratories  (2001):[18] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[19] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[20] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249893, "ingredient1": "Perampanel", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with certain anticonvulsants, such as rufinamide and perampanel, may reduce the efficacy of contraceptive hormones.  The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity by the anticonvulsants.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.  In general, alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) anticonvulsant therapy.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296037/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Banzel (rufinamide).\" Eisai Inc  (2008):[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[5] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Ulipristal, Megestrol acetate, Estradiol, Medroxyprogesterone acetate, Estetrol", "updated_at": 1767369485}, {"id": 249894, "ingredient1": "Pexidartinib", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with pexidartinib may decrease the plasma concentration and efficacy of contraceptive hormones.  The proposed mechanism is increased clearance due to pexidartinib-mediated induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of sex hormones and other steroids.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with pexidartinib.  Alternative or additional methods of birth control should be used during and for at least one month after the final dose of pexidartinib.  In addition, male patients with female partners of reproductive potential should use effective contraception during and for at least one week after the final dose of pexidartinib.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with pexidartinib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296038/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc.  (2019):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249895, "ingredient1": "Phenobarbital", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.  Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) anticonvulsant therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be considered.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable.  If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).  However, there are no data on efficacy, compliance, or side effects of this regimen.  For women with the etonogestrel subdermal implant, the addition of a barrier method is recommended during concomitant use and for 28 days after discontinuation of hepatic enzyme inducing drugs.  It is recommended to remove the implant and to prescribe a nonhormonal method in women who require long-term treatment with hepatic enzyme inducing drugs.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.", "mechanism_text": "Antagonism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296039/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Odlind V, Olsson SE \"Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with norplant implants.\" Contraception 33 (1986):  257-61[3] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[4] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[5] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[6] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[7] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[8] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[9] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[10] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[11] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[12] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[13] Diamond MP, Greene JW, Thompson JM, VanHooydonk JE, Wentz AC \"Interaction of anticonvulsants and oral contraceptives in epileptic adolescents.\" Contraception 31 (1985):  623-32[14] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[15] Rapport DJ, Calabrese JR \"Interactions between carbamazepine and birth control pills.\" Psychosomatics 30 (1989):  462-4[16] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[17] Saano V, Glue P, Banfield CR \"Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive.\" Clin Pharmacol Ther 58 (1995):  523-31[18] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[19] Shane-McWorter L, Cerveny JD, MacFarlane LL, Osborn C \"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.\" Pharmacotherapy 18 (1998):  1360-4[20] Haukkamaa M \"Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.\" Contraception 33 (1986):  559-65[21] Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E \"Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women.\" Epilepsia 40 (1999):  783-7[22] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[23] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[24] \"Product Information. Norplant System (levonorgestrel).\" Wyeth-Ayerst Laboratories  (2001):[25] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[26] Kenyon IE \"Unplanned pregnancy in an epileptic. (Letter to the editor).\" Br Med J 1 (1972):  686[27] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[28] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[29] Schindlbeck C, Janni W, Friese K \"Failure of Implanon contraception in a patient taking carbamazepin for epilepsia.\" Arch Gynecol Obstet 273 (2006):  255-6[30] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[31] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[32] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc  (2013):[33] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249896, "ingredient1": "Phenylbutazone", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Limited clinical data suggest that phenylbutazone may reduce the efficacy of contraceptive hormones, potentially resulting in menstrual abnormalities (e.g., breakthrough bleeding, amenorrhea, irregular menses) or unintended pregnancy.  The proposed mechanism is accelerated clearance of the hormones due to induction of hepatic CYP450 enzymes by phenylbutazone.", "source": "DDInter", "management_text": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with phenylbutazone.  Alternative or additional methods of birth control should be used during and probably for at least one week after short-term and up to one month after long-term (greater than 4 weeks) phenylbutazone therapy.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with phenylbutazone.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296040/", "reference_text": "[1] Kleier DJ, Tucker JE \"Oral contraceptive failure secondary to dentally prescribed drugs: fact or fiction?\" J Colo Dent Assoc 66 (1987):  5-6[2] \"Product Information. NuvaRing (ethinyl estradiol-etonogestrel).\" Organon  (2001):[3] \"Product Information. Ortho Evra (ethinyl estradiol-norelgestromin).\" Janssen Pharmaceuticals  (2001):[4] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Acetylsalicylic acid, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249897, "ingredient1": "Phenytoin", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.  Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) anticonvulsant therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be considered.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable.  If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).  However, there are no data on efficacy, compliance, or side effects of this regimen.  For women with the etonogestrel subdermal implant, the addition of a barrier method is recommended during concomitant use and for 28 days after discontinuation of hepatic enzyme inducing drugs.  It is recommended to remove the implant and to prescribe a nonhormonal method in women who require long-term treatment with hepatic enzyme inducing drugs.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.", "mechanism_text": "Antagonism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296041/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Odlind V, Olsson SE \"Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with norplant implants.\" Contraception 33 (1986):  257-61[3] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[4] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[5] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[6] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[7] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[8] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[9] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[10] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[11] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[12] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[13] Diamond MP, Greene JW, Thompson JM, VanHooydonk JE, Wentz AC \"Interaction of anticonvulsants and oral contraceptives in epileptic adolescents.\" Contraception 31 (1985):  623-32[14] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[15] Rapport DJ, Calabrese JR \"Interactions between carbamazepine and birth control pills.\" Psychosomatics 30 (1989):  462-4[16] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[17] Saano V, Glue P, Banfield CR \"Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive.\" Clin Pharmacol Ther 58 (1995):  523-31[18] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[19] Shane-McWorter L, Cerveny JD, MacFarlane LL, Osborn C \"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.\" Pharmacotherapy 18 (1998):  1360-4[20] Haukkamaa M \"Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.\" Contraception 33 (1986):  559-65[21] Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E \"Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women.\" Epilepsia 40 (1999):  783-7[22] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[23] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[24] \"Product Information. Norplant System (levonorgestrel).\" Wyeth-Ayerst Laboratories  (2001):[25] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[26] Kenyon IE \"Unplanned pregnancy in an epileptic. (Letter to the editor).\" Br Med J 1 (1972):  686[27] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[28] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[29] Schindlbeck C, Janni W, Friese K \"Failure of Implanon contraception in a patient taking carbamazepin for epilepsia.\" Arch Gynecol Obstet 273 (2006):  255-6[30] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[31] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[32] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc  (2013):[33] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249898, "ingredient1": "Pioglitazone", "ingredient2": "Norelgestromin", "severity": "Minor", "effect": "Coadministration with another thiazolidinedione, troglitazone, has been shown to decrease the plasma concentrations of contraceptive hormones.  The proposed mechanism is induction of hormone metabolism via CYP450 3A4.", "source": "DDInter", "management_text": "Coadministration with another thiazolidinedione, troglitazone, has been shown to decrease the plasma concentrations of contraceptive hormones.  The proposed mechanism is induction of hormone metabolism via CYP450 3A4.  In 15 healthy female subjects, troglitazone (60 mg once daily for 3 weeks) decreased the mean steady-state peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of ethinyl estradiol and norethindrone (35 mcg-1 mg) by approximately 30% each compared to administration of the contraceptive alone.  Four subjects experienced breakthrough bleeding during the cycle with troglitazone.  There are no data on the use of contraceptive hormones with pioglitazone.  Because pioglitazone may be a weak inducer of CYP450 3A4, product labeling recommends additional caution in women requiring contraception.  However, some studies have reported no significant effect of pioglitazone on CYP450 3A4.  Rosiglitazone labeling states that the drug given in a dosage of 4 mg twice daily had no clinically relevant effect on the pharmacokinetics of oral contraceptives (ethinyl estradiol and norethindrone).  Intrauterine systems are unlikely to be significantly affected because of their local action.", "mechanism_text": "Metabolism", "recommendation": "Coadministration with another thiazolidinedione, troglitazone, has been shown to decrease the plasma concentrations of contraceptive hormones.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296042/", "reference_text": "[1] \"Product Information. Avandia (rosiglitazone).\" SmithKline Beecham  (2001):[2] \"Product Information. Actos (pioglitazone).\" Takeda Pharmaceuticals America  (2001):[3] Loi CM, Stern R, Koup JR, Vassos AB, Knowlton P, Sedman AJ \"Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent.\" J Clin Pharmacol 39 (1999):  410-7[4] Glazer NB, Cheatham WW \"Thiazolidinediones for type 2 diabetes - No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.\" Br Med J 322 (2001):  235-6[5] Nowak SN, Edwards DJ, Clarke A, Anderson GD, Jaber LA \"Pioglitazone: effect on CYP3A4 activity.\" J Clin Pharmacol 42 (2002):  1299-302", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "Ulipristal", "updated_at": 1767369485}, {"id": 249899, "ingredient1": "Pitolisant", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with pitolisant may decrease the plasma concentrations of contraceptive hormones.  The proposed mechanism is induction of the CYP450 3A4-mediated metabolism of estrogens and progestins by pitolisant and its main metabolites.", "source": "DDInter", "management_text": "The manufacturer recommends that alternative, nonhormonal methods of effective contraception should be used during and for at least 21 days after pitolisant therapy.", "mechanism_text": "Metabolism", "recommendation": "The manufacturer recommends that alternative, nonhormonal methods of effective contraception should be used during and for at least 21 days after pitolisant therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296043/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):[3] \"Product Information. Wakix (pitolisant).\" Harmony Biosciences, LLC  (2019):", "alternatives_a": "Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Amifampridine, Deutetrabenazine, Tafamidis", "alternatives_b": "Megestrol acetate, Estetrol, Estradiol, Medroxyprogesterone acetate", "updated_at": 1767369485}, {"id": 249900, "ingredient1": "Posaconazole", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins.  The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296044/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990):  s327-33[2] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993):  436[3] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989):  851-9[4] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998):  300-4[5] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals  (2002):", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249901, "ingredient1": "Pralsetinib", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with pralsetinib may render hormonal contraceptives ineffective.  The mechanism for the potential interaction has not been established and there are no clinical data regarding the use of pralsetinib with hormonal contraceptives.", "source": "DDInter", "management_text": "Until further data are available, females of reproductive potential should be advised to use effective non-hormonal contraception during treatment and for 2 weeks after the final dose.  In addition, men receiving pralsetinib should use effective contraception during treatment and for 1 week after the final dose.", "mechanism_text": "Others", "recommendation": "Until further data are available, females of reproductive potential should be advised to use effective non-hormonal contraception during treatment and for 2 weeks after the final dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296045/", "reference_text": "[1] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Megestrol acetate, Estetrol", "updated_at": 1767369485}, {"id": 249902, "ingredient1": "Primidone", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with certain anticonvulsants such as carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, and primidone may reduce the efficacy of contraceptive hormones.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.  Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) anticonvulsant therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be considered.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable.  If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).  However, there are no data on efficacy, compliance, or side effects of this regimen.  For women with the etonogestrel subdermal implant, the addition of a barrier method is recommended during concomitant use and for 28 days after discontinuation of hepatic enzyme inducing drugs.  It is recommended to remove the implant and to prescribe a nonhormonal method in women who require long-term treatment with hepatic enzyme inducing drugs.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.", "mechanism_text": "Antagonism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296046/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Odlind V, Olsson SE \"Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with norplant implants.\" Contraception 33 (1986):  257-61[3] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[4] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[5] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[6] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[7] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[8] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[9] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[10] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[11] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[12] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[13] Diamond MP, Greene JW, Thompson JM, VanHooydonk JE, Wentz AC \"Interaction of anticonvulsants and oral contraceptives in epileptic adolescents.\" Contraception 31 (1985):  623-32[14] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[15] Rapport DJ, Calabrese JR \"Interactions between carbamazepine and birth control pills.\" Psychosomatics 30 (1989):  462-4[16] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[17] Saano V, Glue P, Banfield CR \"Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive.\" Clin Pharmacol Ther 58 (1995):  523-31[18] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[19] Shane-McWorter L, Cerveny JD, MacFarlane LL, Osborn C \"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.\" Pharmacotherapy 18 (1998):  1360-4[20] Haukkamaa M \"Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.\" Contraception 33 (1986):  559-65[21] Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E \"Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women.\" Epilepsia 40 (1999):  783-7[22] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[23] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[24] \"Product Information. Norplant System (levonorgestrel).\" Wyeth-Ayerst Laboratories  (2001):[25] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[26] Kenyon IE \"Unplanned pregnancy in an epileptic. (Letter to the editor).\" Br Med J 1 (1972):  686[27] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[28] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[29] Schindlbeck C, Janni W, Friese K \"Failure of Implanon contraception in a patient taking carbamazepin for epilepsia.\" Arch Gynecol Obstet 273 (2006):  255-6[30] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[31] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[32] \"Product Information. Aptiom (eslicarbazepine).\" Sunovion Pharmaceuticals Inc  (2013):[33] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249903, "ingredient1": "Rifabutin", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with rifampin or other rifamycins may reduce the efficacy of contraceptive hormones.The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by rifampin.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant rifamycin therapy, even when given in short courses.  Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) rifamycin therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable.  If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).  However, there are no data on efficacy, compliance, or side effects of this regimen.  For women with the etonogestrel subdermal implant, the addition of a barrier method is recommended during concomitant use and for 28 days after discontinuation of hepatic enzyme inducing drugs.  It is recommended to remove the implant and to prescribe a nonhormonal method in women who require long-term treatment with hepatic enzyme inducing drugs.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by rifamycins.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant rifamycin therapy, even when given in short courses.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296047/", "reference_text": "[1] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[2] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[3] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[4] Joshi JV, Joshi UM, Sankolli GM, et al. \"A study of interaction of a low-dose combination oral contraceptive with anti-tubercular drugs.\" Contraception 21 (1980):  617-29[5] Bint AJ, Burtt I \"Adverse antibiotic drug interactions.\" Drugs 20 (1980):  57-68[6] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[7] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[8] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[9] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[10] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[11] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[12] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[13] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[14] Back DJ, Breckenridge AM, Crawford F, et al. \"The effect of rifampicin on norethisterone pharmacokinetics.\" Eur J Clin Pharmacol 15 (1979):  193-7[15] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[16] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[17] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[18] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[19] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[20] \"Product Information. Priftin (rifapentine).\" Hoechst Marion Roussel  (2001):[21] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[22] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[23] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[24] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[25] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[26] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[27] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[28] Archer JS, Archer DF \"Oral contraceptive efficacy and antibiotic interaction: A myth debunked.\" J Am Acad Dermatol 46 (2002):  917-23[29] DeRossi SS, Hersh EV \"Antibiotics and oral contraceptives.\" Dent Clin North Am 46 (2002):  653-64[30] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[31] Bounds W, Guillebaud J \"Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs.\" J Fam Plann Reprod Health Care 28 (2002):  78-80[32] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249904, "ingredient1": "Rifampicin", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with rifampin or other rifamycins may reduce the efficacy of contraceptive hormones.The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by rifampin.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant rifamycin therapy, even when given in short courses.  Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) rifamycin therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable.  If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).  However, there are no data on efficacy, compliance, or side effects of this regimen.  For women with the etonogestrel subdermal implant, the addition of a barrier method is recommended during concomitant use and for 28 days after discontinuation of hepatic enzyme inducing drugs.  It is recommended to remove the implant and to prescribe a nonhormonal method in women who require long-term treatment with hepatic enzyme inducing drugs.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by rifamycins.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant rifamycin therapy, even when given in short courses.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296048/", "reference_text": "[1] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[2] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[3] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[4] Joshi JV, Joshi UM, Sankolli GM, et al. \"A study of interaction of a low-dose combination oral contraceptive with anti-tubercular drugs.\" Contraception 21 (1980):  617-29[5] Bint AJ, Burtt I \"Adverse antibiotic drug interactions.\" Drugs 20 (1980):  57-68[6] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[7] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[8] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[9] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[10] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[11] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[12] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[13] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[14] Back DJ, Breckenridge AM, Crawford F, et al. \"The effect of rifampicin on norethisterone pharmacokinetics.\" Eur J Clin Pharmacol 15 (1979):  193-7[15] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[16] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[17] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[18] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[19] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[20] \"Product Information. Priftin (rifapentine).\" Hoechst Marion Roussel  (2001):[21] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[22] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[23] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[24] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[25] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[26] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[27] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[28] Archer JS, Archer DF \"Oral contraceptive efficacy and antibiotic interaction: A myth debunked.\" J Am Acad Dermatol 46 (2002):  917-23[29] DeRossi SS, Hersh EV \"Antibiotics and oral contraceptives.\" Dent Clin North Am 46 (2002):  653-64[30] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[31] Bounds W, Guillebaud J \"Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs.\" J Fam Plann Reprod Health Care 28 (2002):  78-80[32] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249905, "ingredient1": "Rifapentine", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with rifampin or other rifamycins may reduce the efficacy of contraceptive hormones.The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and hormone-binding globulin capacity by rifampin.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant rifamycin therapy, even when given in short courses.  Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) rifamycin therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable.  If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).  However, there are no data on efficacy, compliance, or side effects of this regimen.  For women with the etonogestrel subdermal implant, the addition of a barrier method is recommended during concomitant use and for 28 days after discontinuation of hepatic enzyme inducing drugs.  It is recommended to remove the implant and to prescribe a nonhormonal method in women who require long-term treatment with hepatic enzyme inducing drugs.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by rifamycins.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant rifamycin therapy, even when given in short courses.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296049/", "reference_text": "[1] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[2] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[3] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[4] Joshi JV, Joshi UM, Sankolli GM, et al. \"A study of interaction of a low-dose combination oral contraceptive with anti-tubercular drugs.\" Contraception 21 (1980):  617-29[5] Bint AJ, Burtt I \"Adverse antibiotic drug interactions.\" Drugs 20 (1980):  57-68[6] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[7] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[8] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[9] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[10] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[11] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[12] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[13] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[14] Back DJ, Breckenridge AM, Crawford F, et al. \"The effect of rifampicin on norethisterone pharmacokinetics.\" Eur J Clin Pharmacol 15 (1979):  193-7[15] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[16] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[17] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[18] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[19] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[20] \"Product Information. Priftin (rifapentine).\" Hoechst Marion Roussel  (2001):[21] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[22] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[23] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[24] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[25] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[26] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[27] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[28] Archer JS, Archer DF \"Oral contraceptive efficacy and antibiotic interaction: A myth debunked.\" J Am Acad Dermatol 46 (2002):  917-23[29] DeRossi SS, Hersh EV \"Antibiotics and oral contraceptives.\" Dent Clin North Am 46 (2002):  653-64[30] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[31] Bounds W, Guillebaud J \"Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs.\" J Fam Plann Reprod Health Care 28 (2002):  78-80[32] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249906, "ingredient1": "Rilonacept", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296050/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249907, "ingredient1": "Ritonavir", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with ritonavir may decrease the plasma concentrations of contraceptive hormones.The exact mechanism of interaction is unknown but may involve ritonavir induction of glucuronosyltransferase and/or CYP450 hydroxylation.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with ritonavir.  Alternative or additional methods of birth control should be used during and for at least 4 weeks after ritonavir therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable.  If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).  However, there are no data on efficacy, compliance, or side effects of this regimen.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with ritonavir.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296051/", "reference_text": "[1] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[2] Ouellet D, Qian J, Locke CS, Eason CJ, Cavanaugh JH \"Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.\" Br J Clin Pharmacol 46 (1998):  111-6[3] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Megestrol acetate, Estetrol", "updated_at": 1767369485}, {"id": 249908, "ingredient1": "Rosuvastatin", "ingredient2": "Norelgestromin", "severity": "Minor", "effect": "Coadministration with rosuvastatin may increase the plasma concentrations of certain oral contraceptive hormones.  The mechanism of interaction has not been established.", "source": "DDInter", "management_text": "Concurrent use of rosuvastatin and oral contraceptives is not recommended. If simultaneous use is necessary, we recommend reducing the pill while adding additional contraception.", "mechanism_text": "Others", "recommendation": "Concurrent use of rosuvastatin and oral contraceptives is not recommended.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296052/", "reference_text": "[1] \"Product Information. Crestor (rosuvastatin).\" AstraZeneca Pharma Inc  (2003):", "alternatives_a": "Amlodipine, Ramipril, Valsartan, Simvastatin, Lovastatin, Lisinopril, Perindopril, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, More", "alternatives_b": "Megestrol acetate, Ulipristal, Estetrol, Dienogest", "updated_at": 1767369485}, {"id": 249909, "ingredient1": "Rucaparib", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 3A4.  The proposed mechanism is decreased clearance due to rucaparib-mediated inhibition of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296053/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\"   (2013):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, More", "alternatives_b": "Etynodiol, Levonorgestrel, Medroxyprogesterone acetate, Dienogest, Estetrol", "updated_at": 1767369485}, {"id": 249910, "ingredient1": "Rufinamide", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with certain anticonvulsants, such as rufinamide and perampanel, may reduce the efficacy of contraceptive hormones.  The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity by the anticonvulsants.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.  In general, alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) anticonvulsant therapy.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with enzyme-inducing anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296054/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Banzel (rufinamide).\" Eisai Inc  (2008):[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[5] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249911, "ingredient1": "Sarilumab", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296055/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249912, "ingredient1": "Satralizumab", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296056/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249913, "ingredient1": "Secobarbital", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with a barbiturate may reduce the efficacy of contraceptive hormones.The interaction stems from accelerated clearance of contraceptive hormones as well as decreased plasma concentrations of unbound (active) hormones due to induction of hepatic CYP450 enzymatic activity and enhancement of hormone-binding globulin capacity by phenobarbital.  Since all barbiturates are believed to possess enzyme-inducing capabilities, the interaction should be expected with agents in the class other than phenobarbital.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates.  Alternative or additional methods of birth control should be used during and for at least one week after short-term and 4 weeks after long-term (greater than 4 weeks) barbiturate therapy.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by barbiturates.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with barbiturates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296057/", "reference_text": "[1] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[2] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[3] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[4] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[5] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[6] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[7] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[8] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[9] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[10] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[11] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[12] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[13] Kleier DJ, Tucker JE \"Oral contraceptive failure secondary to dentally prescribed drugs: fact or fiction?\" J Colo Dent Assoc 66 (1987):  5-6[14] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[15] Shane-McWorter L, Cerveny JD, MacFarlane LL, Osborn C \"Enhanced metabolism of levonorgestrel during phenobarbital treatment and resultant pregnancy.\" Pharmacotherapy 18 (1998):  1360-4[16] Haukkamaa M \"Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment.\" Contraception 33 (1986):  559-65[17] \"Product Information. Norplant System (levonorgestrel).\" Wyeth-Ayerst Laboratories  (2001):[18] Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM \"Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics.\" Br J Clin Pharmacol 25 (1988):  527-32[19] O'Brien MD, Guillebaud J \"Contraception for women with epilepsy.\" Epilepsia 47 (2006):  1419-22[20] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Suvorexant, Triazolam, Flurazepam, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249914, "ingredient1": "Secukinumab", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296058/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249915, "ingredient1": "Selpercatinib", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with selpercatinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  The mechanism is reduced clearance due to inhibition of CYP450 3A4 by selpercatinib.  The interaction may be particularly important for sensitive substrates or those that demonstrate a narrow therapeutic index.", "source": "DDInter", "management_text": "Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever selpercatinib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296059/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company  (2020):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Dienogest, Estetrol, Etynodiol", "updated_at": 1767369485}, {"id": 249916, "ingredient1": "Selumetinib", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with selumetinib may reduce the effectiveness of hormonal contraceptives.", "source": "DDInter", "management_text": "Until further data are available, females of reproductive potential using hormonal contraceptives should be advised to add a barrier method during treatment with selumetinib and for 1 week after the final dose.  In addition, men with female partners of reproductive potential should also use effective contraception during treatment with selumetinib and for 1 week after the last dose.", "mechanism_text": "Antagonism", "recommendation": "Until further data are available, females of reproductive potential using hormonal contraceptives should be advised to add a barrier method during treatment with selumetinib and for 1 week after the final dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296060/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Megestrol acetate, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249917, "ingredient1": "Siltuximab", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296061/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249918, "ingredient1": "Somapacitan", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296062/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Dienogest, Estetrol, Etynodiol", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 249919, "ingredient1": "Somatrem", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296063/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Dienogest, Estetrol, Etynodiol", "updated_at": 1767369485}, {"id": 249920, "ingredient1": "Somatotropin", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296064/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "alternatives_b": "Dienogest, Estetrol, Etynodiol", "updated_at": 1767369485}, {"id": 249921, "ingredient1": "St. John's Wort", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with St. John's wort may reduce the efficacy of contraceptive hormones.  The exact mechanism of interaction is unknown but may involve reduced absorption as well as accelerated clearance of the hormones due to induction of intestinal P-glycoprotein drug efflux transporter and intestinal/hepatic CYP450 3A4 metabolism by constituents of St. John's wort.", "source": "DDInter", "management_text": "In general, patients should consult a healthcare provider before taking any herbal or alternative medicine.  Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with St. John's wort.  Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) St. John's wort therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For emergency contraception in patients who have used an hepatic enzyme inducer in the past 4 weeks, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable.  If this is not possible, some authorities recommend that the usual dose of levonorgestrel (1.5 mg) should be doubled to 3 mg and taken as a single dose as soon as possible (within 72 hours of unprotected sexual intercourse).  However, there are no data on efficacy, compliance, or side effects of this regimen.  For women with the etonogestrel subdermal implant, the addition of a barrier method is recommended during concomitant use and for 28 days after discontinuation of hepatic enzyme inducing drugs.  It is recommended to remove the implant and to prescribe a nonhormonal method in women who require long-term treatment with hepatic enzyme inducing drugs.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.", "mechanism_text": "Metabolism, Absorption", "recommendation": "In general, patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296066/", "reference_text": "[1] Ernst E \"Second thoughts about safety of St John's wort.\" Lancet 354 (1999):  2014-6[2] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[3] Jobst KA, McIntyre M, St George D, Whitelegg M \"Safety of St John's wort (Hypericum perforatum).\" Lancet 355 (2000):  575[4] De Smet PA, Touw DJ \"Safety of St John's wort (Hypericum perforatum).\" Lancet 355 (2000):  575-6[5] Yue QY, Berquist C, Gerden B \"Safety of St John's wort (Hypericum perforatum).\" Lancet 355 (2000):  576-7[6] Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH \"St John's Wort: Effect on CYP3A4 activity.\" Clin Pharmacol Ther 67 (2000):  451-7[7] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000):  598-604[8] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[9] Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P \"St John's wort (Hypericum perforatum): drug interactions and clinical outcomes.\" Br J Clin Pharmacol 54 (2002):  349-56[10] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003):  112-113[11] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003):  683-90[12] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003):  525-35[13] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002):  P25[14] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001):  A25[15] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[16] Schwarz UI, Buschel B, Kirch W \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003):  112-3[17] Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL \"Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding.\" Contraception 71 (2005):  402-8[18] MHRA. Medicines and Healthcare Regulatory Agency. \"St John's wort: interaction with hormonal contraceptives, including implants--reduced contraceptive effect.  http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON392869\"   (2014):[19] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Estetrol", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More", "updated_at": 1767369485}, {"id": 249922, "ingredient1": "Stiripentol", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "The concomitant administration of stiripentol may significantly increase plasma concentrations, pharmacologic effects, and toxicities of drugs that are substrates of CYP450 2C19, 3A4, and/or 2D6.  The mechanism is inhibition of cytochrome P-450 metabolism by stiripentol.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use.  Dosage adjustments may be required if increased plasma levels or effects are observed.", "mechanism_text": "Metabolism", "recommendation": "Clinical and laboratory monitoring for altered efficacy and safety is recommended during concomitant use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296067/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Ulipristal, Megestrol acetate, Etynodiol, Dienogest, Estetrol", "updated_at": 1767369485}, {"id": 249923, "ingredient1": "Sugammadex", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Sugammadex may decrease the free plasma concentrations and therapeutic efficacy of hormonal contraceptives.", "source": "DDInter", "management_text": "Female patients of reproductive potential receiving hormonal contraceptives (whether oral or non-oral) should use an additional, nonhormonal contraceptive method or backup method of contraception (e.g., condoms and spermicides) for 7 days after sugammadex administration.", "mechanism_text": "Others", "recommendation": "Female patients of reproductive potential receiving hormonal contraceptives (whether oral or non-oral) should use an additional, nonhormonal contraceptive method or backup method of contraception (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296068/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Bridion (sugammadex).\" Merck & Co., Inc  (2015):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Promethazine, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Ulipristal, Megestrol acetate, Estradiol, Estetrol, Ethinylestradiol", "updated_at": 1767369485}, {"id": 249924, "ingredient1": "Sulfinpyrazone", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins.  Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.  The interaction has been reported primarily with oral contraceptives.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.  For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers.  Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).  Individual product labeling should be consulted for specific time frames.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Patients should be advised to notify their physician if they experience inadequate control of symptoms associated with estrogen deficiency (e.g., nocturnal sweating, vasomotor disturbances, atrophic vaginitis) or changes in the uterine bleeding profile.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296069/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[3] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[4] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984):  1125-6[5] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986):  384[6] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990):  124-5[7] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[8] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[9] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990):  101-5[10] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990):  241-7[11] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[12] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[13] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[14] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[15] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[16] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[17] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[19] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[20] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[21] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[22] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984):  1125-6[23] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[24] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[25] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[26] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[27] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[28] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories  (2001):[30] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[31] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[32] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[33] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[34] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[35] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[36] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[37] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[38] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000):  598-604[39] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[40] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[41] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[42] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003):  112-113[43] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003):  683-90[44] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003):  525-35[45] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002):  P25[46] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001):  A25[47] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Pegloticase, Febuxostat, Colchicine, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Dienogest, Estetrol", "updated_at": 1767369485}, {"id": 249925, "ingredient1": "Tazemetostat", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with tazemetostat may decrease the plasma concentrations and efficacy of hormonal contraceptives.  The mechanism involves induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Although the clinical significance of the interaction is unknown, caution is advised when tazemetostat is prescribed in combination with hormonal contraceptives, including all oral, injectable, transdermal, vaginal, and implantable forms.  Because use of tazemetostat may cause fetal harm, it is particularly important that female patients not become pregnant during treatment.  Females of reproductive potential should be advised to use alternative or additional methods of birth control during treatment with tazemetostat and for 6 months after the final dose.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.", "mechanism_text": "Metabolism", "recommendation": "Although the clinical significance of the interaction is unknown, caution is advised when tazemetostat is prescribed in combination with hormonal contraceptives, including all oral, injectable, transdermal, vaginal, and implantable forms.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296070/", "reference_text": "[1] \"Product Information. Tazverik (tazemetostat).\" Epizyme, Inc  (2020):", "alternatives_a": "Pertuzumab, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249926, "ingredient1": "Telaprevir", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir and telaprevir, may decrease the plasma concentrations and efficacy of hormonal contraceptives.  The mechanism involves induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.", "source": "DDInter", "management_text": "Systemic hormonal contraceptives may be continued, but may not be as effective, during and for up to two weeks following treatment with boceprevir or telaprevir.  Because HCV NS3/4A protease inhibitors must be used in combination with peginterferon alfa and ribavirin, and use of ribavirin has been associated with significant birth defects and fetal death, it is particularly important that patients not become pregnant during treatment.  Therefore, systemic hormonal contraceptives should not be relied upon as an effective method of birth control in women of childbearing potential treated with HCV NS3/4A protease inhibitors.  Two alternative, effective methods of contraception, which may include intrauterine devices and barrier methods, should be used during HCV NS3/4A protease inhibitor treatment in combination with peginterferon alfa and ribavirin.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Two weeks after completion of HCV NS3/4A protease inhibitor treatment, hormonal contraceptives are again appropriate as one of the two required effective methods of birth control for patients receiving peginterferon alfa and ribavirin.", "mechanism_text": "Metabolism", "recommendation": "Systemic hormonal contraceptives may be continued, but may not be as effective, during and for up to two weeks following treatment with boceprevir or telaprevir.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296072/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):[2] \"Product Information. Incivek (telaprevir).\" Vertex Pharmaceuticals  (2011):[3] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "Ulipristal, Estetrol", "updated_at": 1767369485}, {"id": 249927, "ingredient1": "Telithromycin", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with telithromycin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by telithromycin.", "source": "DDInter", "management_text": "Caution is advised if telithromycin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever telithromycin is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if telithromycin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296073/", "reference_text": "[1] \"Product Information. Ketek (telithromycin).\" Aventis Pharmaceuticals  (2004):[2] European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products \"European Public Assessment Report Ketek (telithromycin) (Rev. 2)  http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm\"   (2004):", "alternatives_a": "Clindamycin, Troleandomycin, Dirithromycin, Azithromycin, Lincomycin", "alternatives_b": "Dienogest, Estetrol, Etynodiol", "updated_at": 1767369485}, {"id": 249928, "ingredient1": "Telotristat ethyl", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes.  The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296074/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc.  (2017):", "alternatives_a": "Estetrol, Dienogest, Drospirenone, Etynodiol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249929, "ingredient1": "Teriflunomide", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with teriflunomide may increase the plasma concentrations of contraceptive hormones.  The mechanism of interaction has not been described.", "source": "DDInter", "management_text": "Caution is advised if teriflunomide is prescribed in patients receiving hormonal contraceptives due to the potential for increased adverse effects such as thromboembolism.  Consideration should be given to the type or dose of contraceptives used in combination with teriflunomide.", "mechanism_text": "Others", "recommendation": "Caution is advised if teriflunomide is prescribed in patients receiving hormonal contraceptives due to the potential for increased adverse effects such as thromboembolism.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296075/", "reference_text": "[1] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation  (2012):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249930, "ingredient1": "Theophylline", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "The coadministration with contraceptive steroids may increase the plasma concentrations of theophylline and other methylxanthines.  The proposed mechanism is inhibition of methylxanthine metabolism via hepatic microsomal enzymes, of which estrogens and progestins are also substrates.", "source": "DDInter", "management_text": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives.  Serum theophylline levels and pharmacologic response should be monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their theophylline regimen.  Patients should be advised to notify their physician if they experience signs and symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, and irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised during concomitant therapy with methylxanthines and hormonal contraceptives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296076/", "reference_text": "[1] Tornatore KM, Kanarkowski R, McCarthy TL, et al. \"Effect of chronic oral contraceptive steroids on theophylline disposition.\" Eur J Clin Pharmacol 23 (1982):  129-34[2] Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R \"Effects of tobacco smoking and oral contraceptive use on theophylline disposition.\" Br J Clin Pharmacol 16 (1983):  271-80[3] Roberts RK, Grice J, McGuffie, Heilbronn L \"Oral contraceptive steroids impair the elimination of theophylline.\" J Lab Clin Med 101 (1983):  821-25", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More", "alternatives_b": "Megestrol acetate, Ulipristal, Estetrol, Medroxyprogesterone acetate", "updated_at": 1767369485}, {"id": 249931, "ingredient1": "Tivozanib", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with tivozanib may decrease the efficacy of contraceptive hormones.", "source": "DDInter", "management_text": "Until more information is known, caution is advised when tivozanib is prescribed concomitantly with hormonal contraceptives.  Some authorities recommend that female patients of childbearing potential use an additional method of contraception.  An acceptable barrier method (e.g., diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male condom, female condom) in addition to the hormonal contraceptive of choice may be advisable during the duration of tivozanib therapy and for at least one month after completing therapy.", "mechanism_text": "Antagonism", "recommendation": "Until more information is known, caution is advised when tivozanib is prescribed concomitantly with hormonal contraceptives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296078/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Fotivda (tivozanib).\" Aveo Pharmaceuticals, Inc.  (2021):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249932, "ingredient1": "Tocilizumab", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296079/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249933, "ingredient1": "Topiramate", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Coadministration with topiramate, particularly at dosages above 200 mg/day, may decrease the plasma concentrations and efficacy of contraceptive hormones.  The proposed mechanism is topiramate induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of steroidal hormones.", "source": "DDInter", "management_text": "The potential for decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients using hormonal contraceptives (including oral, injectable, transdermal, and implantable forms) during treatment with topiramate, particularly at dosages above 200 mg/day.  Some clinicians and manufacturers recommend that patients on topiramate dosages at or above 200 mg/day who are taking oral contraceptives should receive a preparation containing no less than 30 or 35 mcg of estrogen, while others recommend at least 50 mcg.  Intrauterine systems are unlikely to be significantly affected because of their local action, thus they may be preferable to other routes of administration.  Patients should be advised to report any change in their bleeding patterns, although contraceptive efficacy can be decreased even in the absence of breakthrough bleeding.  Because use of topiramate can cause fetal harm, it is particularly important that patients not become pregnant during treatment.  Counseling should be provided regarding the use of alternative (non-hormonal) or additional (back-up) pregnancy prevention methods during and for at least 28 days after discontinuing topiramate.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Alternative, nonenzyme-inducing anticonvulsants that are not believed to interact significantly with hormonal contraceptives include clonazepam, ethosuximide, gabapentin, levetiracetam, pregabalin, tiagabine, valproic acid, vigabatrin, and zonisamide.", "mechanism_text": "Metabolism", "recommendation": "The potential for decreased contraceptive efficacy and increased breakthrough bleeding should be considered in patients using hormonal contraceptives (including oral, injectable, transdermal, and implantable forms) during treatment with topiramate, particularly at dosages above 200 mg/day.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296080/", "reference_text": "[1] \"Product Information. Depo-Provera (medroxyprogesterone).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Topamax (topiramate).\" Ortho McNeil Pharmaceutical  (2001):[3] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[4] Rosenfeld WE, Doose DR, Walker SA, Nayak RK \"Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.\" Epilepsia 38 (1997):  317-23[5] Patsalos PN, Froscher W, Pisani F, van Rijn CM \"The importance of drug interactions in epilepsy therapy.\" Epilepsia 43 (2002):  365-85[6] Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M \"Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects.\" Epilepsia 44 (2003):  540-9[7] Nallani SC, Glauser TA, Hariparsad N, et al. \"Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate.\" Epilepsia 44 (2003):  1521-8[8] Bialer M, Doose DR, Murthy B, et al. \"Pharmacokinetic interactions of topiramate.\" Clin Pharmacokinet 43 (2004):  763-80[9] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51[10] Perucca E \"Clinically relevant drug interactions with antiepileptic drugs.\" Br J Clin Pharmacol 61 (2006):  246-255[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] Harden CL, Leppik I \"Optimizing therapy of seizures in women who use oral contraceptives.\" Neurology 67(12 Suppl 4) (2006):  S56-8[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Qsymia (phentermine-topiramate).\" Vivus Inc  (2012):[15] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[16] \"Product Information. Nexplanon (etonogestrel).\" Organon Pharmaceuticals  (2017):[17] Sunaga T, Cicali B, Schmidt S, Brown J \"Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system.\" Contraception 103(Issue 4) (2021):  222-4[18] Doodipala SR \"Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives.\" Expert Rev Clin Pharmacol 3 (2010):  183-92", "alternatives_a": "Ezogabine, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Ethotoin, Clonazepam, Paramethadione, Ganaxolone, Vigabatrin, Mephenytoin, More", "alternatives_b": "Megestrol acetate, Estetrol", "updated_at": 1767369485}, {"id": 249934, "ingredient1": "Tranexamic acid", "ingredient2": "Norelgestromin", "severity": "Major", "effect": "Because tranexamic acid is an antifibrinolytic agent, concomitant use may further exacerbate the risk of thrombotic events, including venous thromboembolism as well as arterial thromboses such as stroke and myocardial infarction, associated with hormonal contraceptives.", "source": "DDInter", "management_text": "Due to the potential for increased risk of thrombosis in women receiving hormonal contraceptives, the use of tranexamic acid for the treatment of menorrhagia in this population is considered contraindicated.  Patients receiving hormonal contraceptives should be advised to seek medical attention immediately if they experience potential signs and symptoms of blood clots such as chest pain, shortness of breath, hemoptysis, hematuria, sudden loss of vision, and pain, redness or swelling in an extremity.", "mechanism_text": "Synergism", "recommendation": "Due to the potential for increased risk of thrombosis in women receiving hormonal contraceptives, the use of tranexamic acid for the treatment of menorrhagia in this population is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296081/", "reference_text": "[1] \"Product Information. Cyklokapron (tranexamic acid).\" Pharmacia and Upjohn  (2001):[2] van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR \"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and  progestogen type: results of the MEGA case-control study.\" BMJ 339 (2009):  b2921[3] Lidegaard O, Lokkegaard E, Svendsen AL, Agger C \"Hormonal contraception and risk of venous thromboembolism: national follow-up study.\" BMJ 339 (2009):  b2890[4] \"Product Information. Lysteda (tranexamic acid).\" Xanodyne Pharmaceuticals Inc  (2022):[5] Rosendaal FR, Van Hylckama Vlieg A, Tanis BC, Helmerhorst FM \"Estrogens, progestogens and thrombosis.\" J Thromb Haemost 1 (2003):  1371-80[6] Gomes MP, Deitcher SR \"Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review.\" Arch Intern Med 164 (2004):  1965-76", "alternatives_a": "Aprotinin, Aminocaproic acid", "alternatives_b": "Megestrol acetate, Ulipristal", "updated_at": 1767369485}, {"id": 249935, "ingredient1": "Troglitazone", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with troglitazone may decrease the plasma concentrations and efficacy of contraceptive hormones.  The proposed mechanism is troglitazone induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of sex hormones and other steroids.", "source": "DDInter", "management_text": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with troglitazone.  Alternative or additional methods of birth control should be used during and for at least two weeks after short-term and 4 weeks after long-term (greater than 4 weeks) troglitazone therapy.  If a combination oral contraceptive pill is used, a regimen containing at least 50 mcg of ethinyl estradiol per day or equivalent should be selected.  Although breakthrough bleeding is not necessarily indicative of low ethinyl estradiol serum levels or increased risk of ovulation, some clinicians suggest that women who experience breakthrough bleeding during enzyme-inducing therapy may be prescribed an increased dose of ethinyl estradiol above 50 mcg daily by combining more than one formulation of contraceptive pill if necessary.  For levonorgestrel emergency contraception in patients receiving enzyme-inducing therapy, a regimen consisting of a 1.5 mg dose as soon as possible (within 72 hours of unprotected intercourse) followed by a 0.75 mg or 1.5 mg dose twelve hours later has been recommended by some clinicians.  An alternative is a single 2.25 mg dose as soon as possible following unprotected intercourse.  However, there are no data on efficacy, compliance, or side effects with any of these regimens.  No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.  Injectable progestin-only contraceptives are also thought to be unaffected by enzyme-inducing drugs.", "mechanism_text": "Metabolism", "recommendation": "Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with troglitazone.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296083/", "reference_text": "[1] \"Product Information. Rezulin (troglitazone).\" Parke-Davis  (2001):[2] Loi CM, Stern R, Koup JR, Vassos AB, Knowlton P, Sedman AJ \"Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent.\" J Clin Pharmacol 39 (1999):  410-7[3] Sahi J, Black CB, Hamilton GA, et al. \"Comparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and Inhibition.\" Drug Metab Dispos 31 (2003):  439-446[4] \"FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception.\" J Fam Plann Reprod Health Care 31 (2005):  139-51", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249936, "ingredient1": "Tucatinib", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with tucatinib may increase the plasma concentrations of CYP450 3A4 substrates.  The mechanism involves tucatinib-mediated inhibition of CYP450 3A isoenzymes.", "source": "DDInter", "management_text": "Caution is advised when tucatinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever tucatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when tucatinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296084/", "reference_text": "[1] \"Product Information. Tukysa (tucatinib).\" Seattle Genetics Inc  (2020):", "alternatives_a": "Imatinib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Bosutinib, Ribociclib, Vandetanib, Cobimetinib, Capmatinib, Ibrutinib, More", "alternatives_b": "Megestrol acetate, Etynodiol, Levonorgestrel, Estetrol, Norgestrel", "updated_at": 1767369485}, {"id": 249937, "ingredient1": "Ulipristal", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration of ulipristal with combination hormonal contraceptives may reduce the efficacy of both treatments for the prevention of pregnancy.  Ulipristal and the progestin component of hormonal contraceptives both bind to the progesterone receptor.  Theoretically, competitive inhibition of the receptor may occur, which may diminish the effects of each on ovulation.", "source": "DDInter", "management_text": "Concomitant use of ulipristal with combination hormonal contraceptives should be avoided.  After emergency contraception with ulipristal, routine contraception should be continued or initiated as soon as possible to ensure ongoing prevention of pregnancy.  Patients who wish to use progestogen-containing contraceptives should do so no sooner than 5 days after taking ulipristal, and they should use a reliable barrier method of contraception until their next menstrual period.", "mechanism_text": "Antagonism", "recommendation": "Concomitant use of ulipristal with combination hormonal contraceptives should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296085/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ella (ulipristal).\" Afaxys Inc.  (2022):", "alternatives_a": "Norelgestromin, Norethisterone, Etonogestrel, Megestrol acetate, Norgestimate, Drospirenone, Etynodiol, Estradiol, Levonorgestrel, Medroxyprogesterone acetate, Desogestrel, More", "alternatives_b": "Ulipristal, Megestrol acetate, Estradiol, Estetrol, Ethinylestradiol", "updated_at": 1767369485}, {"id": 249938, "ingredient1": "Ustekinumab", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296086/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, More", "alternatives_b": "Megestrol acetate, Estetrol, Ulipristal, Estradiol", "updated_at": 1767369485}, {"id": 249939, "ingredient1": "Vemurafenib", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins.  Estrogens have been shown in in vitro and in vivo studies to be partially metabolized by CYP450 3A4, and other steroids including progestins are also believed to undergo metabolism by this isoenzyme.  The interaction has been reported primarily with oral contraceptives.", "source": "DDInter", "management_text": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.  For patients receiving hormonal contraceptives, additional or alternative non-hormonal birth control may be advisable during concomitant therapy with CYP450 3A4 inducers.  Additional or alternative non-hormonal birth control may be recommended beyond discontinuation of the CYP450 3A4 inducer(s).  Individual product labeling should be consulted for specific time frames.  Intrauterine systems are unlikely to be significantly affected because of their local action.  Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.  Patients should be advised to notify their physician if they experience inadequate control of symptoms associated with estrogen deficiency (e.g., nocturnal sweating, vasomotor disturbances, atrophic vaginitis) or changes in the uterine bleeding profile.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to estrogens and progestins should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hormone dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296087/", "reference_text": "[1] Crawford P, Chadwick DJ, Martin C, et al. \"The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids.\" Br J Clin Pharmacol 30 (1990):  892-6[2] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992):  47-65[3] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992):  711-6[4] Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J 288 (1984):  1125-6[5] McDaniel PA, Caldroney RD \"Oral contraceptives and griseofulvin interaction.\" Drug Intell Clin Pharm 20 (1986):  384[6] Cote J \"Interaction of griseofulvin and oral contraceptives.\" J Am Acad Dermatol 22 (1990):  124-5[7] Baciewicz AM \"Oral contraceptive drug interactions.\" Ther Drug Monit 7 (1985):  26-35[8] Skolnick JL, Stoler BS, Katz DB, Anderson WH \"Rifampin, oral contraceptives, and pregnancy.\" JAMA 236 (1976):  1382[9] Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S, Lnning PE \"Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.\" Cancer Chemother Pharmacol 27 (1990):  101-5[10] Halpenny O, Bye A, Cranny A, Feely J, Daly PA \"Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate.\" Med Oncol Tumor Pharmacother 7 (1990):  241-7[11] Mumford JP \"Letter: Drugs affecting oral contraceptives.\" Br Med J 2 (1974):  333-4[12] Back DJ, Bates M, Bowden A, et al. \"The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy.\" Contraception 22 (1980):  495-503[13] Dossetor J \"Drug interactions with oral contraceptives.\" Br Med J 4 (1975):  467-8[14] Baciewicz AM, Self TH \"Rifampin drug interactions.\" Arch Intern Med 144 (1984):  1667-71[15] Nocke-finck L \"Effects of rifampicin on menstral cycle and on estrogen excretion in patients taking oral contraceptives.\" JAMA 226 (1973):  378[16] Bolt HM, Bolt M, Kappus H \"Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man.\" Acta Endocrinol (Copenh) 85 (1977):  189-97[17] Back DJ, Breckenridge AM, Crawford FE, et al. \"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.\" Contraception 21 (1980):  135-43[18] Furlan AJ, Rothner AD \"Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[19] Coulam CB, Annegers JF \"Do anticonvulsants reduce the efficacy of oral contraceptives?\" Epilepsia 20 (1979):  519-26[20] Szoka PR, Edgren RA \"Drug interactions with oral contraceptives: compilation and analysis of an adverse experience report database.\" Fertil Steril 49 (1988):  s31-8[21] Mattson RH, Cramer JA, Darney PD, Naftolin F \"Use of oral contraceptives by women with epilepsy.\" JAMA 256 (1986):  238-40[22] van Dijke CP, Weber JC \"Interaction between oral contraceptives and griseofulvin.\" Br Med J (Clin Res Ed) 288 (1984):  1125-6[23] Laengner H, Detering K \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 2 (1974):  600[24] Janz D, Schmidt D \"Letter: Anti-epileptic drugs and failure of oral contraceptives.\" Lancet 1 (1974):  1113[25] Curran MA \"Drug interactions with the pill.\" Med J Aust 144 (1986):  670-1[26] Back DJ, Orme ML \"Pharmacokinetic drug interactions with oral contraceptives.\" Clin Pharmacokinet 18 (1990):  472-84[27] D'Arcy PF \"Drug interactions with oral contraceptives.\" Drug Intell Clin Pharm 20 (1986):  353-62[28] Notelovitz M, Tjapkes J, Ware M \"Interaction between estrogen and dilantin in a menopausal woman.\" N Engl J Med 304 (1981):  788-9[29] \"Product Information. Premarin (conjugated estrogens).\" Wyeth-Ayerst Laboratories  (2001):[30] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997):  2453-8[31] Michalets EL \"Update: clinically significant cytochrome P-450 drug interactions.\" Pharmacotherapy 18 (1998):  84-112[32] Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH \"Interindividual variation and drug interactions with hormonal steroid contraceptives.\" Drugs 21 (1981):  46-61[33] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallee F, Narang PK \"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone.\" J Clin Pharmacol 38 (1998):  1042-50[34] Barditch-Crovo P, Trapnell CB, Ette E, et al. \"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.\" Clin Pharmacol Ther 65 (1999):  428-38[35] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[36] Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP \"Possible interaction between oxcarbazepine and an oral contraceptive.\" Epilepsia 33 (1992):  1149-52[37] Wilbur K, Ensom MHH \"Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants.\" Clin Pharmacokinet 38 (2000):  355-65[38] Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K \"St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.\" Clin Pharmacol Ther 68 (2000):  598-604[39] Weaver K, Glasier A \"Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill: a literature review.\" Contraception 59 (1999):  71-8[40] Zachariassen RD \"Loss of oral contraceptive efficacy by concurrent antibiotic administration.\" Women Health 22 (1994):  17-26[41] Dickinson BD, Altman RD, Nielsen NH, Sterling ML \"Drug interactions between oral contraceptives and antibiotics.\" Obstet Gynecol 98(5 Pt 1) (2001):  853-60[42] \"Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.\" Br J Clin Pharmacol 55 (2003):  112-113[43] Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J \"Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.\" Br J Clin Pharmacol 56 (2003):  683-90[44] Hall SD, Wang Z, Huang SM, et al. \"The interaction between St John's wort and an oral contraceptive.\" Clin Pharmacol Ther 74 (2003):  525-35[45] Gorski JC, Hamman MA, Wang Z, Vasvada N, Huang S, Hall SD \"The effect of St. John's wort on the efficacy of oral contraception.\" Clin Pharmacol Ther 71 (2002):  P25[46] Schwarz UI, Buschel B, Kirch W \"Failure of oral contraceptives because of St. John's wort.\" Eur J Clin Pharmacol 57 (2001):  A25[47] Faculty of Sexual & Reproductive Healthcare \"FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception.  file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf\"   (2016):", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, More", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249940, "ingredient1": "Voriconazole", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Azole antifungal agents may increase the plasma concentrations of estrogens and progestins.  The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.", "source": "DDInter", "management_text": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "mechanism_text": "Metabolism", "recommendation": "During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296088/", "reference_text": "[1] Lazar JD, Wilner KD \"Drug interactions with fluconazole.\" Rev Infect Dis 12 Suppl 3 (1990):  s327-33[2] Pillans PI, Sparrow MJ \"Pregnancy associated with a combined oral contraceptive and itraconazole.\" N Z Med J 106 (1993):  436[3] Devenport MH, Crook D, Wynn V, Lees LJ \"Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.\" Br J Clin Pharmacol 27 (1989):  851-9[4] Sinofsky FE, Pasquale SA \"The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.\" Am J Obstet Gynecol 178 (1998):  300-4[5] Weisberg E \"Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?.\" Clin Pharmacokinet 36 (1999):  309-13[6] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals  (2002):", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "Estetrol", "updated_at": 1767369485}, {"id": 249941, "ingredient1": "Voxelotor", "ingredient2": "Norelgestromin", "severity": "Moderate", "effect": "Coadministration with voxelotor may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  The mechanism is reduced clearance due to inhibition of CYP450 3A4 by voxelotor.  The interaction may be significant for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index.", "source": "DDInter", "management_text": "Caution is advised when voxelotor is used concomitantly with drugs that undergo metabolism by CYP450 3A4.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever voxelotor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when voxelotor is used concomitantly with drugs that undergo metabolism by CYP450 3A4.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296089/", "reference_text": "[1] \"Product Information. Oxbryta (voxelotor).\" Global Blood Therapeutics, Inc.  (2019):", "alternatives_a": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "Megestrol acetate, Etynodiol, Levonorgestrel, Estetrol, Norgestrel", "updated_at": 1767369485}, {"id": 249942, "ingredient1": "Brentuximab vedotin", "ingredient2": "Rosuvastatin", "severity": "Moderate", "effect": "Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk.", "source": "DDInter", "management_text": "The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.  Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296090/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):", "alternatives_a": "Amlodipine, Valsartan, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Indapamide, Gemfibrozil, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 249943, "ingredient1": "Glycopyrronium (topical)", "ingredient2": "Methscopolamine", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties.  The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing.  Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).  Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation, use of a mouthpiece rather than face mask during nebulization, and not touching the eyes following topical application until hands are washed with soap and water.  Patients should be advised to contact their physician if they experience excessive anticholinergic adverse effects or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296093/", "reference_text": "[1] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim  (2002):[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[3] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim  (2002):[4] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals  (2012):[5] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012):  1717-21[6] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline  (2014):[7] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc.  (2018):[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty  (2018):", "alternatives_a": "Tropicamide, Ephedrine, Ketorolac, Phenylephrine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249944, "ingredient1": "Eplerenone", "ingredient2": "Buprenorphine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296094/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Methadone, Levacetylmethadol, Nalmefene, Nicotine, Naltrexone, Oxymorphone, Tapentadol, More", "alternatives_b": "Finerenone", "updated_at": 1767369485}, {"id": 249945, "ingredient1": "Guanfacine", "ingredient2": "Buprenorphine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296095/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Methadone, Levacetylmethadol, Nalmefene, Nicotine, Naltrexone, Oxymorphone, Tapentadol, More", "alternatives_b": "Rauwolfia serpentina root, Deserpidine", "updated_at": 1767369485}, {"id": 249946, "ingredient1": "Diamorphine", "ingredient2": "Buprenorphine", "severity": "Major", "effect": "Concomitant use of buprenorphine with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may increase the risk of buprenorphine overdose, severe respiratory depression, coma, and death.", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Extreme caution is advised when prescribing buprenorphine to patients who are addicted to opioids and also abusing benzodiazepines or alcohol.  Due to potential risk of overdose and death, dependence on sedative-hypnotics such as benzodiazepines or alcohol is considered a relative contraindication for office-based buprenorphine treatment of opioid addiction.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296096/", "reference_text": "[1] \"Product Information. Suboxone (buprenorphine-naloxone).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[2] Kilicarslan T, Sellers EM \"Lack of interaction of buprenorphine with flunitrazepam metabolism.\" Am J Psychiatry 157 (2000):  1164-6[3] Reynaud M, Petit G, Potard D, Courty P \"Six deaths linked to concomitant use of buprenorphine and benzodiazepines.\" Addiction 93 (1998):  1385-92[4] Tracqui A, Kintz P, Ludes B \"Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities.\" J Anal Toxicol 22 (1998):  430-4[5] Reynaud M, Tracqui A, Petit G, Potard D, Courty P \"Six deaths linked to misuse of buprenorphine-benzodiazepine combinations.\" Am J Psychiatry 155 (1998):  448-9[6] Kintz P \"A new series of 13 buprenorphine-related deaths.\" Clin Biochem 35 (2002):  513-6[7] Martin HA \"The possible consequences of combining lorazepam and buprenorphine/naloxone: a case review.\" J Emerg Nurs 37 (2011):  200-2[8] Hakkinen M, Launiainen T, Vuori E, Ojanpera I \"Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning.\" Eur J Clin Pharmacol 68 (2012):  301-9[9] Substance Abuse and Mental Health Services Administration (US) \"Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series, No. 40  http://www.ncbi.nlm.nih.gov/books/NBK64245/\"   (2013):[10] Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ \"Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.\" Drug Alcohol Depend 132 (2013):  580-6[11] Ferrant O, Papin F, Clin B, et al. \"Fatal poisoning due to snorting buprenorphine and alcohol consumption.\" Forensic Sci Int 204 (2011):  e8-11[12] Pirnay S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I \"A critical review of the causes of death among post-morten toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths.\" Addiction 99 (2004):  978-88[13] Kintz P \"Deaths involving buprenorphine: a compendium of French cases.\" Forensic Sci Int 121 (2001):  65-9[14] Sekar M, Mimpriss TJ \"Buprenorphine, benzodiazepines and prolonged respiratory depression.\" Anaesthesia 42 (1987):  567-8[15] Gueye PN, Borron SW, Risede P, et al. \"Buprenorphine and midazolalm act in combination to depress respiration in rats.\" Toxicol Sci 65 (2002):  107-14[16] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Diamorphine, Acamprosate, Varenicline, Disulfiram, Levacetylmethadol, Nalmefene, Nicotine, Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid", "alternatives_b": "Acamprosate, Disulfiram, Nalmefene, Nicotine, Buprenorphine", "updated_at": 1767369485}, {"id": 249947, "ingredient1": "Diamorphine", "ingredient2": "Naloxone", "severity": "Moderate", "effect": "This warning does not apply to the naloxone component in non-injectable formulations of naloxone-containing combination medicines.  Naloxone injection is an antagonist that will reverse the actions of opiates.  This reversal can occur when the opiate drug is being used clinically and when it is being abused.  Physically dependent patients may experience withdrawal symptoms.  Abrupt postoperative opioid reversal has resulted in hypotension, ventricular tachycardia and fibrillation, pulmonary edema, cardiac arrest, encephalopathy, and death.", "source": "DDInter", "management_text": "Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296097/", "reference_text": "[1] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[2] \"Product Information. Narcan (naloxone).\" DuPont Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Magnesium oxide, Prucalopride, More", "alternatives_b": "Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 249948, "ingredient1": "Buprenorphine", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296098/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Levacetylmethadol, Nalmefene, Nicotine, Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249949, "ingredient1": "Buprenorphine", "ingredient2": "Reserpine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296100/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Levacetylmethadol, Nalmefene, Nicotine, Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, More", "alternatives_b": "Rauwolfia serpentina root, Deserpidine, Rauwolfia serpentina root, Deserpidine", "updated_at": 1767369485}, {"id": 249950, "ingredient1": "Buprenorphine", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of buprenorphine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to buprenorphine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the buprenorphine dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to buprenorphine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the buprenorphine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296101/", "reference_text": "[1] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Codeine, Morphine, Naltrexone, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate", "updated_at": 1767369485}, {"id": 249951, "ingredient1": "Buprenorphine", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of buprenorphine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to buprenorphine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the buprenorphine dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to buprenorphine should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the buprenorphine dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296102/", "reference_text": "[1] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249952, "ingredient1": "Buprenorphine", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes.  The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296103/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc.  (2017):", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Morphine, Naltrexone, Oxymorphone, Tapentadol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249953, "ingredient1": "Buprenorphine", "ingredient2": "Upadacitinib", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296105/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Methadone, Levacetylmethadol, Nalmefene, Nicotine, Oliceridine, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Cladribine, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 249954, "ingredient1": "Brentuximab vedotin", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296107/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):", "alternatives_a": "Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 249955, "ingredient1": "Dimethyl fumarate", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296108/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Siponimod, More", "alternatives_b": "Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More", "updated_at": 1767369485}, {"id": 249956, "ingredient1": "Diroximel fumarate", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296109/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Siponimod, More", "alternatives_b": "Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More", "updated_at": 1767369485}, {"id": 249957, "ingredient1": "Erlotinib", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "Coadministration of erlotinib with anti-angiogenic agents, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or taxane-based chemotherapy may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using erlotinib in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as anti-angiogenic agents, corticosteroids, NSAIDs, and taxane-based chemotherapy.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.  The manufacturer recommends that erlotinib should be permanently discontinued in patients who develop gastrointestinal perforation.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using erlotinib in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as anti-angiogenic agents, corticosteroids, NSAIDs, and taxane-based chemotherapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296110/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Tarceva (erlotinib).\" Genentech  (2018):[4] \"Product Information. Tarceva (erlotinib).\" Hoffmann-La Roche Limited  (2018):[5] \"Product Information. Tarceva (erlotinib).\" Roche Products Ltd  (2022):[6] \"Product Information. Tarceva (erlotinib).\" Roche Products Pty Ltd  (2022):[7] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140", "alternatives_a": "Entrectinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, Ribociclib, Vandetanib, More", "alternatives_b": "Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More", "updated_at": 1767369485}, {"id": 249958, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Meloxicam", "severity": "Major", "effect": "Coadministration of radiolabeled ibritumomab tiuxetan and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.", "source": "DDInter", "management_text": "Caution is advised if radiolabeled ibritumomab tiuxetan is used in combination with drugs that interfere with platelet function or coagulation.  Close clinical and laboratory observation for bleeding complications is recommended during and after treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if radiolabeled ibritumomab tiuxetan is used in combination with drugs that interfere with platelet function or coagulation.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296111/", "reference_text": "[1] \"Product Information. In-111 Zevalin (ibritumomab tiuxetan).\" IDEC Pharmaceuticals Corporation", "alternatives_a": "Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More", "alternatives_b": "Iodide I-131", "updated_at": 1767369485}, {"id": 249959, "ingredient1": "Monomethyl fumarate", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296112/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249960, "ingredient1": "Somapacitan", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296115/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Ketoprofen, Piroxicam, Rofecoxib, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 249961, "ingredient1": "Tafasitamab", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "Coadministration of tafasitamab with drugs that can affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextrans, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of bleeding.", "source": "DDInter", "management_text": "When possible, consideration should be given to withholding concomitant medications that may increase bleeding risk in patients treated with tafasitamab.  Close clinical and laboratory monitoring for bleeding complications is recommended if concomitant use is unavoidable.  Refer to the product labeling for guidance on frequency of laboratory monitoring and dose modifications or withholding recommendations for platelet counts below 50,000/mcL.  Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "When possible, consideration should be given to withholding concomitant medications that may increase bleeding risk in patients treated with tafasitamab.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296116/", "reference_text": "[1] \"Product Information. Monjuvi (tafasitamab).\" Morphosys US  (2020):[2] \"Product Information. Minjuvi (tafasitamab).\" Incyte Biosciences UK Ltd  (2022):[3] \"Product Information. Minjuvi (tafasitamab).\" Incyte Corporation  (2021):", "alternatives_a": "Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 249962, "ingredient1": "Upadacitinib", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296117/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Siponimod, More", "updated_at": 1767369485}, {"id": 249963, "ingredient1": "Brentuximab vedotin", "ingredient2": "Naltrexone", "severity": "Moderate", "effect": "Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Periodic monitoring of hepatic function is advisable.", "mechanism_text": "Synergism", "recommendation": "The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296118/", "reference_text": "[1] \"Product Information. ReVia (naltrexone).\" DuPont Pharmaceuticals  (2001):", "alternatives_a": "Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Codeine, Nalbuphine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 249964, "ingredient1": "Gemtuzumab ozogamicin", "ingredient2": "Naltrexone", "severity": "Moderate", "effect": "Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Periodic monitoring of hepatic function is advisable.", "mechanism_text": "Synergism", "recommendation": "The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296119/", "reference_text": "[1] \"Product Information. ReVia (naltrexone).\" DuPont Pharmaceuticals  (2001):", "alternatives_a": "Oxymorphone, Oxycodone, Methadone, Pentazocine, Buprenorphine, Oliceridine, Morphine, Butorphanol, Fentanyl, Ibuprofen, Codeine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 249965, "ingredient1": "Diamorphine", "ingredient2": "Naltrexone", "severity": "Major", "effect": "Naltrexone can antagonize the effects of opioids via competitive inhibition of opioid receptors.  Patients receiving naltrexone may not benefit from opioid-containing medications such as cough and cold products, antidiarrheal preparations, and narcotic analgesics.", "source": "DDInter", "management_text": "The use of naltrexone is considered contraindicated in patients receiving opioids or dependent on opioids, including those maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine).  Naltrexone should also not be given to patients in acute opioid withdrawal.  In an urgent situation when analgesia may be required in a patient who has received full blocking doses of naltrexone, consideration should be given to regional analgesia, conscious sedation with a benzodiazepine, use of non-opioid analgesics, or general anesthesia.  If opioid analgesia is required, the amount of opioid needed may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.  A rapidly-acting opioid analgesic that minimizes the duration of respiratory depression is preferred.  Clinicians should be aware that reversal of full naltrexone blockade by administration of large doses of opiates can cause histamine release.  Therefore, patients may experience non-opioid receptor-mediated effects such as facial swelling, itching, generalized erythema, and bronchoconstriction.  Irrespective of the drug chosen to reverse naltrexone blockade, the patient should be monitored closely by appropriately trained personnel in a setting equipped and staffed for cardiopulmonary resuscitation.", "mechanism_text": "Antagonism", "recommendation": "The use of naltrexone is considered contraindicated in patients receiving opioids or dependent on opioids, including those maintained on opiate agonists (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296120/", "reference_text": "[1] \"Product Information. ReVia (naltrexone).\" DuPont Pharmaceuticals  (2001):", "alternatives_a": "Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid, Diamorphine, Acamprosate, Varenicline, Disulfiram, Levacetylmethadol, Nalmefene, More", "alternatives_b": "Nalmefene, Nicotine, Naltrexone", "updated_at": 1767369485}, {"id": 249966, "ingredient1": "Gadoxetic acid", "ingredient2": "Nebivolol", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media.  In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.  The mechanism is unknown.  Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.  If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine.  Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm.  Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296122/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Valsartan, Irbesartan, Hydrochlorothiazide, Losartan, Olmesartan, Azilsartan medoxomil, Telmisartan, Candesartan, Sacubitril, More", "alternatives_b": "Ferumoxsil", "updated_at": 1767369485}, {"id": 249967, "ingredient1": "Diamorphine", "ingredient2": "Nebivolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296123/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Sacubitril, Aliskiren, Carteolol", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 249968, "ingredient1": "Patiromer", "ingredient2": "Nebivolol", "severity": "Moderate", "effect": "Patiromer can bind to some orally administered drugs, which may decrease their gastrointestinal absorption and reduce their effectiveness.  According to the manufacturer, in vitro studies observed potentially clinically significant binding between patiromer and telmisartan, bisoprolol, carvedilol, nebivolol, mycophenolate mofetil, quinidine, and thiamine.", "source": "DDInter", "management_text": "Patiromer should be administered at least 3 hours before or 3 hours after other oral medications, particularly ciprofloxacin, levothyroxine, metformin, telmisartan, bisoprolol, carvedilol, nebivolol, mycophenolate mofetil, quinidine, and thiamine.  Alternatives to patiromer or the other medications should be considered if adequate dosing separation is not possible.  Otherwise, clinical response and/or blood levels should be monitored where possible.", "mechanism_text": "Absorption", "recommendation": "Patiromer should be administered at least 3 hours before or 3 hours after other oral medications, particularly ciprofloxacin, levothyroxine, metformin, telmisartan, bisoprolol, carvedilol, nebivolol, mycophenolate mofetil, quinidine, and thiamine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296124/", "reference_text": "[1] \"Product Information. Veltassa (patiromer).\" Relypsa, Inc.  (2015):[2] \"Product Information. Veltassa (patiromer).\" Vifor Pharma Pty Ltd  (2023):[3] \"Product Information. Veltassa (patiromer).\" Vifor Fresenius Medical Care Renal Pharma UK Ltd  (2022):", "alternatives_a": "Felodipine, Amlodipine, Propranolol, Metoprolol, Carvedilol, Nifedipine, Ivabradine, Sotalol, Acetylsalicylic acid, Atenolol, Amlodipine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249969, "ingredient1": "Brentuximab vedotin", "ingredient2": "Rilpivirine", "severity": "Moderate", "effect": "Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296127/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):", "alternatives_a": "Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Dolutegravir, Oseltamivir, Acyclovir, Brincidofovir, Elbasvir, Famciclovir, Doravirine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 249970, "ingredient1": "Somapacitan", "ingredient2": "Rilpivirine", "severity": "Moderate", "effect": "Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.  Data from an interaction study performed in growth hormone deficient adults suggest that growth hormone (somatropin) administration can increase the clearance of compounds known to be metabolized by cytochrome P450 isoenzymes, especially CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296131/", "reference_text": "[1] \"Product Information. Humatrope (somatropin).\" Lilly, Eli and Company  (2003):[2] \"Product Information. Zorbtive (somatropin).\" Serono Laboratories Inc  (2004):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Lamivudine, Tenofovir alafenamide, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Remdesivir, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 249971, "ingredient1": "St. John's Wort", "ingredient2": "Rilpivirine", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of rilpivirine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of rilpivirine with potent CYP450 3A4 inducers is considered contraindicated.", "mechanism_text": "Metabolism", "recommendation": "Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of rilpivirine with potent CYP450 3A4 inducers is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296132/", "reference_text": "[1] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.[2] Patel S, Robinson R, Burk M \"Hypertensive crisis associated with St. John's Wort.\" Am J Med 112 (2002): 507-8[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Oseltamivir, Acyclovir, Brincidofovir, Stavudine, Elbasvir, More", "alternatives_b": "Phenelzine, Duloxetine, Tranylcypromine, Vilazodone, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, More", "updated_at": 1767369485}, {"id": 249972, "ingredient1": "Telotristat ethyl", "ingredient2": "Rilpivirine", "severity": "Moderate", "effect": "Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes.  The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.", "source": "DDInter", "management_text": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296133/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Xermelo (telotristat ethyl).\" Lexicon Pharmaceuticals, Inc.  (2017):", "alternatives_a": "Lamivudine, Glecaprevir, Tenofovir alafenamide, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Dolutegravir, Oseltamivir, Cobicistat, Acyclovir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249973, "ingredient1": "Ergotamine", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296138/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Methergine (methylergonovine).\" Novartis Pharmaceuticals  (2010):", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, Almotriptan, Fremanezumab", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant", "updated_at": 1767369485}, {"id": 249974, "ingredient1": "Ergotamine", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296139/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Methergine (methylergonovine).\" Novartis Pharmaceuticals  (2010):", "alternatives_a": "Eptinezumab, Erenumab, Galcanezumab, Fremanezumab", "alternatives_b": "Desipramine, Esketamine", "updated_at": 1767369485}, {"id": 249975, "ingredient1": "Ergotamine", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ergot alkaloids, which are substrates of the isoenzyme.", "source": "DDInter", "management_text": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "The potential for diminished pharmacologic effects of ergot alkaloids should be considered during coadministration with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296141/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Methergine (methylergonovine).\" Novartis Pharmaceuticals  (2010):", "alternatives_a": "Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Clonidine, Almotriptan, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249976, "ingredient1": "Clevidipine", "ingredient2": "Calcium carbonate", "severity": "Moderate", "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium.  Calcium chloride has been used to manage acute severe verapamil toxicity.", "source": "DDInter", "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "mechanism_text": "Antagonism", "recommendation": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296143/", "reference_text": "[1] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985):  334-6[2] Moller IW \"Cardiac arrest following intravenous verapamil combined with halothane anaesthesia.\" Br J Anaesth 59 (1987):  522-6[3] Oszko MA, Klutman NE \"Use of calcium salts during cardiopulmonary resuscitation for reversing verapamil-associated hypotension.\" Clin Pharm 6 (1987):  448-9[4] Schoen MD, Parker RB, Hoon TJ, et al. \"Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects.\" Am J Cardiol 67 (1991):  300-4[5] O'Quinn SV, Wohns DH, Clarke S, Koch G, Patterson JH, Adams KF \"Influence of calcium on the hemodynamic and anti-ischemic effects of nifedipine observed during treadmill exercise testing.\" Pharmacotherapy 10 (1990):  247[6] Woie L, Storstein L \"Successful treatment of suicidal verapamil poisoning with calcium gluconate.\" Eur Heart J 2 (1981):  239-42[7] Morris DL, Goldschlager N \"Calcium infusion for reversal of adverse effects of intravenous verapamil.\" JAMA 249 (1983):  3212-3[8] Guadagnino V, Greengart A, Hollander G, Solar M, Shani J, Lichstein E \"Treatment of severe left ventricular dysfunction with calcium chloride in patients receiving verapamil.\" J Clin Pharmacol 27 (1987):  407-9[9] Luscher TF, Noll G, Sturmer T, Huser B, Wenk M \"Calcium gluconate in severe verapamil intoxication.\" N Engl J Med 330 (1994):  718-20[10] Bar-Or D, Gasiel Y \"Calcium and calciferol antagonise effect of verapamil in atrial fibrillation.\" Br Med J (Clin Res Ed) 282 (1981):  1585-6[11] Lipman J, Jardine I, Roos C, Dreosti L \"Intravenous calcium chloride as an antidote to verapamil-induced hypotension.\" Intensive Care Med 8 (1982):  55-7[12] McMillan R \"Management of acute severe verapamil intoxication.\" J Emerg Med 6 (1988):  193-6[13] Perkins CM \"Serious verapamil poisoning: treatment with intravenous calcium gluconate.\" Br Med J 2 (1978):  1127[14] Moroni F, Mannaioni PF, Dolara A, Ciaccheri M \"Calcium gluconate and hypertonic sodium chloride in a case of massive verapamil poisoning.\" Clin Toxicol 17 (1980):  395-400", "alternatives_a": "Aluminum hydroxide, Magnesium oxide, Magaldrate, Magnesium hydroxide, Magnesium carbonate, Calcium glucoheptonate, Calcium lactate, Calcium chloride, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, More", "alternatives_b": "Celecoxib", "updated_at": 1767369485}, {"id": 249977, "ingredient1": "Diflunisal", "ingredient2": "Calcium carbonate", "severity": "Moderate", "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates.  The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance", "source": "DDInter", "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.", "mechanism_text": "Excretion", "recommendation": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296144/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987):  607-17[2] Gaspari F, Vigano G, Locatelli M, Remuzzi G \"Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis.\" Am J Kidney Dis 11 (1988):  338-42[3] Furst DE \"Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications.\" J Rheumatol Suppl 17 (1988):  58-62[4] Miners JO \"Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.\" Clin Pharmacokinet 17 (1989):  327-44[5] Levy G, Lampman T, Kamath BL, Garrettson LK \"Decreased serum salicylate concentrations in children with rheumatic fever treated with antacid.\" N Engl J Med 293 (1975):  323-5[6] Shastri RA \"Effect of antacids on salicylate kinetics.\" Int J Clin Pharmacol Ther Toxicol 23 (1985):  480-4[7] Covington TR, eds., Lawson LC, Young LL \"Handbook of Nonprescription Drugs.\" Washington, DC: American Pharmaceutical Association  (1993):[8] Brouwers JRBJ, Desmet PAGM \"Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.\" Clin Pharmacokinet 27 (1994):  462-85", "alternatives_a": "Calcium glucoheptonate, Calcium lactate, Calcium chloride, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium Phosphate, Ascorbic acid, Calcium chloride, Calcium citrate, Calcium acetate, Calcium Phosphate", "alternatives_b": "Acetaminophen, Ziconotide, Methoxyflurane", "updated_at": 1767369485}, {"id": 249978, "ingredient1": "Gefitinib", "ingredient2": "Calcium carbonate", "severity": "Major", "effect": "Coadministration with drugs that elevate gastric pH such as H2-receptor antagonists and antacids may decrease the plasma concentrations of gefitinib.  According to the manufacturer, the solubility of gefitinib is pH-dependent and decreases sharply between pH 4 and 6, becoming practically insoluble above pH 7.", "source": "DDInter", "management_text": "The possibility of a diminished therapeutic response to gefitinib should be considered during coadministration with H2-receptor antagonists or antacids.  If concomitant treatment is required, the manufacturer recommends administering gefitinib 6 hours before or 6 hours after an H2-receptor antagonist or antacid.", "mechanism_text": "Absorption", "recommendation": "The possibility of a diminished therapeutic response to gefitinib should be considered during coadministration with H2-receptor antagonists or antacids.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296145/", "reference_text": "[1] \"Product Information. Iressa (gefitinib).\" Astra-Zeneca Pharmaceuticals  (2023):[2] \"Product Information. Apo-Gefitinib (gefitinib).\" Apotex Inc  (2022):[3] \"Product Information. Iressa (gefitinib).\" AstraZeneca UK Ltd  (2023):[4] \"Product Information. Iressa (gefitinib).\" AstraZeneca Pty Ltd  (2021):[5] Tang W, Tomkinson H, Masson E \"Effect of sustained elevated gastric pH levels on gefitinib exposure.\" Clin Pharmacol Drug Dev 6 (2017):  517-23", "alternatives_a": "Magaldrate, Calcium glucoheptonate, Calcium lactate, Calcium chloride, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium Phosphate, Ascorbic acid, Calcium chloride, Calcium citrate, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Asciminib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Vemurafenib, More", "updated_at": 1767369485}, {"id": 249979, "ingredient1": "Diamorphine", "ingredient2": "Sodium oxybate", "severity": "Major", "effect": "The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects.", "source": "DDInter", "management_text": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.  Otherwise, close monitoring and/or dosage reductions should be considered.  If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate.  All patients treated with sodium oxybate should be advised not to drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking the second nightly dose of sodium oxybate and until they know how the medication affects them.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296150/", "reference_text": "[1] \"Product Information. Xyrem (sodium oxybate).\" Orphan Medical  (2002):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Xywav (calcium/magnesium/potass/sodium oxybates).\" Jazz Pharmaceuticals  (2020):", "alternatives_a": "Etomidate, Dalfampridine, Riluzole, Inotersen, Pitolisant, Tafamidis", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 249980, "ingredient1": "Sodium oxybate", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296151/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Halothane, Thiopental, Remifentanil, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Sufentanil, Propofol, Enflurane, Esketamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249981, "ingredient1": "St. John's Wort", "ingredient2": "Sodium oxybate", "severity": "Major", "effect": "The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects.", "source": "DDInter", "management_text": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.  Otherwise, close monitoring and/or dosage reductions should be considered.  If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate.  All patients treated with sodium oxybate should be advised not to drive, operate machinery, or engage in potentially hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking the second nightly dose of sodium oxybate and until they know how the medication affects them.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296155/", "reference_text": "[1] \"Product Information. Xyrem (sodium oxybate).\" Orphan Medical  (2002):[2] \"Product Information. Xywav (calcium/magnesium/potass/sodium oxybates).\" Jazz Pharmaceuticals  (2020):", "alternatives_a": "Isoflurane, Nitrous oxide, Desflurane, Enflurane, Esketamine, Halothane, Etomidate, Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "Duloxetine, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran", "updated_at": 1767369485}, {"id": 249982, "ingredient1": "Canagliflozin", "ingredient2": "Brentuximab vedotin", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296156/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Guar gum", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 249983, "ingredient1": "Canagliflozin", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators.  Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction.", "source": "DDInter", "management_text": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.  Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary.  Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure.  If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296158/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals  (2013):[4] \"Product Information. Farxiga (dapagliflozin).\" Bristol-Myers Squibb  (2014):[5] \"Product Information. Jardiance (empagliflozin).\" Boehringer Ingelheim  (2014):[6] \"Product Information. Brenzavvy (bexagliflozin).\" TheracosBio, LLC  (2023):", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249984, "ingredient1": "Canagliflozin", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296159/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Guar gum, Rosuvastatin", "alternatives_b": "Mecasermin, Mecasermin rinfabate", "updated_at": 1767369485}, {"id": 249985, "ingredient1": "Canagliflozin", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Coadministration with uridine diphosphoglucuronate-glucuronosyltransferase (UGT) inducers such as rifampin, phenytoin, phenobarbital, and ritonavir may decrease area under the curve (AUC) of canagliflozin by up to 51%.  This may decrease efficacy of canagliflozin.", "source": "DDInter", "management_text": "If coadministration with a UGT inducer is required, a higher dose of canagliflozin may be needed based on tolerability, glycemic control, and renal function.  Monitor glycemic control and refer to the product labeling for specific guidelines on dosing adjustments.", "mechanism_text": "Metabolism", "recommendation": "If coadministration with a UGT inducer is required, a higher dose of canagliflozin may be needed based on tolerability, glycemic control, and renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296160/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Invokana (canagliflozin).\" Janssen Pharmaceuticals  (2013):", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More", "updated_at": 1767369485}, {"id": 249986, "ingredient1": "Canagliflozin", "ingredient2": "Thyrotropin alfa", "severity": "Moderate", "effect": "The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, sirolimus, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents.  These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.", "source": "DDInter", "management_text": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.  Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.  Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.  Likewise, patients should be observed for hypoglycemia when these drugs are withdrawn from their therapeutic regimen.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when drugs that can interfere with glucose metabolism are prescribed to patients with diabetes.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296161/", "reference_text": "[1] Greenstone MA, Shaw AB \"Alternate day corticosteroid causes alternate day hyperglycaemia.\" Postgrad Med J 63 (1987):  761-4[2] Pollare T, Lithell H, Berne C \"A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension.\" N Engl J Med 321 (1989):  868-73[3] Carter BL, Small RE, Mandel MD, Starkman MT \"Phenytoin-induced hyperglycemia.\" Am J Hosp Pharm 38 (1981):  1508-12[4] Al-Rubeaan K, Ryan EA \"Phenytoin-induced insulin insensitivity.\" Diabet Med 8 (1991):  968-70[5] Chaudhuri ML, Catania J \"A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly.\" Br J Clin Pract 42 (1988):  427-9[6] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de \"Effect of chlorothiazide on intravenous glucose tolerance in pregnancy.\" Am J Obstet Gynecol 105 (1969):  556-60[7] Miller NR, Moses H \"Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance.\" JAMA 240 (1978):  1887-8[8] Kansal PC, Buse J, Buse MG \"Thiazide diuretics and control of diabetes mellitus.\" South Med J 62 (1969):  1372-9[9] Andersen OO, Persson I \"Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid.\" Br Med J 2 (1968):  798-801[10] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG \"Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma.\" JAMA 220 (1972):  1592-3[11] Chowdhury FR, Bleicher SJ \"Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism.\" Horm Metab Res 2 (1970):  13-6[12] Diamond MT \"Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis.\" N Y State J Med 72 (1972):  1741-2[13] Jones IG, Pickens PT \"Diabetes mellitus following oral diuretics.\" Practitioner 199 (1967):  209-10[14] Black DM, Filak AT \"Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection.\" J Fam Pract 28 (1989):  462-3[15] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG \"Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?\" Scand J Urol Nephrol Suppl 54 (1980):  135-8[16] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT \"Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up.\" Lancet 2 (1982):  1293-5[17] Seltzer HS, Allen EW \"Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man.\" Diabetes 18 (1969):  19-28[18] Jori A, Carrara MC \"On the mechanism of the hyperglycaemic effect of chlorpromazine.\" J Pharm Pharmacol 18 (1966):  623-4[19] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C \"Effect of chlorpromazine on blood glucose and plasma insulin in man.\" Eur J Clin Pharmacol 11 (1977):  15-8[20] \"Product Information. Thorazine (chlorpromazine).\" SmithKline Beecham  (2002):[21] \"Product Information. Diabinese (chlorpropamide).\" Pfizer U.S. Pharmaceuticals  (2002):[22] \"Product Information. Glucotrol (glipizide).\" Pfizer U.S. Pharmaceuticals  (2002):[23] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[24] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical  (2002):[25] \"Product Information. Carafate (sucralfate).\" Hoechst Marion Roussel  (2001):[26] Stambaugh JE, Tucker DC \"Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia.\" Diabetes 23 (1974):  679-83[27] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH \"Effect of diphenylhydantoin on insulin secretion in man.\" N Engl J Med 286 (1972):  339-42[28] Javier Z, Gershberg H, Hulse M \"Ovulatory suppressants, estrogens, and carbohydrate metabolism.\" Metabolism 17 (1968):  443-56[29] Sotaniemi E, Kontturi M, Larmi T \"Effect of diethylstilbestrol on blood glucose of prostatic cancer patients.\" Invest Urol 10 (1973):  438-41[30] Bell DS \"Insulin resistance. An often unrecognized problem accompanying chronic medical disorders.\" Postgrad Med 93 (1993):  99-103,[31] Berlin I \"Prazosin, diuretics, and glucose intolerance.\" Ann Intern Med 119 (1993):  860[32] Rowe P, Mather H \"Hyperosmolar non-ketotic diabetes mellitus associated with metolazone.\" Br Med J 291 (1985):  25-6[33] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE \"Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters.\" Contraception 39 (1989):  619-32[34] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D \"Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study.\" Int J Gynaecol Obstet 24 (1986):  291-6[35] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S \"Furosemide-induced hyperglycaemia - the implication of glycolytic kinases.\" Horm Metab Res 25 (1993):  557-9[36] Goldman JA, Ovadia JL \"The effect of estrogen on intravenous glucose tolerance in woman.\" Am J Obstet Gynecol 103 (1969):  172-8[37] Hannaford PC, Kay CR \"Oral contraceptives and diabetes mellitus.\" BMJ 299 (1989):  1315-6[38] Spellacy WN, Ellingson AB, Tsibris JC \"The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.\" Fertil Steril 51 (1989):  71-4[39] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R \"Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans.\" Diabetologia 36 (1993):  84-7[40] Domenet JG \"Diabetogenic effect of oral diuretics.\" Br Med J 3 (1968):  188[41] Coni NK, Gordon PW, Mukherjee AP, Read PR \"The effect of frusemide and ethacrynic acid on carbohydrate metabolism.\" Age Ageing 3 (1974):  85-90[42] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H \"Insulin action in insulin-dependent diabetics after short-term thiazide therapy.\" Diabetes Care 9 (1986):  631-6[43] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM \"Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.\" Arch Int Pharmacodyn Ther 253 (1981):  154-63[44] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L \"Incidence and importance of metabolic side-effects during antihypertensive therapy.\" Acta Med Scand Suppl 672 (1983):  79-83[45] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC \"Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations.\" Clin Pharmacol Ther 28 (1980):  611-8[46] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H \"The metabolic effects of thiazide therapy in the elderly: a population study.\" Age Ageing 15 (1986):  151-5[47] \"Product Information. Glucophage (metformin).\" Bristol-Myers Squibb  (2001):[48] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM \"A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.\" Diabetologia 38 (1995):  853-9[49] \"Product Information. Precose (acarbose).\" Bayer  (2001):[50] \"Product Information. Norvir (ritonavir).\" Abbott Pharmaceutical  (2001):[51] \"Product Information. Amaryl (glimepiride).\" Hoechst Marion Roussel  (2001):[52] Charan VD, Desai N, Singh AP, Choudhry VP \"Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy.\" Indian Pediatr 30 (1993):  809-10[53] Seifer DB, Freedman LN, Cavender JR, Baker RA \"Insulin-dependent diabetes mellitus associated with danazol.\" Am J Obstet Gynecol 162 (1990):  474-5[54] \"Product Information. Crixivan (indinavir).\" Merck & Co., Inc  (2001):[55] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS \"Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?\" Diabetologia 39 (1996):  861-4[56] \"Product Information. Viracept (nelfinavir).\" Agouron Pharma Inc  (2001):[57] Dube MP, Johnson DL, Currier JS, Leedom JM \"Protease inhibitor-associated hyperglycaemia.\" Lancet 350 (1997):  713-4[58] \"Product Information. Oncaspar (pegaspargase).\" Rhone Poulenc Rorer  (2001):[59] \"Product Information. Prandin (repaglinide).\" Novo Nordisk Pharmaceuticals Inc  (2001):[60] \"Product Information. Elspar (asparaginase).\" Merck & Co., Inc  (2001):[61] \"Product Information. Hyperstat (diazoxide).\" Apothecon Inc  (2022):[62] \"Product Information. Megace (megestrol).\" Bristol-Myers Squibb  (2001):[63] Walli R, Demant T \"Impaired glucose tolerance and protease inhibitors.\" Ann Intern Med 129 (1998):  837-8[64] \"Product Information. Agenerase (amprenavir).\" Glaxo Wellcome  (2001):[65] Mauss S, Wolf E, Jaeger H \"Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors.\" Ann Intern Med 130 (1999):  162-3[66] Kaufman MB, Simionatto C \"A review of protease inhibitor-induced hyperglycemia.\" Pharmacotherapy 19 (1999):  114-7[67] \"Product Information. Tolinase (tolazamide).\" Pharmacia and Upjohn  (2001):[68] \"Product Information. Orinase (tolbutamide).\" Pharmacia and Upjohn  (2001):[69] \"Product Information. Dymelor (acetohexamide).\" Lilly, Eli and Company  (2001):[70] Wehring H, Alexander B, Perry PJ \"Diabetes mellitus associated with clozapine therapy.\" Pharmacotherapy 20 (2000):  844-7[71] Tsiodras S, Mantzoros C, Hammer S, Samore M \"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study.\" Arch Intern Med 160 (2000):  2050-6[72] \"Product Information. Fortovase (saquinavir).\" Roche Laboratories  (2001):[73] \"Product Information. Starlix (nateglinide).\" Novartis Pharmaceuticals  (2001):[74] Hardy H, Esch LD, Morse GD \"Glucose disorders associated with HIV and its drug therapy.\" Ann Pharmacother 35 (2001):  343-51[75] Leary WP, Reyes AJ \"Drug interactions with diuretics.\" S Afr Med J 65 (1984):  455-61[76] \"Product Information. NovoLOG Mix 70/30 (insulin aspart-insulin aspart protamine).\" Novo Nordisk Pharmaceuticals Inc  (2022):[77] \"Product Information. Reyataz (atazanavir).\" Bristol-Myers Squibb  (2003):[78] \"Product Information. Lexiva (fosamprenavir).\" GlaxoSmithKline  (2003):[79] \"Product Information. Apidra (insulin glulisine).\" Aventis Pharmaceuticals  (2004):[80] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):[81] \"Product Information. Zolinza (vorinostat).\" Merck & Co., Inc  (2006):[82] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories  (2007):[83] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):[84] \"Product Information. Elzonris (tagraxofusp).\" Stemline Therapeutics  (2019):[85] \"Product Information. Piqray (alpelisib).\" Novartis Pharmaceuticals  (2019):", "alternatives_a": "Simvastatin, Guar gum, Rosuvastatin", "alternatives_b": "Mecasermin, Mecasermin rinfabate", "updated_at": 1767369485}, {"id": 249987, "ingredient1": "Amobarbital", "ingredient2": "Captopril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296162/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More", "alternatives_b": "Ramipril, Indapamide, Ramipril", "updated_at": 1767369485}, {"id": 249988, "ingredient1": "Captopril", "ingredient2": "Brentuximab vedotin", "severity": "Moderate", "effect": "Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296163/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):", "alternatives_a": "Felodipine, Amlodipine, Bisoprolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 249989, "ingredient1": "Chlorphenesin", "ingredient2": "Captopril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296164/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Quinapril, Trandolapril, Moexipril, Ramipril, Felodipine, Moexipril, Ramipril, Quinapril, Trandolapril, Indapamide", "alternatives_b": "Selenium Sulfide, Thiabendazole, Miconazole, Ciclopirox, Griseofulvin, Terbinafine, Econazole, Flucytosine, Tioconazole", "updated_at": 1767369485}, {"id": 249990, "ingredient1": "Chlorzoxazone", "ingredient2": "Captopril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296165/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trandolapril, Ramipril, Felodipine, Trandolapril, Indapamide, Ramipril", "alternatives_b": "Chlormezanone", "updated_at": 1767369485}, {"id": 249991, "ingredient1": "Dimethyl fumarate", "ingredient2": "Captopril", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296166/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Lisinopril, Ramipril, Felodipine, Amlodipine, Ramipril, Verapamil, Lisinopril, Bisoprolol, Indapamide", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 249992, "ingredient1": "Diroximel fumarate", "ingredient2": "Captopril", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296167/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Ramipril, Felodipine, Amlodipine, Ramipril, Verapamil, Bisoprolol, Indapamide", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Upadacitinib, More", "updated_at": 1767369485}, {"id": 249993, "ingredient1": "Ethanol", "ingredient2": "Captopril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296168/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Ramipril, Felodipine, Ramipril", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "updated_at": 1767369485}, {"id": 249994, "ingredient1": "Diamorphine", "ingredient2": "Captopril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296169/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Nalmefene, Disulfiram, Levacetylmethadol, Acamprosate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249995, "ingredient1": "Captopril", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296170/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Felodipine", "alternatives_b": "Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More", "updated_at": 1767369485}, {"id": 249996, "ingredient1": "Captopril", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296171/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Ramipril, Felodipine, Amlodipine, Ramipril, Verapamil, Bisoprolol, Indapamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 249997, "ingredient1": "Captopril", "ingredient2": "Nitroprusside", "severity": "Minor", "effect": "The dosage of nitroprusside required to achieve a given hypotensive response is significantly reduced when captopril is coadministered.  The mechanism is unknown.", "source": "DDInter", "management_text": "Since the risk of side effects from nitroprusside may be significantly decreased with lower doses, this interaction may be advantageous.", "mechanism_text": "Others", "recommendation": "Since the risk of side effects from nitroprusside may be significantly decreased with lower doses, this interaction may be advantageous.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296172/", "reference_text": "[1] Woodside J Jr, Garner L, Beford RF, et al. \"Captopril reduces the dose requirement for sodium nitroprusside induced hypotension.\" Anesthesiology 60 (1984):  413-7", "alternatives_a": "Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Fosinopril, Felodipine, Enalapril, More", "alternatives_b": "Diazoxide", "updated_at": 1767369485}, {"id": 249998, "ingredient1": "Captopril", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296174/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Ramipril, Felodipine, Indapamide, Ramipril", "alternatives_b": "Desipramine, Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Escitalopram", "updated_at": 1767369485}, {"id": 249999, "ingredient1": "Captopril", "ingredient2": "Sufentanil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296175/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Indapamide", "alternatives_b": "Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Enflurane, Esketamine, Halothane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 250000, "ingredient1": "Diclofenac (topical)", "ingredient2": "Brentuximab vedotin", "severity": "Moderate", "effect": "Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/296176/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):", "alternatives_a": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Salicylic acid, Fluocinolone acetonide, Cortisone, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}]